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ABSTRACT:
The enzyme choline acetyltransferase (ChAT) mediates synthesis of the neurotransmitter
acetylcholine required for cholinergic neurotransmission. ChAT mutations are linked to
congenital myasthenic syndrome (CMS), a rare neuromuscular disorder. One CMS-related
mutation, V18M, reduces ChAT enzyme activity and cellular protein levels, and is located
within a highly-conserved N-terminal proline-rich motif at residues

14PKLPVPP20.

It is

currently unknown if this motif regulates ChAT function. In this thesis, I demonstrate that
disruption of this proline-rich motif in mouse cholinergic SN56 cells reduces both the
protein levels and cellular enzymatic activity of mutated P17A/P19A- and V18M-ChAT.
The cellular loss of mutant ChAT protein appears to be a result of increased proteasomedependent degradation due to enhanced ChAT ubiquitination. Using a novel fluorescentbiorthogonal pulse-chase protocol, I determined that the cellular protein half-life of
P17A/P19A-ChAT (2.2 h) is substantially reduced compared to wild-type ChAT (19.7 h),
and that proteasome inhibition by MG132 treatment increases the half-life and steady-state
levels of ChAT protein. By proximity-dependent biotin identification (BioID), coimmunoprecipitation, and in situ proximity-ligation assay (PLA), I identified the heat shock
proteins HSC/HSP70 and HSP90 as novel ChAT protein-interactors that are enriched in
cells expressing mutant P17A/P19A-ChAT. Pharmacological inhibition of these HSPs by
treatment with the HSC/HSP70 inhibitors 2-phenylethynesulfonamide (PES) or VER155008, or the HSP90 inhibitor 17-AAG reduced cellular ChAT activity and solubility, and
enhanced ubiquitination and proteasomal loss of ChAT protein. The effects of HSP
inhibition were greatest for mutant P17A/P19A- and V18M-ChAT. While I observed that
ChAT interacts in situ with the HSP-associated E3 ubiquitin ligase CHIP, siRNA-mediated
knock-down of CHIP had no effect on ChAT protein levels. Inhibition of HSC/HSP70 by
PES treatment sensitized ChAT to H2O2-induced insolubilization, and ChAT ubiquitination
was enhanced following H2O2 treatment. Lastly, inhibition of the endoplasmic reticulum
(ER)- and HSP-associated co-chaperone Cdc48/p97/Valosin-containing protein (VCP)
prevented the degradation of ubiquitinated ChAT. Together my results identify novel
mechanisms for the functional regulation of wild-type and CMS-related mutant ChAT by

ii

multiple molecular chaperones and the ubiquitin-proteasome system that, importantly, may
have broader implications for ChAT function during cellular stress and disease.

KEYWORDS:
Choline acetyltransferase (ChAT), molecular chaperones, protein degradation, protein
quality control, proteasome, ubiquitination, click chemistry, BioID, proximity-ligation
assay (PLA), HSC/HSP70, HSP90, CHIP/Stub1, Cdc48/p97/VCP, oxidative stress.
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CHAPTER 1: INTRODUCTION
1.1: Proteostasis and protein quality control mechanisms
Preservation of protein homeostasis (i.e. proteostasis) is critical for the maintenance of
cellular function under both physiological conditions and during cellular stress, whereas
dysregulation of proteostatic mechanisms is a hallmark of many diseases. Regulation of
cellular proteostasis relies on a complex interconnected network of cellular factors that
collectively function as protein quality control mechanisms to promote protein function.
These factors can be separated into four broadly defined systems (Figure 1.1); first, factors
related to mRNA synthesis, processing, and stability, along with ribosome biogenesis
regulate the synthesis of nascent proteins [1-3]. Second, nascent proteins are folded into
mature, functional, and active proteins by various endoplasmic reticulum (ER)-associated
and/or cytoplasmic molecular chaperones, such as heat shock proteins (HSPs), that
cooperate with other cellular factors that regulate disulfide-bond formation, glycosylation,
and protein phosphorylation [4-6]. Third, molecular chaperones play a critical role in the
maintenance of protein function in cells exposed to various proteotoxic conditions, such as
hyperthermia and oxidative stress, by preventing stress-induced protein misfolding and
aggregation [7-10]. Fourth, and lastly, the proteolytic degradation of cellular proteins is
essential for the timely turnover and attenuation of signalling proteins (e.g. transcription
factors), and for the removal of excess, stress-damaged, misfolded, and dysfunctional
proteins. Proteolysis of proteins is regulated through two major distinct cellular pathways,
these being the autophagy-lysosome and the ubiquitin-proteasome systems [11-13], and,
importantly, dysregulation of these proteolytic systems is known to be a critical feature of
cancer and of various human neurodegenerative diseases [14-15]. Of note, many of these
distinct protein quality control mechanisms not only work in tandem, but can also directly
interact with one another, such as in the case for degradation of misfolded proteins by ERassociated protein degradation (ERAD) via the ubiquitin-proteasome system [16]. This
thesis will hereafter explore in detail cellular mechanisms related to the ubiquitinproteasome system and protein degradation, as well as various molecular chaperones that
promote protein folding and stability and that target misfolded proteins for degradation.
1

Figure 1.1: Protein quality control overview. Regulation of protein homeostasis (i.e.
proteostasis) is a critical process required for the maintenance of cellular function. Cellular
proteostasis relies on protein quality control mechanisms that involve a complex
interconnected network of cellular factors that regulate protein synthesis (e.g. ribosome
biogenesis), maturation (e.g. endoplasmic reticulum (ER)-associated and cytoplasmic
protein chaperones), protein maintenance during cellular stress, and protein degradation
through, for example, the ubiquitin-proteasome system (UPS). Of note, many of these
distinct cellular mechanisms not only work in tandem, but also interact with one another,
such as in the case for ER-associated protein degradation (ERAD) of misfolded proteins
via the ubiquitin-proteasome system.
2

1.2: The ubiquitin-proteasome system
1.2.1: The proteasome
The ubiquitin-proteasome system is one of two major cellular pathways responsible for the
highly selective degradation of intracellular proteins in eukaryotic cells [11-12]. This
system relies on two core components, the proteolytic 26S proteasome, and the small 8.5
kDa signalling protein ubiquitin (Figure 1.2). The eukaryotic 26S proteasome is a multisubunit protein complex that consists of a hollow catalytic 20S core particle that is
sandwiched between two ATP-dependent 19S regulatory particles [17-19]. The 20S core
itself contains four stacked heptagonal rings consisting of two structural α-subunits that
interact with the 19S regulatory particle and that are flank by two central β-subunits that
impart threonine-dependent proteolytic activity to the 26S proteasome [20-22]. Multiple
small molecule inhibitors that target the 20S proteasome core have been identified that are
commonly used in cellular and molecular studies, such as MG132 and lactacystin [23-26],
or that have been shown to have in vivo anti-tumorigenic properties such as bortezomib
[27-28]. Substrate-specificity and activation of the 26S proteasome in regulated by the
ATP-dependent 19S regulatory particles. These protein complexes contain multiple Rpt
proteins, members of the ATPases associated with diverse cellular activities (AAAATPase) family, and non-ATPase Rpn proteins that together form a “molecular lid” that
gates entry of substrates into 20S core particle for proteolytic breakdown [22, 29-32].
Recognition of proteasome substrates is mediated through interaction of Rpn proteins
within the 19S regulatory particle, specifically Rpn10 and Rpn13, with the small protein
ubiquitin when it is covalently attached to cellular proteins destined for proteolysis [33-36].

1.2.2: Ubiquitin
Ubiquitin is a highly-conserved 76 amino acid (8.5 kDa) regulatory protein expressed
ubiquitously across eukaryota [37-40]. In mammals, ubiquitin is expressed from four
different genes as precursor proteins that are either bound to the ribosomal biogenic
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Figure 1.2: The ubiquitin-proteasome system. Cellular proteins are selectively targeted
for proteasomal degradation by ATP-dependent post-translational modification with the
small 8.5 kDa protein ubiquitin (Ub). Construction of substrate-bound polyubiquitin chains
targets ubiquitinated proteins for proteolytic degradation by the 26S proteasome, a large
multimeric protein complex consisting of a hollow catalytic 20S core particle sandwiched
between two 19S regulatory particles. Binding of polyubiquitin chains to the Rpn proteins
Rpn10 and Rpn13 located within the 19S regulatory particles promotes the
deubiquitination, unfolding, and uptake of proteasome-targeted proteins into the 20S core
where they are subsequently degraded in an ATP-dependent manner. Small molecule
inhibitors of the proteasome, such as MG132 and lactacystin, interfere with the 20S core
β-subunits, leading to accumulation of ubiquitinated proteasome substrates [36].

proteins L40 or S27 [41-42] or are expressed as tandem repeats that are post-translationally
processed into free monomeric ubiquitin by deubiquitinating enzymes (DUBs) [43]. In the
cell ubiquitin can most often be found either in its free and unbound monomeric state or
covalently bound to other cellular proteins as either monomers or as a polyubiquitin (polyUb) chain [43-44]. Canonically, ubiquitination of cellular proteins occurs through the
formation of a covalent isopeptide bond between residue Gly76 at the extreme C-terminus
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of ubiquitin and the ε-amino group of a targeted lysine residue located either on a substrate
protein or on a substrate-conjugated ubiquitin molecule [44-46]. Alternatively, protein
ubiquitination has also been shown to occur on serine and threonine residues, as well as on
N-terminal methionine residues [47-49]. Ubiquitination has been shown to have multiple
diverse effects on protein function, including regulation of enzyme activity and subcellular
trafficking, though is known foremost to promote the proteasome-dependent degradation
of ubiquitinated proteins [44, 50-51].

1.2.3: Ubiquitination mechanisms
Conjugation of ubiquitin onto cellular proteins is a well-characterized multistep process
that involves three distinct classes of enzymes in addition to ubiquitin (Figure 1.3). First,
in an ATP-dependent manner monomeric free ubiquitin binds to and forms a thioester bond
between the C-terminal residue Gly76 of ubiquitin and the catalytic cysteine residue of an
E1 ubiquitin-activating enzyme. Second, the activated ubiquitin is transferred to the active
site cysteine of an E2 ubiquitin-conjugating enzyme. Third, E3 ubiquitin ligases facilitate
transfer of the active ubiquitin molecule onto a protein substrate by formation of a covalent
isopeptide bond between reside Gly76 of ubiquitin and the ε-amino group of a substrate
lysine residue. Conjugation of a single ubiquitin molecule on a protein substrate (i.e.
monoubiquitination) can then serve as a primer for the construction of larger proteolytic
poly-Ub chains by isopeptide attachment of free monomeric ubiquitin onto lysine residues
within substrate-bound ubiquitin molecules. Alternatively, poly-Ub chains can be
deconstructed and removed from substrate proteins by various DUBs [34, 44, 52-54]. While
this process is known to exhibit a high degree of substrate specificity, it is believed that
over 800 distinct cellular proteins are involved directly in the regulation of protein
ubiquitination. Specifically, in humans two genes encode for two different E1 activating-enzymes (UBA1 and UBA6) that are solely responsible for ubiquitin activation [55].
Conversely, it is estimated that approximately 40 different E2 conjugating-enzymes, over
600 unique E3 ubiquitin ligases, and roughly 100 distinct DUBs are expressed in human
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Figure 1.3: The ubiquitination pathway. Ubiquitination of cellular proteins involves
three distinct classes of enzymes. First, monomeric free ubiquitin (Ub) covalently binds to
the catalytic cysteine residue of an E1 ubiquitin-activating enzyme in an ATP-dependent
manner. Second, the activated ubiquitin molecule is transferred to the active site cysteine
of an E2 ubiquitin-conjugating enzyme. Third, E3 ubiquitin ligases facilitate transfer of the
active ubiquitin molecule onto protein substrates by promoting the formation of a covalent
isopeptide bond between the C-terminal residue Gly76 of ubiquitin and the ε-amino group
of a lysine residues on the substrate protein. Attachment of a single ubiquitin molecule (i.e.
monoubiquitination) can then serve as a primer for the construction of larger proteolytic
polyubiquitin (poly-Ub) chains by isopeptide attachment of free monomeric ubiquitin onto
lysine residues located within substrate-bound ubiquitin molecules. Alternatively, poly-Ub
chains can be deconstructed and monomeric ubiquitin can be removed from substrate
proteins by various deubiquitinating enzymes (DUBs) [40, 43-44, 52, 61].
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cells [56-59]. Subsequently, due to the substantial number of and their role in directly
interacting with protein substrates, E3 ubiquitin ligases are thought to provide the majority
of substrate specificity to the cellular ubiquitination system [44, 60-61].
E3 ubiquitin ligases can be categorized into two major families defined by their
sequence/structural homology and the mechanism by which they transfer ubiquitin from
E2 conjugating-enzymes onto their substrates. First, members of the homologous to the E6AP carboxy terminus (HECT) family are characterized by their ability to first accept
ubiquitin from E2 enzymes by formation of a covalent intermediate thioester bond via a
conserved catalytic cysteine within the E3 HECT domain, then subsequently covalently
transfer ubiquitin onto their substrates [62-63]. Of the over 600 estimated E3 ubiquitin
ligases, to date only 28 HECT family members have been identified based on homology to
the E3 ligase E6-associated protein (E6-AP) [57], with the WW-domain containing
NEDD4 [64-66] and the BH3-domain containing HUWE1/Mule [67-68] representing two
well-characterized HECT E3 ligases. Conversely, the large majority of E3 ubiquitin ligases
belong to the really interesting new gene (RING) family that are characterized for their
ability to facilitate direct conjugation of ubiquitin from E2 enzymes onto their substrates
without forming covalent intermediates [69-70]. One notable feature of the RING family
is the tendency of these E3 ubiquitin ligases to form large multi-protein heterocomplexes,
particularly in collaboration with scaffolding Cullin proteins, with two well-documented
examples being the Skp1-Cul1-F-box (SCF) complex and the anaphase-promoting
complex (APC) [71-72]. Lastly, a smaller third family of RING-like E3 ubiquitin ligases
has been identified that contain a conserved catalytic U-box domain [73-75], with the HSPassociated C-terminus of HSC70-interacting protein (CHIP/Stub1) being a notable U-box
E3 ubiquitin ligase critical to the chaperone-mediated degradation of misfolded proteins
[76-78]. It is important to note that E3 ubiquitin ligases can contain aspects from both
HECT and RING ligases, such as Parkin [79], and that members from all E3 families are
capable of both mono- and polyubiquitination of their protein substrates [44, 59-60].
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1.2.4: The ubiquitin code
Protein ubiquitination has been shown to have both proteolytic and non-proteolytic
functions. For example, studies have shown that monoubiquitination can regulate various
cellular processes including cell cycle progression, mitosis/meiosis, and transcriptional
activity [80-81], as well as endocytosis of plasma membrane-bound receptors and channels
[82-84] and viral budding [85-87]. Conversely, the construction of substrate-bound polyUb chains canonically promotes the proteasome-dependent degradation of ubiquitinated
cellular proteins, though polyubiquitination has also been shown to have non-proteolytic
functions. The function of poly-Ub chains is dependent on the “lysine-linkages” between
individual ubiquitin molecules within a substrate-bound poly-Ub chain, where ubiquitin
contains seven lysine residues at positions K6, 11, 27, 29, 33, 48, and 63 that can be used
to form differential ubiquitin-ubiquitin isopeptide linkages to construct poly-Ub chains
(Figure 1.4). These different linkages produce structurally-distinct poly-Ub chains, such as
for K48- and K63-linked chains, that allow for differential recognition by ubiquitin-binding
proteins containing ubiquitin-binding domains (UBD) [88-90]. Classically, the proteolytic
features of ubiquitination have been best characterized for K48-linked chains where
modification of cellular proteins with poly-Ub chains containing at least four K48-linked
ubiquitin molecules targets these polyubiquitinated proteins for proteasome-dependent
degradation [44-45, 54, 60, 91-93]. Though, more recently K11-linked chains have also
been shown to target substrates for proteasomal degradation and have been shown to
regulate cellular processes such as cell cycle progression by the APC [94-96] or ERAD
through interaction of K11-linked chains with the ER-associated AAA-ATPase
cdc48/p97/Valosin-containing protein (VCP) [50, 97-98]. In contrast, K63-linked chains
largely perform non-proteolytic functions and have been shown to regulate endocytic
protein trafficking, DNA repair mechanisms, kinase activation, and ribosomal function [99102]. Interestingly, multiple studies have also documented the degradation of K63-linked
substrates in a proteasome-independent nature via the autophagy-lysosome system [103105]. The remaining poly-Ub linkages (K6-, K27-, K29-, and K33-linked chains) have been
less characterized and have unclear and/or unknown functions [44, 54, 60, 106].
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Figure 1.4: The ubiquitin code. (A) Three-dimensional (3D) ribbon diagram of the crystal
structure of human erythrocytic ubiquitin (PDB: 1UBQ) [107]. Ubiquitin contains seven
lysine residues (shown in green) at positions K6, 11, 27, 29, 33, 48, and 63 that can all be
used for the extension of poly-ubiquitin chains by formation of covalent isopeptide linkages
between the C-terminal Gly76 residue (red) of a free ubiquitin molecule and lysine residues
within substrate-bound ubiquitin. (B) Cellular proteins targeted for degradation are first
monoubiquitinated by covalent attachment of monomeric ubiquitin (Ub) onto substrate
lysine residues by E3 ubiquitin ligases. Monoubiquitination can then either alter substrate
protein function (i.e. subcellular trafficking and/or protein signalling) or can serve as a
primer for the construction of larger proteolytic poly-Ub chains. Classically, proteasomedependent degradation of cellular proteins requires recognition of substrate-bound K48linked poly-Ub chains by the 26S proteasome. Alternatively, K11-linked poly-Ub chains
have also been implicated in the proteasomal degradation of cell cycle modulators by the
anaphase-promoting complex (APC) and of endoplasmic-reticulum-associated protein
degradation (ERAD) substrates. Conversely, K63-linked poly-Ub chains largely perform
non-proteolytic functions (i.e. regulation of endosomal trafficking, kinase activation, and
DNA repair mechanisms), though can also promote the lysosomal-dependent degradation
of K63-linked proteins. K6-, 27-, 29-, and 33-linked poly-Ub chains have unclear and/or
unknown functions [44, 50-51, 54, 60, 87].

1.2.5: Autophagy-lysosomal degradation
In addition to the ubiquitin-proteasome system, the autophagy-lysosome system is another
distinct cellular pathway that mediates degradation of intracellular proteins. Cytoplasmic
materials destined for lysosomal degradation, such as damaged organelles and excess,
foreign, insoluble, and/or aggregated proteins, are first enveloped into autophagosome
vesicles through a process called autophagy [108-109]. Subsequently, autophagosomes
fuse with the lysosome, a membrane-bound acidic organelle that contains various pHsensitive proteases with broad proteolytic activity, resulting in the gross proteolysis of
cytoplasmic materials within autophagosomes [110-111]. Though multiple mechanisms
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can direct cellular proteins to the lysosome, ubiquitination of lysosomal targets with K63linked poly-Ub chains is a well documented signal for lysosomal proteolysis [51, 103-105,
112-113]. In addition, alternative poly-Ub chains, such as K27- or K29-linked chains, have
been shown to target cellular proteins for lysosomal degradation [114-115]. Lastly,
important to the molecular study of lysosome function, multiple lysosomal inhibitors have
been identified, such as the vacuolar-type H+-ATPase inhibitor bafilomycin-A1 [116] and
the lysosomotropic agent chloroquine [117].

1.3: Protein folding and molecular chaperones
1.3.1: Molecular chaperones overview
Cellular proteolytic pathways are essential to protein quality control and the maintenance
of proteome integrity through the break-down of excessive, foreign, misfolded, and
dysfunctional proteins, as well as for the turn-over of short-lived signaling proteins. To
balance these pro-degradative pathways, cells also rely on opposing molecular mechanisms
that promote the stabilization of cellular protein through protein folding, maturation, and
maintenance. Proper and completed protein folding of not only newly synthesized nascent
proteins, but also of misfolded proteins during cellular stress, represents a critical
proteostatic mechanism as the stability and function of most cellular proteins is dependent
on obtaining specific three-dimensionally folded structures. The cellular mechanisms that
oversee protein folding are extensively varied, though central to this process are molecular
chaperones that not only interact with and promote the folding of nascent and
misfolded/aggregated proteins but can also “triage” terminally misfolded proteins for
proteolytic degradation (Figure 1.5) [118-121]. As such, dysregulation of protein
chaperones has been associated with the accumulation of mutated, misfolded, and/or
aggregated proteins in several human diseases, such as cancer and age-related
neurodegeneration [122-125].
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Figure 1.5: Molecular chaperones regulate cellular proteostasis. Molecular chaperones
interact with and promote the folding and stabilization of non-native nascent and semifolded proteins. Additionally, molecular chaperones assist in the refolding and
disaggregation of misfolded and/or aggregated proteins following cellular stress (e.g.
hyperthermia and oxidative stress) or in the case of mutated or disease-related aggregateprone proteins (e.g. poly-Q-expanded huntingtin, β-amyloid (Aβ), and α-synuclein). Lastly,
molecular chaperones can promote ubiquitination and degradation of terminally misfolded
and/or aggregated proteins through either the ubiquitin-proteasome system or the
autophagy-lysosome system [119-121].
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The term protein chaperone was first introduced in 1978 to describe the ability of
the nuclear protein nucleoplasmin to facilitate assembly of nucleosomes, the core subunits
of chromatin [126-127]. Later, this term was extended to encompass both prokaryotic and
eukaryotic proteins that actively promote the folding of nascent proteins and the assembly
of oligomeric protein complexes [128-130]. Today, this classification has expanded to
cover over 200 different molecular chaperones that are found throughout the cell, many of
which are localized to specific organelles or subcellular regions, and that collectively
regulate an exhaustive array of cellular process. Examples of these molecular chaperones
include ribosome-binding chaperones (e.g. nascent-chain-associated and ribosomeassociated complexes) [131], ER-associated chaperones (e.g. 78 kDa glucose-regulated
protein (GRP-78) and protein disulfide isomerase) [132-133], cytoplasmic chaperones (e.g.
heat shock proteins (HSPs) and chaperonins) [134-135], mitochondrial chaperones (e.g.
Ssc1 and Ssq1) [136], and the aforementioned nuclear chaperone nucleoplasmin [119-120].
Of these, HSPs represent a diverse family of molecular chaperones containing members
that are localized throughout the cell and that are involved in the protein folding and
stabilization of a multitude of differing cellular proteins [118-120, 135, 137-138].

1.3.2: Heat shock proteins and the heat shock response
HSPs belong to a ubiquitous family of molecular chaperones that are involved in many
diverse protein quality control functions, including nascent protein folding, refolding of
stress-misfolded and/or aggregated proteins, subcellular trafficking, and in the degradation
of terminally misfolded proteins [118, 120, 135]. Interestingly, HSPs were inadvertently
discovered in 1962 when Dr. Ferruccio Ritossa first observed chromosome puffing in
Drosophila larvae following exposure to elevated temperatures, suggesting the presence of
heat-induced changes in gene transcription [139]. This was later confirmed in 1974 by
Tissières et al. when Drosophila chromosome puffing was correlated with heat-induced
protein expression [140], a response that has since been shown to be a universal response
to acute heat shock from bacteria to humans [141-143]. To date numerous HSP family
members have been identified that can be separated into six major subfamilies based on
13

function, homology, and molecular mass, including small HSPs such as HSP27 and HSP33,
HSP40/DnaJs, HSP60s, HSP70s, HSP90s, and HSP100s [8, 144-145]. Importantly, though
first discovered in the context of acute heat stress, many HSP are now known to be
constitutively expressed under non-stressed physiological conditions, such as heat shock
cognate 71 kDa protein (HSC70) and HSP90-β, whereas others, such as HSP70 and HSP90α, are expressed when cells are exposed to protein-misfolding stresses such as hyperthermia
and oxidative stress [8, 135, 146].
Elevated expression of stress-inducible HSPs during cellular stress is a critical event
required to prevent stress-induced misfolding and aggregation of cellular proteins [8, 135,
144]. The stress-induced expression of HSPs in mammalian cells, i.e. the heat shock
response, is regulated by the transcription factor heat shock factor 1 (HSF1) which, under
non-stressed conditions, is maintained as an inactive cytosolic monomer by interaction with
various constitutively-expressed HSPs [147-149]. The accumulation of stress-denatured
proteins following acute proteotoxic stress competes with HSF1 for interaction with these
constitutively-expressed HSPs, thus relieving the HSP-mediated sequestration of HSF1 and
allowing for trimerization and nuclear import of HSF1 and subsequent stress-induced
expression of HSP70 and HSP90-α [150-153]. In turn, HSF1-mediated expression of HSPs
protects cells from stress-induced accumulation of misfolded proteins, cellular dysfunction,
and apoptosis by chaperoning stress-denatured proteins [8, 154-158]. Lastly, once cellular
stress has been relieved HSPs can bind to, sequester, and inactivate HSF1, resulting in
abrogation of the heat shock response and restoration of cellular proteostasis [159-161].
Importantly, while many HSP subfamilies contain both constitutive and stress-expressed
members, many of these, such as inducible HSP90-α and constitutive HSP90-β, share a
high degree of sequence, structural, mechanistic, and substrate homology.

1.3.3: The HSP chaperone network
Despite their name, most members of the HSP family are constitutively-expressed under
non-stressed physiological conditions, such as HSP40/DnaJ, HSC70, and HSP90-β that act
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together to promote the folding of nascent proteins and to prevent aggregation of misfolded
and/or mutant proteins [120, 146, 162]. These HSPs have been shown to chaperone
substrate proteins in a cooperative and processive manner (Figure 1.6) where non-native
nascent proteins are first recognized by and bind to the co-chaperone HSP40 that then
interacts with HSC/HSP70 to form a ternary chaperone-substrate complex [163-165].
Affinity of these HSPs for their protein substrates is mediated through interaction of their
substrate-binding domains with exposed peptide sequences rich in hydrophobic amino
acids that are located within non-native substrate proteins [166-169]. Next, HSP40
stimulates hydrolysis of HSC/HSP70-bound ATP, causing HSC/HSP70 to adopt an ADPbound closed-conformation that secures the non-native substrate protein and promotes
protein folding [164, 170-171]. Lastly, nucleotide exchange factors (NEF), such as BAG
family molecular chaperone regulator 1 (BAG-1) [172] and HSP70-binding protein 1
(HspBP1) [173], promote ADP-to-ATP exchange, causing HSC/HSP70 to adopt an ATPbound open-conformation that releases the folded substrate protein [174-175]. Though, if
a native fully-folded state is not obtained, semi-folded HSP substrates can re-enter this
chaperone cycle through repeated interaction with HSP40 and HSC/HSP70 [176-177].
Alternatively, semi-folded HSC/HSP70 substrates can be transferred to HSP90 for further
processing by the HSP70-HSP90 organizing protein (HOP/STI1) that reversibly links and
mediates transfer of proteins between these molecular chaperones [179-180]. In addition to
nascent proteins, misfolded and aggregated proteins can also enter the HSP chaperone
network through interaction with the disaggregases HSP104 and HSP110 in cooperation
with HSP40 and HSC/HSP70 [181-183]. Lastly, if the native-folded state of a substrate
protein cannot be obtained, HSC/HSP70 and HSP90 can triage terminally misfolded
proteins for proteasome-dependent degradation through interaction with the HSPassociated E3 ubiquitin ligase C-terminus of HSC70-interacting protein (CHIP) [76-78,
184]. Though many HSPs regulate protein folding, both HSC/HSP70 and HSP90 are
central to the maintenance of proteostasis, and as such this thesis will continue to review
these HSPs with a focus on their dual roles in protein folding and promoting degradation
of misfolded proteins.
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Figure 1.6: The HSP chaperone network. (1) Non-native nascent and misfolded proteins
bind via exposed hydrophobic regions to the co-chaperone HSP40/DnaJ that then interacts
with HSC/HSP70 to form a ternary chaperone-substrate complex. (2) HSP40 stimulates
hydrolysis of HSC/HSP70-bound ATP, causing HSC/HSP70 to adopt an ADP-bound
closed-conformation that secures non-native protein substrates and promotes protein
folding. (3) Nucleotide exchange factors (NEF), such as BAG-1 and HspBP1, promote
ADP-to-ATP exchange of HSC/HSP70 (4), causing HSC/HSP70 to adopt an ATP-bound
open-conformation that releases the folded substrate protein (5a). If folding is incomplete
(5b), non-native semi-folded substrates can re-enter this chaperone cycle through repeated
interaction with HSP40 and HSC/HSP70, or (6) can be transferred to HSP90 for further
processing by the HSP70-HSP90 organizing protein (HOP/STI1), a tetratricopeptide repeat
(TPR)-containing co-chaperone that reversibly links and mediates transfer of substrate
proteins between HSC/HSP70 and HSP90. (7) Aggregated proteins can also enter the HSP
chaperone network via interaction with the disaggregases HSP104/110 and HSP110 in
cooperation with HSP40 and HSC/HSP70. (8) Lastly, HSC/HSP70 and HSP90 can
alternatively triage terminally misfolded proteins for proteasome-dependent degradation
through interaction with the HSP-associated and TPR-containing E3 ubiquitin ligase Cterminus of HSC70-interacting protein (CHIP) [6, 118, 137, 176].

1.3.4: HSC/HSP70
The HSC/HSP70 family is an extensively studied chaperone subfamily that consists of
multiple highly-related proteins found through both prokaryota and eukaryota that range in
molecular mass from 66 kDa to 78 kDa. While best know for their role in the co- or posttranslational folding of approximately 20% of all nascent proteins [185-187], HSC/HSP70
proteins can also regulate the subcellular trafficking of substrate proteins [188-189] and the
degradation of misfolded proteins [78, 184, 190]. Multiple genes in eukaryotes encode for
HSC/HSP70 proteins that differ in their molecular mass, expression profile, and subcellular
localization [146, 191-193]. For example, the prototypical 70-kDa stress-inducible HSP701a/b (collectively termed HSP70) [191, 193] and the constitutively-expressed HSP70-8 (i.e.
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HSC70) are primarily localized to the cell cytoplasm [194-195]. In comparison, the
constitutively-expressed HSP70-5 and HSP70-9, known respectively as 78-kDa glucoseregulated protein (GRP-78/BiP) [196-197] and mortalin (mtHSP70/GRP-75) [198], are
localized to the ER lumen or mitochondrial matrix respectively. This contrasts with
prokaryotes that express only three HSC/HSP70 homologs, including DnaK, Hsc66, and
Hsc62 [199-200]. Of note, many eukaryotic HSC/HSP70 proteins have overlapping
functions and share similar substrates, though also have distinct functions typically
determined by their subcellular localization [146].
Though differences in expression profile and subcellular localization exist, all
known members of the HSC/HSP70 family share highly homologous amino acid sequences
and conserved domain structures. These domains include an N-terminal nucleotide-binding
domain (NBD) with weak ATPase activity, a hydrophobic linker region, a C-terminal
substrate-binding domain (SBD), and an extreme C-terminal EEVD-motif that facilitates
interaction of HSC/HSP70 proteins with various tetratricopeptide repeat (TPR)-containing
co-chaperones such as HSP40, BAG-1, HspBP1, HOP/STI1, and CHIP [6, 146, 176]. The
C-terminal SBD can be further subdivided into an α-helical lid that sits adjacent to a
substrate-binding β-sandwich that recognizes label and solvent-exposed 4-7 amino acid
sequences within substrate proteins enriched in hydrophobic residues [166-169, 201-202].
Mechanistically, ATP-ADP binding to the N-terminal NBD alters affinity of HSC/HSP70
for non-native protein substrates by allosterically altering the C-terminal SBD. Specifically,
cycling of HSC/HSP70 between a low-affinity ATP-bound state and a high-affinity ADPbound state by HSP40 and various NEFs is responsible, respectively, for the allosteric
opening or closing of the C-terminal α-lid domain onto protein substrates bound to the Cterminal substrate-binding β-sandwich [203-206]. Accordingly, HSC/HSP70-mediated
protein folding is believed to function through a process of kinetic partitioning where nonnative hydrophobic regions within protein substrates transiently interact with the Cterminal SBD of HSC/HSP70, thus preventing substrate aggregation by allowing for the
unobstructed folding of hydrophilic domains and the subsequent burial of hydrophobic
residues/domains upon substrate release [4, 6, 8, 176]. Importantly, the availability of
exposed hydrophobic regions within HSC/HSP70 substrates can promote repeated HSP-
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substrate binding and folding either until a fully-folded native state is achieved or, if not,
the non-native substrate is transferred to HSP90 for further processing or is targeted for
proteolytic degradation [118, 137, 176].
Multiple small molecule inhibitors of HSC/HSP70 have been discovered and
characterized that can bind to and alter the activity and function of HSC/HSP70 [195, 207208]. Due to the ATP-dependent nature of HSC/HSP70-mediated protein folding,
inhibition of the N-terminal NBD has proven to be a successful route for the discovery and
design of HSC/HSP70 inhibitors, including 3’-sulfogalactolipids [209], the allosteric small
molecules MAL3-101 and MKT-007 [210-211], and the ATP mimetic VER-155008 [212214]. Alternatively, compounds that interfere with the C-terminal SBD of HSC/HSP70
have also been characterized, including neutralizing peptide aptamers [215], and the small
molecules 2-phenylethynesulfonamide (PES) and the modified PES-Cl [216-218]. Lastly,
the small molecule 15-deoxyspergualin (15-DSG) and its associated derivatives have been
shown to act through multiple means by inhibiting ATPase activity, substrate binding, and
by blocking the extreme C-terminal EEVD-motif required for co-chaperone interaction
with HSC/HSP70 [210, 219-220]. Importantly, inhibition of HSC/HSP70 substrate binding
(e.g. PES) has been shown to result in the accumulation of misfolded and aggregated
HSC/HSP70 substrates [216-217], while inhibition of HSC/HSP70 ATPase activity (e.g.
VER-155008) results in enhanced degradation of HSC/HSP70 substrates [213-214, 221].
Altogether, the variety of available HSC/HSP70 inhibitors has greatly enhanced the
molecular study of HSC/HSP70 function and of their protein substrates, and subsequently
has impacted research into human diseases associated with dysregulation of HSPs and
proteostasis [218, 222-225].

1.3.5: HSP90
The HSP90 family is another well-conserved subfamily of both constitutive and stressinduced molecular chaperones that make up an estimated 1-2% of all intracellular proteins
under physiological conditions [162, 226-227]. Like HSC/HSP70, HSP90 proteins play a
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critical role in both the folding and stabilization of nascent and stress-damaged proteins
[149, 228-229], as well as in the degradation of misfolded proteins [184, 230-231]. HSP90s
are believed to interact with and regulate the function of at least 200 different cellular
proteins [232], though, despite this apparent promiscuity, HSP90 is thought to contain a
greater substrate specificity compared to that of HSC/HSP70 which, respectively, interacts
with a diverse and extensive range of non-native proteins [233-235]. Specifically, in the
current model (Figure 1.6) HSP90 acts downstream of HSC/HSP70 to interact with semior pre-folded proteins and appears to play a notable role in the structural maturation and
conformational activation of signalling proteins such as steroid receptors and kinases [236238]. Subsequently, a high proportion of identified HSP90 substrates are either enzymes
and/or kinases involved in the regulation of cell cycle control [239-240], cell survival [241],
epigenetics [242-243], or in hormone receptor and cell signalling [244-247]. Thus, HSP90
functions as a critical regulator of a subset of the proteome that integrates together several
cellular signalling pathways through its chaperoning function [232, 235, 248].
Similar to HSC/HSP70, multiple genes in eukaryotes encode for HSP90 proteins
that differ in their molecular mass, expression profile, and subcellular localization [249250]. Specifically, three cytoplasmic isoforms of the prototypical 90-kDa HSP90 have been
identified including the constitutively-expressed HSP90-β and the stress-inducible HSP90α1/α2 [251-253]. Additionally, ER- and mitochondrial-localized isoforms of HSP90 have
been identified, including ERp99/GRP-94 [254-255] and tumor necrosis factor receptorassociated protein 1 (TRAP-1) respectively [256]. In contrast, prokaryotes express a single
HSP90 homolog, high-temperature protein G (HtpG) [257].
All known members of the eukaryotic HSP90 family share highly conserved
domains that consist of a nucleotide-binding N-terminal domain (NTD) with ATPase
activity, a charged linker region, a substrate-binding middle domain (MD), and a Cterminal domain (CTD) responsible for HSP90 dimerization [4, 162, 227, 235].
Furthermore, HSP90s contain an extreme C-terminal MEEVD-motif that allows for
interaction with various TPR-containing co-chaperones such as HOP/STI1 [258-260],
peptidyl-prolyl-isomerases (e.g. cyclophilin 40) [261], and serine/threonine-protein
phosphatase type 5 (PP5) [262]. Mechanistically, HSP90 functions as a C-terminally-bound
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homodimer where ATP-ADP cycling at the NTD causes allosteric conformational changes
to the CTD that facilitates substrate folding (Figure 1.7). Specifically, HSP90 in the absence
of nucleotide binding forms an early-stage “apo-open” complex that binds to semi-folded
protein substrates in complex with HSC/HSP70 and HOP/STI1 [178-180, 263-264]. Like
other HSPs, binding of non-native proteins to HSP90 is promoted by the availability of
exposed hydrophobic sequences within protein substrates [234, 246. 265]. Next, ATP
binding to the NTDs of HSP90, and subsequent ATP hydrolysis, causes dimerization of the
NTDs with concomitant compaction of the HSP90 dimer into a “closed” conformation,
securing and promoting the conformational folding of protein substrates [266-268].
Following ATP hydrolysis, the NTDs separate, release ADP, and the folded protein
substrate is released, thus returning HSP90 to the apo-open state ready for new or repeated
substrate binding [263, 268-269]. Multiple co-chaperones can directly influence the HSP90
chaperone cycle, including HOP/STI1 and Cdc37/p50 which both stabilize HSP90 in its
open conformation and inhibit ATP hydrolysis [270-271], while HOP/STI1 additionally
facilitates substrate transfer from HSC/HSP70 to HSP90 [178-180]. Furthermore,
following ATP and protein substrate binding to HSP90, two molecules of p23 can bind to
the ATP-bound NTDs and stabilize the substrate-bound HSP90 dimer prior to ATP
hydrolysis [272-273]. Conversely, the co-chaperone activator of 90 kDa heat shock protein
ATPase homology 1 (Aha1) can stimulate the inherent ATPase activity of HSP90 by
binding to the MD of HSP90, causing transition of HSP90 to its closed, pro-folding
conformation [271, 274]. In addition, various TPR-containing co-chaperones can interact
with HSP90 through its C-terminal MEEVD-motif, such as peptidyl-prolyl-isomerases, to
assist in the final conformation folding and activation of HSP90 substrates [261-262].
Lastly, HSP90 can interact with the E3 ubiquitin ligase CHIP in a TPR-mediated fashion
that promotes degradation of terminally misfolded protein substrates [230, 275-276].
Various small molecules have been discovered and characterized that can bind to
and alter the activity and function of HSP90 [277-278]. Most of these inhibitors target the
NTDs of HSP90 and their associated ATPase activity, such as the natural antibiotics
radicicol [279-280] and geldanamycin, of which was instrumental in deciphering the
structural and molecular mechanisms of the HSP90-ATP chaperone cycle [279-282].
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Figure 1.7: The HSP90 chaperone cycle: (1) In the absence of HSP90 nucleotide-binding
semi-folded non-native protein substrates, in complex with HSC/HSP70 and HOP/STI1,
interact with a HSP90 homodimer bound together by the C-terminal domains (CTD) of
HSP90. The co-chaperone Cdc37 prevents binding of ATP to the N-terminal domains
(NTD) of HSP90 and maintains an early-stage “apo-open” complex. (2) ATP binds to and
induce dimerization of the HSP90 NTDs. The co-chaperone p23 stabilizes an
“intermediate” substrate-bound HSP90 dimer prior to ATP hydrolysis by binding to the
ATP-bound NTDs. (3) Binding of the co-chaperone Aha1 to the middle domain (MD) of
HSP90 promotes ATP hydrolysis, causing an allosteric compaction of the HSP90 dimer
into a “closed” conformation, securing and promoting conformational folding of protein
substrates. Various tetratricopeptide repeat (TPR)-containing co-chaperones, such as
peptidyl-prolyl-isomerases (PPI) and serine/threonine-protein phosphatase type 5 (PP5),
interact with the HSP90 C-terminal MEEVD-motif to aid in substrate folding. Following
ATP hydrolysis, the HSP90 NTDs separate, release ADP, and the folded protein substrate
is released (4), returning HSP90 to the apo-open state where it is ready for new or (5a)
repeated protein substrate binding. Alternatively, (5b) HSP90 can interact with the TPRcontaining E3 ubiquitin ligase CHIP to promote degradation of terminally misfolded
HSP90 substrates [162, 227, 235].

Subsequently, a geldanamycin derivative, 17-allylamino-17-demethoxygeldanamycin (17AAG), has been shown to be a potent inhibitor of HSP90 activity [283-284], resulting in
enhanced proteasomal degradation of HSP90 substrates [230, 285-287]. Lastly, coumarin
antibiotics, such as novobiocin, have been shown to interfere with the dimerization function
of the HSP90 CTD, resulting in proteolytic loss of cellular HSP90 substrates [288-289].

1.3.6: Ubiquitin E3 ligase CHIP
Degradation of dysfunctional, mutated, and misfolded/aggregated proteins is a critical
event required to maintain cellular proteostasis. Importantly, both HSC/HSP70 and HSP90
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can triage misfolded proteins for proteolytic degradation through interaction with the E3
ubiquitin ligase CHIP/Stub1 [184, 276, 290]. CHIP is a cytosolic member of the U-box
family of RING-like E3 ubiquitin ligases that contains a C-terminal U-box domain with E3
ligase activity [77, 291-292] and three tandem N-terminal TPR domains that facilitate
interaction of CHIP with the C-terminal EEDV-motifs of HSC/HSP70 and HSP90 [76-78,
293]. CHIP has been shown to regulate diverse cellular functions due to its capacity to
ubiquitinate a multitude of HSC/HSP70 and HSP90 substrates, including the glucocorticoid
receptor [184, 294], hypoxia-inducible factor 1-alpha (HIF-1α) [295], the receptor tyrosine
kinase ErbB2 [230, 285], the transcription factors Foxp3 and RFX1 [296-297], and the
cystic fibrosis transmembrane conductance regulator (CFTR) [298-299]. Importantly,
CHIP can target its protein substrates to distinct proteolytic pathways through the synthesis
of either K48- or K63-linked poly-Ub chains. Specifically, interaction of CHIP with the E2
ubiquitin-conjugating enzyme UbcH5 promotes K48-linked polyubiquitination and
proteasome-dependent degradation of CHIP substrates [292, 300-301], whereas interaction
with the E2 enzyme Ubc13 has been shown to promote K63-linked polyubiquitination and
endocytosis of growth hormone receptors [302-303]. Owing to its regulatory roles in a
range of diverse cellular processes, CHIP mutations are associated with development of
hereditary cerebellar ataxias, including Gordon Holms spinocerebellar ataxia syndrome
[304-305], as well as widespread multisystemic neurodegeneration [306].
The substrate specificity of CHIP is dependent on interaction with HSPs where it
preferentially ubiquitinates HSP-bound misfolded proteins [77, 184, 291]. Of note, various
HSP-interacting co-chaperones have also been shown to affect CHIP function, including
BAG-1 which cooperates with CHIP to target HSC/HSP70 substrates for degradation [307308], as well as BAG-2 and HspBP1 which, conversely, inhibit CHIP ligase activity [299,
309-310]. To date no small molecule inhibitors of CHIP have been identified, though
siRNA-mediated knock-down of CHIP has proven to be an effective means for
investigating CHIP-substrate dynamics [296, 311-312]. In addition to HSP-bound protein
substrates, CHIP can also directly ubiquitinate and regulate both the activity and the
degradation of HSC/HSP70 and HSP90 under non-stressed conditions [291, 313-315], and
furthermore plays a key role in restoring cellular proteostasis following cellular stress by
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degrading stress-induced HSPs [316-317]. Though CHIP is well-known for its role in
chaperone-mediated proteolysis, one intriguing and yet unclear question is which factors
regulate the triage decisioning between folding or degradation of HSP substrates. One
leading theory stipulates that CHIP can compete through its tandem N-terminal TPR
domains with other pro-folding TPR-containing co-chaperones for binding to the Cterminal EEVD-motif of HSC/HSP70 and HSP90. In support, CHIP has been shown to
compete with HOP/STI1 for binding to C-terminus of HSP70 and HSP90, and subsequently
that C-terminal phosphorylation of these HSPs regulates the alternate binding of profolding HOP/STI1 and pro-degradative CHIP [276, 315, 318].

1.4: Molecular chaperones in human disease
1.4.1: HSPs in Cancer
Provided their essential role in maintaining cellular proteostasis, HSPs have been
implicated in the pathogenesis of many human cancers and neurodegenerative diseases. In
respect to cancers, one of the defining features and drivers of tumorigenesis is the build-up
of mutated and dysregulated proteins, especially those associated with regulation of cell
cycle and cell survival mechanisms [319-321]. Importantly, HSPs such as HSC/HSP70 and
HSP90 have been shown to chaperone and stabilize mutant and dysregulated cancer-related
proteins, such as mutated and inactive p53, thereby promoting cell cycle dysregulation and
tumorigenesis [322-323]. Additionally, HSPs play a critical anti-apoptotic role during
tumorigenesis by preventing stress-induced apoptosis due to hypoxic build-up of oxidative
and proteotoxic stress within the microtumor environment [324-325]. Consequently,
dysregulated and heightened expression of both constitutive and stress-induced HSPs is a
common feature of many cancers which often correlates with poorer clinical prognosis and
can promote resistance to chemotherapy [323, 326]. Therefore, an area of intense study for
cancer therapy is the development of clinically-relevant inhibitors of HSPs, such as the
HSP90 inhibitor 17-AAG that has shown promising results in clinical trial [327-328].
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1.4.2: HSPs in aging and neurodegeneration
The functions of HSPs have also been implicated during the aging process and in the
pathology of human neurodegenerative diseases [10, 329]. One significant feature of
cellular aging is a decline in both the constitutive and stress-inducible expression of HSPs,
resulting in a diminished capacity of aging cells to chaperone non-native proteins, as well
as respond to cellular and proteotoxic stress [330-332]. In turn, this age-related decline in
chaperoning capacity can lead to the accumulation of misfolded aggregate-prone proteins,
loss of cellular proteostasis, and accelerated cell death [332-333]. Importantly, increased
aberrant protein misfolding and accumulation of protein aggregates during aging has been
associated with the development of type 2 diabetes mellitus [334] as well as various
neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s and
Huntington’s disease, and amyotrophic lateral sclerosis (ALS) [4, 6, 10]. Although the
mechanisms responsible for these different age-related diseases are varied, one common
pathological feature is the accumulation of cytotoxic amyloid or amyloid-like oligomers
and aggregates [335-336].
The cytotoxic properties of these age-related misfolded and aggregated proteins
have been foremost attributed to their ability to directly impair organelle function, such as
mitochondria [337], the ER [338], and autophagosomes [339]. To exacerbate this issue,
protein aggregates can inadvertently interact with exposed hydrophobic regions found
within non-native nascent proteins and in numerous structurally-labile proteins, such as
enzymes, kinases, and transcription factors, thereby co-aggregating with and sequestering
these cellular proteins from performing their normal functions, resulting in multifactorial
cytotoxicity [122, 340-341]. Lastly, protein aggregates can directly impair activity of the
ubiquitin-proteasome system, leading to the establishment of an aggregate-driven positive
feedback system that promotes the build-up of pathogenic protein aggregates, resulting in
gross proteostatic dysregulation, induction of proteotoxic cellular stress, and enhanced cell
death [4, 124, 342-343]. Of note, multiple studies have demonstrated that HSPs have
cytoprotective properties in multiple neurological protein misfolded diseases [10, 344345]. Specifically, in the case of Huntington’s disease, HSP70 and HSP40 have been shown
to chaperone and prevent the assembly of mutant polyglutamine-expanded proteins, such
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as huntingtin, into cytotoxic aggregates [346-347]. Additionally, HSPs can interfere with
the toxic accumulation of AD-associated hyperphosphorylated tau protein or β-amyloid
(Aβ) [348-349], or with Parkinson’s-associated α-synuclein [350]. Consequently,
pharmacological upregulation of HSP expression or chaperone activity [351-352],
enhancement of proteasome activity [353-354], or stimulation of the ubiquitination of
misfolded and aggregated protein [15, 355-356] represent exciting new avenues for the
treatment of protein misfolding neurodegenerative diseases.

1.4.3: HSPs and oxidative stress
Common to both cancer and neurodegenerative diseases is the build-up of oxidative stress
and concomitant acceleration of protein misfolding and cell death [357-358]. A powerful
and significant source of cellular oxidative stress is the generation of free reactive oxygen
species (ROS) that have the capacity to oxidize cellular components, including cellular
proteins, lipids, and DNA [359-361]. For example, ROS-mediated oxidation of thiolcontaining cysteine residues within cellular proteins can either promote the formation of
aberrant intra- and intermolecular disulfide bonds or can stimulate modification of oxidized
proteins with various protective antioxidant modifications such as glutathione or
thioredoxin [362-364]. Though the formation of disulfide bonds during the synthesis of
nascent proteins is often required for proper protein function, the formation of stressinduced disulfide bonds during oxidative stress can induce protein misfolding with severe
and damaging functional consequences [361, 364-365]. Therefore, provided the critical role
of cysteine residues in disulfide bond formation and protein folding, it is reasonable to
hypothesize that cysteine-rich proteins may be more susceptible to oxidative misfolding
and dysfunction. One such protein, the disease-associated E3 ubiquitin ligase Parkin, has a
higher-than-average cysteine content of 7.5% compared to 2.26% for the global human
proteome [366] or 1.6% for intracellular mammalian proteins [367]. Importantly, studies
have demonstrated that exposure of Parkin to H2O2, a potent inducer of cellular oxidative
damage, can induce misfolding, inactivation, and aggregation of Parkin [368-370].
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Interestingly, HSPs play a key role in mitigating the cytotoxic and pro-apoptotic
effects of oxidative stress by chaperoning stress-damaged and aggregate-prone proteins [7,
371]. Of note, prolonged cellular exposure to oxidative stress can lead to the induction of
the heat shock response through oxidative depletion of glutathione, an antioxidant and
redox modulator that can compete with and prevent the formation of aberrant oxidative
disulfide bonds [372-374]. Oxidative depletion of glutathione in turn promotes the
oxidation of cellular proteins and formation of non-native disulfide bonds, causing gross
cellular protein misfolding that subsequently stimulates activation of HSF-1 and the heat
shock response [375-377]. Consequently, stress-induced HSP70 and HSP90 can either bind
to and chaperone oxidized proteins to maintain and/or restore protein function, or
alternatively can promote proteasomal degradation of oxidatively damaged proteins [371,
378-379]. In addition to their stress-induced functions, HSPs have also been found to
constitutively maintain an available pool of reduced glutathione that can buffer against
acute oxidative stress [380-381]. Lastly, in the case of neurodegenerative diseases various
HSPs have been shown to suppress the oxidative properties of mutant and misfolded
huntingtin, Aβ1-42, and the ALS-associated DNA-binding protein TDP-43 [382-384]. Taken
together, these studies establish a critical role for HSPs not only in the regulation of nascent
protein folding, but also in the maintenance of cellular proteostasis during exposure to
cellular stress and in human disease.

1.5: Cholinergic neurobiology
1.5.1: The cholinergic synapse
Build-up of oxidative stress and dysregulation of cellular proteostasis are common cellular
events observed during aging and in many age-related neurodegenerative diseases,
including AD, and may represent mechanisms that are critical to the pathogenesis of these
diseases. Work in the Rylett Laboratory is primarily focused on the role of cholinergic
neurons in the brain during aging and AD [385-386] as these neurons appear to be
particularly sensitive to oxidative stress and to AD-related dysfunction and degeneration
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[387-388]. Cholinergic neurons are critical components of the central, autonomic, and the
somatic nervous system where they are essential to the regulation of bodily homeostasis
through their ability to synthesize and release the neurotransmitter acetylcholine (ACh)
[389-390]. In turn, ACh regulates diverse processes throughout the human body, including
cognitive functions such as behaviour and memory, as well as autonomic (e.g. heart rate,
pupil dilation, and gastric function) and neuromuscular processes. Consequently,
dysregulation of ACh synthesis and/or neurotransmission has been observed in multiple
neurodegenerative and neuromuscular disorders [388, 391].
Cholinergic neurotransmission has been extensively studied over the past fifty-plus
years and is known now to involve the cooperative actions of multiple presynaptic proteins
that oversee the synthesis and release of ACh, as well as postsynaptic ACh receptors that
relay cholinergic neural activity into discreet post-synaptic signalling events (Figure 1.8).
Briefly, in this system ACh is first produced in the presynaptic terminals of cholinergic
neurons by the cytoplasmic enzyme choline acetyltransferase (ChAT) using the substrates
choline and acetyl coenzyme A (acetyl-CoA) [392]. ACh is then transported and stored in
presynaptic lipid-bound vesicles by the vesicular acetylcholine transporter (VAChT) [393].
Depolarization and activation of cholinergic neurons induces calcium-dependent fusion of
ACh-containing vesicles with the presynaptic terminal plasma membrane, resulting in
release of ACh into the synaptic cleft [394-395]. Subsequently, released ACh then binds to
postsynaptic membrane-bound receptors, such as nicotinic and muscarinic ACh receptors,
that then initiate downstream postsynaptic signalling events [396-397]. To attenuate
cholinergic signalling, ACh is broken down into choline and acetate by the enzyme
acetylcholinesterase (AChE) located within the synaptic cleft [398]. Lastly, extracellular
choline is transported back into the presynaptic terminals of cholinergic neurons by the
high-affinity choline transporter (CHT) where it can be used by ChAT for the renewed
synthesis of ACh [390, 399]. Importantly, many of these cholinergic proteins have been
found to be dysregulated in neurodegenerative and neuromuscular diseases [400-402],
prompting researchers to develop treatment-oriented cholinergic modulators, such as the
acetylcholinesterase inhibitors donepezil and rivastigmine for the treatment of AD [403].
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Figure 1.8: The cholinergic synapse. (1) In the presynaptic terminals of cholinergic
neurons, the enzyme choline acetyltransferase (ChAT) synthesizes the neurotransmitter
acetylcholine (ACh) using the substrates choline and acetyl-CoA. (2) ACh is transported
into and stored in lipid-bound synaptic vesicles by the vesicular acetylcholine transporter
(VAChT). (3) Depolarization and activation of cholinergic neurons induces Ca2+ influx into
the presynaptic terminals through voltage-gated calcium channels (VGCCs), resulting in
fusion of ACh-containing vesicles with the terminal plasma membrane and release of ACh
into the synaptic cleft. (4) ACh binds to postsynaptic membrane-bound nicotinic and/or
muscarinic acetylcholine receptors (n/mAChRs), resulting in the opening of ligand-gated
ion channels (nicotinic) and/or activation of G-coupled protein signalling (muscarinic) that
alters postsynaptic ion dynamics and downstream subcellular signalling. (5) Cholinergic
signalling is attenuated by breakdown of ACh in the synaptic cleft into choline and acetate
by the enzyme acetylcholinesterase (AChE). (6) Lastly, free choline is transported back
into cholinergic presynaptic terminals by the high-affinity choline transporter (CHT) where
it can be used again as a substrate for ChAT in the repeated synthesis of ACh [389, 392].

1.5.2: Choline acetyltransferase (ChAT)
The enzyme ChAT holds a particularly vital role in cholinergic neural function as it is the
sole protein responsible for the synthesis of ACh. ChAT is a member of the CoA-dependent
superfamily of acyltransferases that includes, for example, carnitine and chloramphenicol
acetyltransferases [404-405], and is a phenotypic marker of central, autonomic, and somatic
cholinergic neurons [389-390]. To date, multiple ChAT transcripts have been identified in
both human and rodents that are formed by alternative splicing and differential use of the
non-coding exons R, N, M, S and H [392, 406-408]. All transcripts encode a common 69kDa ChAT enzyme that is localized predominantly to the neuronal cytoplasm where it
generates ACh, while the spinal cord-isolated S-transcript also encodes for a 74-kDa
isoform [407, 409-411]. Additionally, unique to humans and non-human primates the Mtranscript also encodes for an 82-kDa ChAT protein in addition to 69-kDa ChAT due to the
presence of a unique in-frame translation initiation codon located 5’ to the common
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translation initiation site for 69-kDa ChAT [407, 411, 412-413]. This primate-specific 82kDa ChAT protein contains a nuclear localization signal (NLS) located within its extended
118 amino acid N-terminus that directs it to the nuclei in human brain and spinal cord
cholinergic neurons [385, 414-415]. While our laboratory has shown that 82-kDa ChAT
can synthesize ACh [386, 414-415], the function/s of this nuclear ChAT isoform remain
under investigation, though more recent studies have gathered evidence that 82-kDa ChAT
may be involved in regulating chromatin organization and the gene expression of important
amyloid precursor protein (APP) processing proteins such as GGA3 [386, 416-417].
Though different molecular mass ChAT protein isoforms exist, the cytoplasmic 69kDa variant is considered the canonical ChAT enzyme responsible for ACh synthesis due
to its shared expression from the aforementioned mRNA transcripts in multiple animal
species. Consequently, provided its essential role in cholinergic neurotransmission,
multiple studies have investigated the regulation of ChAT enzyme activity with a focus on
the structural and/or molecular and biochemical properties of 69-kDa ChAT. Importantly,
the crystal structures of both rat [418-419] and human 69-kDa ChAT [420] have been
solved. Structurally, human ChAT contains two functional domains, a substrate-binding
domain that binds to its two substrates choline and acetyl-CoA, and a catalytic domain with
an interfacial active site tunnel that runs between these two domains [420]. An active site
histidine residue, His324, catalyzes transfer of the acetyl group from acetyl-CoA to choline
in a sequential reaction resulting in ACh synthesis [420-422]. Impaired in vitro activity of
purified recombinant ChAT has been demonstrated under oxidative conditions and when
ChAT is exposed to either sulfhydryl-reactive or arginine-modifying reagents [423-424].
Subsequently, the arginine residues Arg442 and Arg443 have been shown to be indirectly
involved in CoA-binding through interactions with a surface “P-loop” that stabilizes acetylCoA within the active site [420, 425]. In addition to these structural determinants of ChAT
activity, post-translational phosphorylation of ChAT has also been shown to regulate its
enzymatic activity where phosphorylation by protein kinase C (PKC) and casein kinase II
(PK2) increases the in vitro activity of recombinant human ChAT [426]. Importantly, in
human HEK293 or IMR32 neuroblastoma cells residues Ser440 and Ser476 of human 69-kDa
ChAT have been shown to be phosphorylated by PKC in a hierarchical fashion such that
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phosphorylation of Ser476 regulates the basal activity of ChAT and where PKC activation
promotes phosphorylation of residue Ser440, subsequently enhancing ChAT activity [410,
427]. Interestingly, mutation of residue Arg442 not only prevents PKC-mediated
phosphorylation of ChAT at residue Ser440 but also dramatically reduces basal ChAT
enzymatic activity [427]. Analysis of the human ChAT crystal structure reveals that these
residues, Ser440 and Arg442, can form hydrogen bonds between each other [420], suggesting
a potential biochemical link between ChAT phosphorylation and protein structural changes
that may influence acetyl-CoA binding and subsequent enzymatic activity of human ChAT.

1.5.3: ChAT in neurodegenerative diseases
Alterations in ChAT activity have been found in multiple neurological disorders, including
AD [428-429], ALS [430] and in Huntington’s disease [431]. Of significance, impairment
of ChAT activity [432-435] and reduced ChAT mRNA expression [436-437] have been
associated with the clinical progression of AD. Furthermore, exposure of cells to ADrelated and cytotoxic Aβ1-42 oligomers results in calcium/calmodulin-dependent kinase II
(CaMKII)-mediated phosphorylation of ChAT on residue Thr456, altering ChAT activity,
and promoting interaction of ChAT with the ER- and HSP-associated co-chaperone
Cdc48/p97/VCP [438-440]. VCP is a critical mediator for the proteasome-dependent
degradation of ubiquitinated ERAD substrates [50, 97, 441-442], as well as for the
maturation of ubiquitin-containing autophagosomes that are critical to the autophagylysosome system [443-445]. While it is currently unknown whether ChAT protein stability
and function is regulated by either the ubiquitin-proteasome and/or autophagy-lysosome
system, these studies collectively suggest that ChAT ubiquitination and protein stability
may be altered following exposure to cytotoxic Aβ stress. Lastly, aggregated forms of Aβ
have been found to reduce ChAT activity in vivo in the striatum of aged rats [446]. These
studies detailing alteration in ChAT enzyme activity during AD or following exposure to
cytotoxic Aβ, together with the observation that significant loss of cholinergic neurons
occurs in patients with AD [447-449], forms the basis for the cholinergic hypothesis of AD
and suggest a critical role for ChAT during AD [450-451]. Subsequently, studies have
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investigated whether coding and non-coding single-nucleotide polymorphisms (SNPs)
within the human ChAT gene are genetically linked to the development of AD, though
comparison of these studies reveals variable results [452-456].

1.5.4: Congenial myasthenic syndrome (CMS)
Though alterations in ChAT activity and mRNA expression have been correlated with the
progression of AD and other neurodegenerative diseases, direct and conclusive genetic
linkage of ChAT missense mutations with these neurodegenerative diseases has yet to be
observed. Conversely, ChAT mutations have been causatively-linked to the development
of the rare neuromuscular disorder congenital myasthenic syndrome (CMS) [411, 457458]. CMS is an inheritable and heterogeneous disorder with an early-childhood onset in
which neuromuscular synaptic mechanisms are compromised, resulting in chronic muscle
weakness (i.e. myasthenia), difficulties in movement, eating, and breathing, and in severe
cases of CMS periods of episodic apnea that can be fatal without medical intervention [402,
459]. Of note, CMS differs from other myasthenic diseases, such as myasthenia gravis and
Lambert-Eaton syndrome, due to the genetic/mutational origins of CMS compared to the
non-genetic autoimmune features of these other myasthenic diseases [402, 460-461].
Myasthenic syndromes, including CMS, are often highly-treatable disease, though
treatment efficacy specifically for CMS patients is highly dependent on the underlying
genetic cause for a patients CMS diagnosis. Importantly, to date mutations in no fewer than
20 different neuromuscular proteins, including cholinergic proteins, have been causativelylinked to CMS development [402, 462-463].
While mutations in various proteins localized either pre- and/or postsynaptically at
neuromuscular junctions are linked to CMS [402, 459], early in vitro electrophysiological
studies of CMS patients revealed that ACh synthesis can be directly impaired, suggesting
a role for ChAT in the pathogenesis of CMS [464-466]. Subsequently, multiple studies
have identified over 40 unique CMS-related missense mutations in the human 69-kDa
ChAT protein, many of which have been biochemically characterized [411, 457-458, 467-
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473]. The severity of CMS-related ChAT mutations has been associated with the position
of the mutated residues within the three-dimensional structure of ChAT where, in general,
mutations involving the ChAT active site can severely impair enzymatic activity, often
through alterations in acetyl-CoA binding. Furthermore, these active site mutations often
display a concomitant reduction in ChAT protein levels, resulting in a synergistic loss in
ACh synthesis associated with development of severe CMS (Figure 1.9) [411, 457-458].
One CMS-related mutations located within the ChAT active site tunnel is an arginine-tohistidine mutation of residue Arg442, a residue our laboratory has shown to regulate both
basal ChAT activity and the PKC-mediated phosphorylation of ChAT on residue Ser440
[420, 427]. Residue Arg442 is hypothesized to indirectly stabilize acetyl-CoA binding to
ChAT, and while the CMS-related R442H mutation does not appear to affect ChAT protein
levels in cells [411, 427], this mutation does dramatically reduce the in vitro affinity of
recombinant R442H-ChAT for acetyl-CoA, causing a 99% loss in catalytic activity [411].

1.5.5: V18M-ChAT and the ChAT N-terminus
Interestingly, several catalytically-deficient CMS-related ChAT mutations have been found
that are positioned distal to the ChAT active site and are hypothesized to work through
allosteric mechanisms, though these mutations tend to produce less severe catalytic defects
and often do not affect protein expression of ChAT [411, 457-458]. One notable exception
is a valine-to-methionine mutation of the N-terminal residue Val18 that was identified in
four unrelated CMS patients with severe myasthenic symptoms [457-458]. Biochemical
characterization of this mutation not only revealed a notable decrease in the in vitro affinity
of recombinant V18M-ChAT for acetyl-CoA, leading to a 30-75% loss in overall catalytic
efficiency, but also a remarkable 30-40% reduction in the steady-state protein levels of
mutant V18M-ChAT compared to wild-type ChAT when transiently expressed in either
BOSC 23 or HEK293 cells (Figure 1.9) [457-458]. Furthermore, this V18M mutation was
found to have negligible effects on the in vitro thermal stability of the enzyme [457],
suggesting that the loss of V18M-ChAT catalytic activity and cellular protein expression
is not likely due to gross alterations in ChAT protein folding.
35

36

Figure 1.9: Missense mutations within human ChAT are associated with development
of the neuromuscular disorder congenital myasthenic syndrome (CMS). CMS-related
ChAT mutations disrupt ChAT function by (A) reducing the steady-state protein levels of
mutant ChAT in cells and/or (B) by altering choline (chol) and/or acetyl-CoA (AcCoA)
binding. In general, mutations involving the ChAT active site (red asterisks) severely
impair ChAT enzymatic activity, frequently due to a loss in AcCoA affinity, and are often
accompanied by a concomitant reduction in ChAT protein levels resulting in a synergistic
loss in ACh synthesis that is associated with development of severe CMS. Interestingly a
valine-to-methionine mutation of the N-terminal residue Val18 has been identified in four
unrelated CMS patients with severe myasthenic symptoms. This residue is positioned distal
to the ChAT active site where mutation of Val18 has been found to reduce both the cellular
steady-state levels protein levels of and the in vitro AcCoA affinity of mutant V18M-ChAT
(green asterisks; D and E). Shown are anti-ChAT immunoblot from transfected COS cells
(A), in vitro kinetic parameters (B), and mutation summaries (C, D, and E) for various
CMS-related ChAT mutants collated from three independent studies completed previously
by other laboratories [A-C, 411; D, 457; E, 458]. Amino acid numbering corresponds to
the human 82-kDa ChAT protein sequence (+118 amino acids vs. 69-kDa ChAT).

The mechanisms by which this CMS-related V18M mutation enacts its effects on
cellular ChAT function remains to be elucidated. One hypothesis provided by the authors
of the above studies is that mutation of residue Val18 may disrupt a hydrogen-bond network
that involves other active site-localized residues that contribute to acetyl-CoA binding, such
as residue Ser440 [457-458]. Importantly, in silico analysis of the human 69-kDa ChAT
amino acid sequence revealed that residue Val18 is positioned within a highly-conserved Nterminal proline-rich motif with sequence

14

PKLPVPP20 (Figure 1.10). This motif is

positioned distal to the ChAT active site, is surface-exposed, and forms part of a stablyfolded domain (Figure 1.11) where neither Val18 nor any other residue in this motif
participates directly in acetyl-CoA binding [420, 457-458]. Interestingly, this highlyconserved proline-rich motif of ChAT shares structural and sequence homology with the
core PxxP-binding motif for Src homology 3 (SH3)-binding domains [420, 474-475].
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Figure 1.10: Comparative sequence alignment of the highly-conserved N-terminal
proline-rich motif of ChAT from multiple divergent animal species. An in silico NCBI
Blastp search with downstream sequence alignment using Clustal Omega (EMBL-EBI)
was completed to compare the first 50 N-terminal amino acids of human 69-kDa ChAT to
the indicated animal species. The sequence for the N-terminal proline-rich motif of human
ChAT (14PKLPVPP20), including the CMS-related residue Val18 (i.e. V18M), is indicated.
Sequence alignment revealed either complete (green) or a high degree (yellow) of amino
acid conservation within the ChAT proline-rich motif between multiple species, with
residues differing from the human 69-kDa ChAT sequence highlighted in purple.
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Figure 1.11: Three-dimensional crystal structure of human 69-kDa ChAT. Shown is a
space-fill 3D model of the human 69-kDa ChAT structure, bound to acetyl-CoA, that was
solved previously in the Rylett Laboratory (PDB: 2FY4) [420]. ChAT contains a highlyconserved N-terminal proline-rich motif at residues
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PKLPVPP20 (green) that shares

homology with the core PxxP-binding motif for Src homology 3 (SH3)-binding domains.
SH3-mediated protein-protein interactions are abundant within intracellular signalling
networks and regulate diverse protein and cellular functions [474-479]. A CMS-related
valine-to-methionine mutations of residue Val18 (red) has been identified from four
unrelated CMS patients with severe myasthenia. This mutation is located within the ChAT
N-terminal proline-rich motif and has been shown previously to reduce the cellular steadystate protein levels and in vitro catalytic activity of mutant V18M-ChAT [457-458].
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Protein-protein interactions between SH3-motifs and SH3-domain-containing proteins are
abundant within intracellular signalling networks and have been shown to regulate the
subcellular trafficking, phosphorylation, activity, and stability of multiple cellular proteins
[475-479]. To date only a handful of protein-protein interaction involving human ChAT
has been identified, including the protein kinases PKC and CaMKII and the co-chaperone
VCP [438]. As such, it is currently unknown whether ChAT engages in SH3-mediated
protein-protein interactions that may alter ChAT function, or furthermore if the ChAT Nterminal proline-rich motif may play a functional role in the regulation of ChAT enzyme
activity and/or protein stability.

1.6: Study rationale, aims, and hypothesis
Maintenance of cellular proteostasis represents an intricate, ongoing, and critical process
required for the preservation of cellular function and cell survival. To accomplish this, cells
utilize a complex network of pro-stabilizing molecular chaperones, such as HSPs, and prodegradation proteins, such as those involved with the ubiquitin-proteasome system, to
efficiently triage cellular proteins between these two opposing cellular fates. In addition,
HSPs play a significant role in the protection against cellular proteotoxic stress (e.g.
hyperthermia and oxidative stress) by either chaperoning stress-misfolded proteins to
promote their folding and stability or, conversely, to triage terminally misfolded proteins
for proteolytic degradation, thereby maintaining proteostasis and preventing stress-induced
cell death. Chronic exposure to oxidative stress, and the associated dysregulation of
molecular chaperones and cellular proteostasis is a common factor in the pathogenesis of
multiple human diseases, including cancer and many neurodegenerative diseases such as
AD. Work in our laboratory is focused on the regulation of cholinergic neural function
during aging as cholinergic neurons appear to be especially sensitive to oxidative stress and
AD-related dysfunction. The cholinergic enzyme ChAT is responsible for the synthesis of
the neurotransmitter ACh and is essential to cholinergic neural function. Missense
mutations found within human 69-kDa ChAT protein have been causatively-linked to the
rare inheritable neuromuscular disorder CMS. One CMS-related ChAT mutation, V18M,
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reduces both in vitro enzyme activity and cellular steady-state protein levels, and is
positioned within a highly-conserved, surface-exposed, N-terminal proline-rich motif at
residues

14

PKLPVPP20 that share homology with SH3-binding motifs. It is currently

unknown what cellular factors regulate ChAT protein stability, and whether the N-terminal
proline-rich motif of ChAT regulates ChAT function.
The specific aims of my present study were to two-fold. First, I was to assess the
role of the ChAT N-terminus, and in particular the proline-rich motif surrounding the CMSrelated residue Val18, in the regulation of ChAT protein function. Second, and in
conjunction with my first aim, I was to determine cellular mechanisms involved in the
regulation of ChAT protein stability, potentially through alteration of the ChAT Nterminus. Thus, I hypothesized that ChAT protein stability and enzyme activity are
regulated by the highly-conserved N-terminal proline-rich motif of ChAT, and
furthermore that ChAT protein stability is regulated by molecular chaperones in
collaboration with the ubiquitin-proteasome system.
Briefly, to evaluate these hypothesises I addressed the cellular protein expression,
enzymatic activity, and the degradation of both wild-type and CMS-mutant ChAT protein
in transiently transfected mouse cholinergic SN56 neural cells. To assess the role of the
proline-rich motif on ChAT protein function, CMS-related V18M-ChAT was compared to
an engineered proline-to-alanine ChAT mutant, P17A/P19A-ChAT. Initial assessment was
carried out by anti-ChAT immunoblotting and by radioenzymatic assay to assess cellular
ChAT protein levels and activity respectively. Additionally, mechanisms that regulate the
degradation of ChAT were determined using the proteasome inhibitor MG132 and the
lysosome inhibitor chloroquine, and subsequently ChAT ubiquitination was tested by antiubiquitin immunoblotting from anti-ChAT immunoprecipitation protein samples. Together
these experiments formed the basis for further experimentation into the regulation of ChAT
protein stability and function.
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CHAPTER 2: MATERIALS AND METHODS
2.1: Protein expression plasmids
For expression in mammalian cells, cDNA encoding wild-type human 69-kDa ChAT,
ligated to pcDNA3.1+ vector [440], was used as a template for preparation of N-terminally
truncated, proline-mutant, and CMS-mutant ChAT. Multiple N-terminally truncated ChAT
isoforms (1-5, 1-10, 1-15, 1-20 and 1-30) were prepared by PCR amplification and
ligated to pcDNA3.1+ vector. Additionally, multiple proline-to-alanine ChAT mutants
(P14A, P17A, P19A, P20A and P17A/P19A) and CMS-mutant ChAT (V18M, A513T and
T490N) [457-458] were prepared by site-directed mutagenesis according to the
QuikChange II Kit (Agilent/Stratagene). For bacterial expression, cDNA encoding wildtype human 69-kDa ChAT, ligated to pProEXHTa vector [480], was used as a template for
preparation of P17A-, P19A- and P17A/P19A-ChAT mutants by site-directed mutagenesis.
Plasmids encoding wild-type and mutant HA-tagged ubiquitin [481-482] were purchased
from Addgene: wild-type (#17608), K0 (#17603), K11 (#22901), K48 (#17605), K48R
(#17604), and K63 (#17606). For BioID experiments, pcDNA3.1/MCS-BirA(R118G)-HA
(BirA*; Addgene #36047) [483] served as a template for the ligation of PCR-amplified
wild-type and P17A/P19A-ChAT cDNA. For the heterologous expression of wild-type and
CHIP mutants (ΔTPR and ΔU-box), plasmids were kindly provided by Dr. Yosef Shaul
(Weizmann Institute of Science) [484] with permission by Dr. Cam Patterson (UNC School
of Medicine). CHIP cDNA was PCR amplified with the addition of a C-terminal FLAGtag and ligated to pcDNA3.1+ vector. Expression plasmids were validated by full-length
DNA sequencing prior to use for mammalian/bacterial expression.

2.2: Cell culture, experimental treatments, and cell lysis
Mouse cholinergic SN56 neural cells (gift from Dr. J.K. Blusztajn, Boston University)
[485] or human HEK293 cells (ATCC) were grown as monolayers in DMEM
supplemented with 5-10% FBS (Invitrogen) and 1% Pen-Strep at 37C with 5% CO2. Prior
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to experimental treatments, cells were transiently transfected with protein expression
plasmids (detailed above) by either calcium phosphate [486] or using Lipofectamine
2000/3000 (Invitrogen) at ~50% confluence for 18-24 h at 37C. All laboratory procedures
were conducted with Biosafety Approval BIO-RRI-0022.
For determination of ChAT steady-state protein levels and cellular ChAT activity of
wild-type or mutant ChAT, ChAT-expressing SN56 cells were collected and lysed on ice
in ChAT assay lysis buffer (10 mM Na2HPO4; pH 7.4, 0.87 mM EDTA, 0.5% Triton X100 and 1.5 mM eserine sulphate) supplemented with mammalian protease inhibitor
cocktail (Sigma), phosphatase inhibitor cocktail (10 mM NaF, 1 mM Na3VO4, 20 mM
Na2HPO4, 3 mM -glycerolphosphate, 5 mM sodium pyrophosphate), and 50 µM MG132
(Enzo Life Sciences). Lysates were centrifuged for 10 min at 21,000 g at 4C and protein
concentrations were measured by Bradford Protein Assay (Bio-Rad). Lysate supernatants
were prepared for analysis of ChAT protein levels by denaturing aliquots of cell lysate in
1x Laemmli sample buffer (63 mM Tris-HCl; pH 6.8, 10% glycerol, 2% SDS, 0.005%
bromophenol blue, 2.5% 2-mercaptoethanol) at 95C for 10 min followed by anti-ChAT
immunoblotting. Additionally, cell lysates were used to determine cellular ChAT activity
by modified radioenzymatic assay [487-488]. To investigate the effect of proteasome
and/or lysosome inhibitors on ChAT steady-state protein levels and cellular ChAT activity,
SN56 cells transiently expressing wild-type, P17A/P19A-ChAT, or CMS-mutant ChAT
were treated with 5 µM MG132, 25 µM chloroquine (Sigma), or vehicle (DMSO or water
respectively) for 18 h at 37C prior to immunoblotting or radioenzymatic assay.
The impact of inhibition of HSC/HSP70, HSP90, or p97/VCP function on ChAT
steady-state protein levels was determined in SN56 cells expressing either wild-type or
mutant ChAT proteins that were treated with varying concentrations of the HSC/HSP70
inhibitor VER-155008 (5 – 50 µM; Sigma), the HSP90 inhibitor 17-AAG (0.5 – 2 µM;
StressMarq Biosciences), or the p97/VCP inhibitor Eeyarestatin-I (Eer1; 5 – 10 µM;
Sigma) for 18 – 24 h at 37°C. Cells were collected and lysed on ice in RIPA buffer (50 mM
Tris-HCl; pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS)
supplemented with protease/phosphatase inhibitors (above), 50 µM MG132, 10 mM N-
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ethylmaleimide (NEM; Calbiochem), and 800 U/ml DNase I (Invitrogen). Lysates were
centrifuged for 10 min at 21,000 g at 4C, protein concentrations were measured by BCA
protein assay (Thermo), and lysate supernatants were denatured in 1x Laemmli sample
buffer at 95C for 10 min then analyzed by anti-ChAT immunoblotting.
To measure cellular ChAT activity following HSC/HSP70 and/or HSP90 inhibition
SN56 cells expressing wild-type or mutant ChAT proteins were treated with either 40 µM
VER-155008 or 1 µM 17-AAG either alone or in combination at 37°C for 24 h. Cells were
collected and lysed on ice in ChAT assay lysis buffer (above) supplemented with
protease/phosphatase inhibitors and 50 µM MG132. Lysates were centrifuged for 10 min
at 21,000 g at 4C and used for analysis of cellular ChAT activity as described above.
The effects of either proteasome or lysosome inhibition on ChAT steady-state protein
levels during HSC/HSP70 and HSP90 inhibition were investigated in SN56 cells
expressing wild-type or mutant ChAT. Cells were treated either alone with 40 µM VER155008 or 1 µM 17-AAG at 37°C for 24 h or co-treated for 18 h with either 5 µM MG132
or 50 µM chloroquine. To lyse cells and release aggregated proteins following HSP and
proteasome inhibition, cells were boiled at 95°C for 5 min and sonicated in 1% SDS lysis
buffer (50 mM Tris-HCl; pH 8.0, 150 mM NaCl, 1% SDS) supplemented with
protease/phosphatase inhibitors, 50 µM MG132 and 10 mM NEM. Protein samples were
prepared for anti-ChAT immunoblotting as above.
For ubiquitination studies, SN56 cells were transiently transfected to express wildtype, P17A/P19A-ChAT or CMS-mutant ChAT alone, or in combination, with HA-tagged
wild-type, K0, K11, K48, K48R or K63-ubiquitin, then treated with either 5 µM MG132,
2.5 µM lactacystin (EMD), or 25 µM chloroquine for 18 h at 37C. For oxidative stress
studies SN56 cells transiently co-expressing wild-type ChAT with HA-ubiquitin were pretreated for 18 h with 5 µM MG132 then co-treated for an additional 30 or 60 min with 1
mM H2O2. Alternatively, SN56 cells transfected to express either wild-type or mutant
ChAT were treated at 37°C with 40 µM VER-155008 for 24 h, 1 µM 17-AAG for either 8
or 24 h, or 10 µM Eer1 for 18 h to inhibit HSC/HSP70, HSP90, or p97/VCP respectively.
To block degradation of ubiquitinated ChAT following HSP inhibition cells were co-treated
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with 20 µM MG132 for 6 h prior to being collected; MG132 co-treatment was omitted
when cells were treated with Eer1. Cells were collected and lysed on ice in RIPA buffer
(above) or in RIPA buffer supplemented with 0.5% SDS. Lysates were sonicated to shear
DNA, centrifuged for 10 min at 21,000 g at 4C, then either anti-HA or anti-ChAT
immunoprecipitations were completed and analyzed by immunoblotting.

2.3: Immunoprecipitation (IP) to assess ChAT ubiquitination
For anti-HA IPs, 1 mg aliquots of cleared whole cell lysate were diluted to a final volume
of 1 ml in supplemented RIPA buffer (above), pre-cleared by incubation with 30 µl of antimouse IgG-agarose beads (Sigma) for 1 h at 4C, then HA-tagged ubiquitinated proteins
were immunocaptured onto 25 µl of monoclonal anti-HA-agarose beads (Sigma) for 3 h at
4C. For anti-ChAT IPs, 2-4 mg aliquots of cleared whole cell lysate were diluted to a final
volume of 1 ml in supplemented RIPA buffer, incubated with 25 µg/mg cellular protein of
anti-ChAT primary antibody (CTab) [440] at 4C for 18 h, then immune complexes were
captured onto 50 µl of protein-G Dynabeads (Invitrogen) for 1 h at 4C. For both anti-HA
and anti-ChAT IPs, immunocaptured samples were washed 4-6 times with ice-cold RIPA
buffer and immune complexes were eluted into 50 µl of 2x Laemmli sample buffer (above)
by heating samples at 85C for 15 min with intermittent mixing. IP samples were analyzed
by immunoblotting with anti-ChAT, anti-HA, and anti-ubiquitin primary antibodies. Total
protein samples were prepared by denaturing whole cell lysates in 1x Laemmli sample
buffer at 95C for 5-10 min prior to immunoblotting.

2.4: Co-immunoprecipitation (co-IP) of ChAT with CHIP or HSPs
For co-IP of ChAT with endogenous HSPs, endogenous CHIP, or heterologous FLAGtagged CHIP either HEK293 or SN56 cells were transfected to transiently express either
wild-type or mutant ChAT protein alone or to be co-expressed with either FLAG-CHIP or
with mutant FLAG-CHIP-ΔTPR or FLAG-CHIP-ΔU-box. For co-IP of ChAT with
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endogenous HSPs following oxidative stress, SN56 cells transiently expressing wild-type
ChAT were treated with either 100 µM H2O2 for 1 – 8 h or with 1 mM H2O2 for 1 h at
37°C. Cells were collected on ice and lysed in co-IP lysis buffer (10 mM HEPES; pH 7.4,
5 mM MgCl2, 1 mM EGTA, 50 mM NaCl, 5% glycerol, 0.5% Triton X-100) supplemented
with protease/phosphatase inhibitors, 50 µM MG132, and 10 mM NEM. Lysates were
centrifuged for 15 min at 15,000 g at 4C, protein concentrations were measured by
Bradford protein assay, then aliquots of cleared whole cell lysates containing either 2 mg
(FLAG-CHIP) or 4 mg (endogenous proteins) of protein were incubated with CTab primary
antibody at 4C for 18 h. Immune complexes were captured onto 50 µl of protein-G
Dynabeads for 1 h at 4C, washed 4-6 times in co-IP lysis buffer, then eluted into 50 µl of
2x Laemmli sample buffer by heating samples at 85C for 15 min with intermittent mixing.
Co-IP samples were analyzed by immunoblotting. Total protein samples were prepared by
denaturing whole cell lysates in 1x Laemmli sample buffer at 95C for 5-10 min.

2.5: SDS-PAGE and immunoblotting analysis
Denatured protein samples from whole cell lysates and IP/co-IPs were resolved on 7.5, 10,
12, or 15% SDS-PAGE gels, then transferred to PVDF membranes (Bio-Rad) by semi-dry
or wet-tank electroblotting. For immunoblotting, membranes were blocked for 1 h at 21°C
in 5% non-fat milk powder in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8
mM KH2PO4; pH 7.4) containing 0.15% Triton X-100 (PBST), followed by incubation
overnight at 4C with primary antibody. Probed membranes were washed with PBST, and
primary antibodies were detected using 1:10,000 peroxidase-coupled secondary antibodies
(Jackson ImmunoResearch) and Clarity Western ECL Substrate (Bio-Rad) on a ChemiDoc
MP system (Bio-Rad). The following primary antibodies were used: 1:1000 ChAT (CTab)
[440], either 1:1000 actin (Santa Cruz) or 1:10,000 β-actin (Sigma), 1:10,000 GAPDH (Cell
Signalling), 1:1000 HSC70 (StressMarq), 1:2000 HSP70 (Thermo), 1:2000 HSP90
(StressMarq), 1:1000 CHIP (Santa Cruz), 1:500 HA (Roche), 1:1000 ubiquitin (Santa
Cruz), 1:1000 FLAG-M2 (Sigma), and 1:1000 LC3B (Thermo). For anti-CHIP
immunoblotting from anti-ChAT co-IP samples, 1:1000 VeriBlot IP secondary antibody
46

(Abcam) was used as a substitute for standard secondary antibodies to reduce IgG lightchain interference of endogenous 35-kDa CHIP detection.

2.6: Purification of recombinant ChAT
Chemically competent E. coli BL21 (DE3) cells were heat shock transformed at 42°C with
pProEXHTa expression plasmids encoding N-terminal His6-tagged wild-type, P17A-,
P19A- or P17A/P19A-ChAT and grown in auto-induction media (1% tryptone, 0.5% yeast
extract, 50 mM Na2HPO4, 50 mM KH2PO4, 25 mM (NH4)2SO4, 0.5% glycerol, 0.05%
glucose, and 0.2% lactose) at 18C on a shaker (225 rpm) for 48 h until OD600 = ~8.0. Cells
were pelleted by centrifugation at 5,000 g for 20 min at 4C, resuspended in Ni2+-column
buffer (50 mM Na2HPO4; pH 7.5, 1.0 M KCl, 10% glycerol) supplemented with 50 mM
imidazole. Purification of His6-tagged ChAT was completed by Ni2+-affinity purification
with follow-up cation exchange chromatography over either Ni2+-Chelating Sepharose Fast
Flow or SP-Sepharose Fast Flow (GE Healthcare), respectively, as performed previously
in our laboratory [480]. Following cation exchange chromatography, protein samples were
analyzed on Coomassie-stained SDS-PAGE gels and eluent fractions containing purified
recombinant ChAT were pooled, flash-frozen in liquid nitrogen, and stored at -80C. Final
protein concentrations of pooled fractions containing purified recombinant ChAT protein
were determined using a Nanodrop UV spectrometer (Thermo) with Abs0.1% = 0.789 at 280
nm. Samples of purified recombinant ChAT were denatured in 1x Laemmli sample buffer
at 95C for 5 min, resolved on 10% SDS-PAGE gels, stained with Imperial Protein Stain
(Thermo), and imaged using a ChemiDoc MP system. In vitro specific activity of purified
recombinant ChAT proteins was assessed by radioenzymatic assay [487-488].

2.7: Circular dichroism (CD) analysis and thermal denaturation
Purified recombinant wild-type, P17A-, P17A/P19A- and P19A-ChAT were dialyzed
overnight at 4C against cation exchange buffer without NaN3 (10 mM Na2HPO4; pH 7.0,
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10% glycerol, 0.5 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP; Sigma)).
Proteins were diluted to 0.2 mg/ml in cation exchange buffer without NaN3 and CD spectra
were generated using a Jasco J-810 spectropolarimeter at 4C in a 0.1 cm path length
cuvette over a wavelength range of 195-260 nm at 0.5 nm intervals. A total of 20 reads
were averaged per recombinant ChAT protein, and CD spectra were finalized by correcting
for background buffer spectra and calculating mean residue ellipticity (MRE). Following
CD, the thermal denaturation midpoint (Tm) was determined for each recombinant ChAT
protein by measuring the loss of helicity at 222 nm over a 4-95C range at 0.5C intervals.
Tm was calculated as previously described [489].

2.8: Strain-promoted alkyne-azide cycloaddition (SPAAC) pulse-chase
SN56 cells grown to ~90% confluence on 100 mm dishes were transfected by
Lipofectamine 2000 for 6 h at 37C to mediate transient expression of wild-type or
P17A/P19A-ChAT, then trypsinized and re-plated onto 60 mm dishes and grown overnight.
SPAAC pulse-chase was initiated by first live-labeling (pulse) cells at 37C for 4 h in
methionine-free DMEM (Invitrogen) supplemented with 5% dialyzed FBS (Invitrogen)
and 50 μM Click-iT L-azidohomoalanine (AHA; Invitrogen). Control cells were grown for
4 h in methionine-containing DMEM with 5% FBS. AHA-labeled cells were then washed
once with and subsequently incubated in methionine-containing DMEM with 5% FBS for
2 - 24 h at 37C (chase). For studies of ChAT protein half-life during proteasome inhibition
cells were treated with 5 µM MG132 throughout both the 4 h pulse and 24 h chase period.
Cells were collected on ice either immediately following the pulse period (control and 0 h)
or following the chase periods (2, 4, 10, and 24 h). For fluorescent labeling of AHA-labeled
proteins from whole cell lysates, collected cells were lysed on ice in 300 µl RIPA buffer
supplemented with protease/phosphatase inhibitors, 50 µM MG132, 10 mM NEM, and 10
mM of freshly prepared iodoacetamide. Lysates were centrifuged for 10 min at 21,000 g at
4C and 50 µl aliquots of whole cell lysate were fluorescently-labelled by incubating with
10 μM Click-iT TAMRA-DIBO (Invitrogen) for 1 h at 21°C followed by denaturation in
1x Laemmli sample buffer at 95C for 5 min. For analysis, equal amounts of proteins (e.g.
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25 µg) from each experimental sample were resolved on 7.5% SDS-PAGE gels and
fluorescence was detected in-gel using a ChemiDoc MP system at an excitation/emission
of 555/580 nm. Additionally, for downstream analysis anti-ChAT immunoblotting of
AHA/TAMRA-labeled protein samples from whole cell lysates was also completed.
To determine ChAT protein half-life, anti-ChAT IPs were prepared from AHAlabeled cells by diluting 200 µl of cleared whole cell lysate, as prepared above, with 300 µl
of supplemented RIPA buffer. Diluted lysates were incubated with 25 µg of anti-ChAT
CTab primary antibody at 4C for 3 h followed by immunocapture onto 50 µl of protein-G
Dynabeads for 1 h at 4C. Immunocaptured samples were washed four times with RIPA
buffer, once with PBS to remove detergents, then subsequently reacted with 10 μM ClickiT TAMRA-DIBO in 1x PBS for 1 h at 21°C with gentle agitation. Samples were washed
twice with RIPA buffer to remove excess TAMRA-DIBO and AHA/TAMRA-labeled
ChAT was eluted into 50 µl of 2x Laemmli sample buffer at 85C for 15 min with
intermittent mixing. For analysis, equal volumes of immunoprecipitated AHA/TAMRAlabeled ChAT (e.g. 20 µl) were resolved on 7.5% SDS-PAGE gels and in-gel fluorescence
was detected as above. Additionally, for downstream analysis anti-ChAT immunoblotting
of AHA/TAMRA-labeled protein samples from anti-ChAT IPs was also completed.
To calculate ChAT protein half-life, I assumed that the amount of fluorescent
AHA/TAMRA-labeled ChAT, P(t), decays exponentially under first order kinetics
according to the equation, P(t) = Poe-t, where Po is the fluorescence intensity at t = 0. The
slope of decay () was calculated by plotting fluorescence intensity of immunoprecipitated
AHA/TAMRA-labeled ChAT, corrected for the levels of total immunoprecipitated ChAT
as measured by parallel anti-ChAT immunoblotting, on a semi-logarithmic scale and
performing linear regression. ChAT protein half-life, T1/2, was calculated according to first
order kinetics where T1/2 = ln(2)/ [490].
Validation of SPAAC pulse-chase was performed using a cycloheximide (CHX)chase assay. SN56 cells were transfected and plated as for SPAAC pulse-chase to
transiently express wild-type or P17A/P19A-ChAT. Cells were treated with either 100
µg/ml CHX for 2, 4, 6 or 8 h, or with DMSO-control for 8 h. Cells were collected and lysed
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on ice in supplemented RIPA buffer, lysates were centrifuged for 10 min at 21,000 g at
4C, and protein samples were prepared for anti-ChAT immunoblotting by denaturing cell
lysates in 1x Laemmli sample buffer at 95C for 5 min. ChAT immunoreactive bands were
quantified by densitometry, plotted on semi-logarithmic scale, and analyzed as above by
linear regression to determine a slope of decay for wild-type and P17A/P19A-ChAT.

2.9: Soluble/insoluble Triton X-100 cellular fractionation and semidenaturing detergent agarose gel electrophoresis (SDD-AGE)
ChAT protein solubility was assessed in SN56 cells, transiently expressing either wild-type
or mutant ChAT following treatment with 20 µM 2-phenylethynesulfonamide (PES;
Sigma), a HSC/HSP70 inhibitor, at 37°C for 24 h. Alternatively, ChAT-expressing SN56
cells were treated with varying concentrations of H2O2 for either 24 h (100 nM – 200 µM)
or for 1 h (1 µM – 2 mM) alone or were pre-treated with 20 µM PES for 24 h followed by
co-treatment with 100 µM H2O2 for 1 – 8 h at 37°C. Cells were collected and lysed on ice
in 0.1% Triton X-100 lysis buffer (50 mM Tris-HCL; pH 8.0, 150 mM NaCl, 0.1% Triton
X-100) supplemented with protease/phosphatase inhibitors, 50 µM MG132 and 10 mM
NEM. Lysates were centrifuged for 15 min at 15,000 g at 4C and aliquots of Triton-soluble
supernatant were prepared for immunoblotting by denaturing in 1x Laemmli sample buffer
at 95C for 10 min. Triton-insoluble proteins were prepared for immunoblotting by
washing Triton-insoluble pellets once with ice-cold PBS, then denaturing the pellets in an
equal volume of 2x Laemmli sample buffer with 5% 2-mercaptoethanol at 85C for 15 min
prior to separation on SDS-PAGE gels. For analysis of ChAT solubility following coexpression of either FLAG-CHIP or with mutant FLAG-CHIP-ΔTPR or FLAG-CHIP-ΔUbox, cells were lysed in 0.5% Triton X-100 co-IP lysis buffer (above) and Tritonsoluble/insoluble protein samples were prepared as above.
In some cases, following PES treatment Triton-insoluble proteins were further
analyzed in parallel by semi-denaturing detergent agarose gel electrophoresis (SDD-AGE)
[491] to determine if PES treatment results in the generation of SDS-resistant ChAT
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aggregates. Briefly, Triton-insoluble protein samples were loaded onto 1.8% agarose gels
containing 0.5% SDS and resolved by electrophoresis at 80V for ~2 h in 1x TAE buffer
(40 mM Tris-HCl; pH 7.6, 20 mM acetic acid, 1 mM EDTA) supplemented with 0.1%
SDS. Resolved proteins were transferred to PVDF membranes by overnight capillary
transfer in 1x TBS (50 mM Tris-HCl; pH 7.6, 150 mM NaCl) with 10% methanol at 21°C.
Membranes were blocked for 1 h at 21°C in 5% non-fat milk powder in PBST then
immunoblotted for ChAT protein as described above.

2.10: Proximity-dependent biotin identification (BioID)
HEK293 cells expressing wild-type- or P17A/P19A-ChAT-BirA* fusion proteins were
live-labeled with 50 µM biotin at 37°C for 24 h to allow proximity-dependent biotinylation
of cellular proteins. Controls cells were transfected with either empty vector or plasmids
encoding untagged ChAT or BirA* [483]. Cells were washed three times on ice with PBS
to remove excess biotin, lysed in supplemented RIPA buffer (above), centrifuged for 10
min at 21,000 g at 4C, then aliquots of cleared whole cell lysate containing 5 mg protein
were incubated with 50 µl of MyOne Streptavidin C1 Dynabeads (Invitrogen) at 4°C for
18 h. Streptavidin pull-down (PD) samples were washed once with 1% SDS lysis buffer
(50 mM Tris-HCl; pH 8.0, 150 mM NaCl, 1% SDS), 3-4 times with RIPA buffer, then
biotinylated proteins were eluted into 50 µl of 2x Laemmli sample buffer at 85C for 15
min. Biotinylated proteins were resolved on SDS-PAGE gels, transferred to PVDF
membranes, and membranes were blocked overnight at 4°C in PBST with 5% BSA prior
to incubation with, and subsequent blotting using 1:20,000 Pierce High Sensitivity
Streptavidin-HRP (Thermo) for 1 h at 21°C. Total protein samples were prepared by
denaturing whole cell lysates in 1x Laemmli sample buffer at 95C for 10 min prior to
immunoblotting. For large-scale BioID to identify novel ChAT protein-interactors,
HEK293 cells expressing either untagged ChAT (control) or ChAT-BirA* fusion proteins
were live labeled with 50 µM biotin then collected, washed, lysed and centrifuged as above.
Aliquots of cleared whole cell lysate containing 25 mg protein were incubated with 250 µl
of MyOne Streptavidin C1 Dynabeads at 4°C for 18 h. Streptavidin PD samples were
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washed as described above, eluted into 100 µl of 2x Laemmli sample buffer, and resolved
on 10% SDS-PAGE gels. To visualize biotinylated proteins, the SDS-PAGE gel was
stained using Pierce Silver Stain for Mass Spectrometry (Thermo).

2.11: Mass spectrometry
Following large-scale BioID proteins of interest were excised from silver-stained SDSPAGE gels using an Ettan Spot Picker (GE Healthcare Life Sciences). In-gel digestion was
performed at the London Regional Proteomics Center - Functional Proteomics Facility
(FPF; Western University) using a MassPREP automated digester station (PerkinElmer)
where gel pieces were first de-stained (50 mM Na2S2O3 and 15 mM K3Fe(CN)6), followed
by protein reduction (10 mM dithiothreitol), alkylation (55 mM iodoacetamide), and tryptic
digestion. Digested peptides were extracted in 1% formic acid with 2% acetonitrile,
lyophilized, then dissolved in 10% acetonitrile containing 0.1% trifluoroacetic acid prior to
mass spectrometry by either matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF-MS) or by liquid chromatography-electrospray ionizationtandem mass spectrometry (LC-ESI-MS/MS).
For MALDI-TOF-MS tryptic-digested peptides were mixed 1:1 (v/v) with a 5
mg/mL –cyano-4–hydroxycinnamic acid MALDI matrix that was prepared in 6 mM
NH4H2PO4, 50% acetonitrile, and 0.1% trifluoroacetic acid, then submitted to the London
Regional Proteomics Center - FPF for analysis. Mass spectrum were obtained using a
TOF/TOF 5800 System (Applied Biosystems, Sciex) equipped with a 349 nm OptiBeam
On-Axis laser using a laser pulse-rate of 400 Hz. Reflectron positive mode was used and
was externally calibrated at 50 ppm mass tolerance and internally at 10 ppm. Each mass
spectrum was collected as a sum of 500 shots. Data acquisition and processing were
completed using a TOF/TOF Series Explorer and Data Explorer respectively (Applied
Biosystems, Sciex). The resulting data were analyzed using the online Mascot Server
(Matrix Science) against the NCBI Human protein database with the following selected as
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variable modifications; biotin (K), carbamidomethyl (C), NEM (C), oxidation (M). Peptide
tolerance was set at ± 50 ppm for protein identification.
For LC-ESI-MS/MS, tryptic-digested peptides were submitted for protein
identification by the London Regional Proteomics Center – Biological Mass Spectrometry
Laboratory (BMSL; Western University). Briefly, digested peptides were injected into and
analyzed using a LC-ESI-MS/MS system comprised of a nanoAcquity UPLC (Waters)
followed by an in-line QExactive Hybrid Quadrupole-Orbitrap mass spectrometer
(Thermo) using a top-12 double-play method. For LC, peptides were trapped onto a
reverse-phase Acquity Symmetry C18 column, 5 µm, 180 µm x 200 mm (Waters), and
subsequently were separated/eluted using a H2O-acetonitrile with 0.1% formic acid solvent
gradient applied to a Acquity Peptide BEH C18 column, 1.7 um, 75 um x 250 mm (Waters).
Resulting data were analyzed using Peaks 7.5 software (Bioinformatics Solutions Inc.)
against the NCBI Human protein database allowing for variable carbamidomethylation or
modification of cysteine residues with NEM with filter criteria set to FDR = 1% and UP =
1 (unique protein) to show protein identification.

2.12: In situ proximity ligation assay (PLA)
To evaluate in situ ChAT protein-interactors, SN56 cells were plated on 35 mm glassbottom confocal dishes and transiently transfected to express wild-type 69-kDa ChAT.
Cells were washed with HBSS, formalin-fixed (4% paraformaldehyde in HBSS) for 15
min, permeabilized with 0.1% Triton X-100, blocked for 1 h in HBSS supplemented with
3% donkey serum, then finally incubated for 1 h with primary antibodies targeting ChAT
(1:100; Chemicon, goat primary) together with either endogenous HSC70 (1:100;
StressMarq, mouse primary), HSP90 (1:200; StressMarq, mouse primary) or CHIP (1:200;
Santa Cruz, rabbit primary); all steps were performed at 21°C. Controls cells were
transfected with empty vector or were not incubated with primary antibodies. DuoLink
PLA technology (Sigma) was utilized to visualize in situ interactions by incubating cells
with Duolink oligonucleotide-linked secondary antibodies (anti-goat PLUS with either
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anti-mouse MINUS or anti-rabbit MINUS) for 1 h at 37°C. Cells were washed with Duolink
In Situ Wash Buffer A, then incubated with 1 U/µL DNA ligase for 30 min followed by 10
U/µL DNA polymerase for 2 h at 37°C according to manufacturer’s instructions. Finally,
cells were washed with Duolink In Situ Wash Buffer B and were overlaid with Duolink In
Situ Mounting Medium with DAPI. Images were acquired using a Leica True Confocal
Scanner (TCS) 8 SpectroPhotometer (SP8; Leica Microsystems Inc.) confocal laser
microscope with a 63x-magnification oil-immersion objective (NA = 1.4) and processed
using ImageJ 1.50b software (NIH).

2.13: Small-interfering RNA (siRNA)
SN56 cells were incubated for a total of 72 h at 37°C with 25 nM of siRNA targeting either
mouse Stub1/CHIP (Silencer Select ID: s80537; Thermo) or mouse HSP70 (sc-35605;
Santa Cruz) following transfection with siLentFect Lipid Reagent (Bio-Rad). As a control,
cells were either mock transfected with siLentFect alone or transfected with 25 nM of
scramble-control siRNA (Silencer Select #4390843; Thermo). After 24 h of endogenous
CHIP/HSP70 knock-down, cells were transfected with Lipofectamine 3000 to transiently
express either heterologous wild-type or mutant ChAT for an additional 48 h at 37°C.
Additionally, cells incubated with anti-HSP70 siRNA were treated with 1 µM 17-AAG for
the final 24 h of HSP70 knock-down at 37°C. Cells were then collected and lysed on ice in
RIPA buffer containing 0.5% SDS, protease/phosphatase inhibitors, 50 µM MG132 and 10
mM NEM. Lysates were sonicated, centrifuged for 10 min at 21,000 g at 4C, denatured in
1x Laemmli sample buffer at 95C for 10 min, then analyzed by immunoblotting.

2.14: Statistical analysis
For statistical analysis of steady-state proteins levels from immunoblots prepared using
whole cell lysates, immunoreactive protein levels were measured by densitometry using
ImageLab 5.0 software (Bio-Rad), normalized to either β-actin or GAPDH protein levels,
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and graphed as mean ± SEM from individual independent replicate experiments (n). For
analysis of anti-ChAT co-IP immunoblots, immunoreactive bands for each coimmunoprecipitated protein (i.e. wild-type and mutant ChAT proteins, HSC70/HSP70,
HSP90 or FLAG-CHIP) were separately measured by densitometry then internally
normalized to the total densitometric value for that protein from within their respective
immunoblots to obtain the relative levels of each co-immunoprecipitated protein. These
relative levels of HSPs or FLAG-ChAT were then expressed as a function of the relative
level of co-immunoprecipitated ChAT, and data was graphed as mean ± SEM from n
number of independent replicate co-IP experiments. Statistical analysis for experiments
completed within this thesis was performed by Student’s t-test, one-way ANOVA with
either Tukey’s or Dunnett’s post-hoc test, or by two-way ANOVA with Bonferroni’s posthoc test using GraphPad Prism software. Statistical significance was set at p≤0.05.
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CHAPTER 3: RESULTS
3.1: ChAT mutations reduce steady-state protein levels and cellular
enzymatic activity of ChAT
Multiple missense mutations have been identified in the human 69-kDa ChAT protein that
have a causative association with development of CMS, with several of these mutations
reducing both the in vitro enzyme activity of purified recombinant ChAT and the cellular
steady-state protein levels of mutant ChAT when expressed in COS, BOSC 23, or HEK293
cells (Figure 1.9) [411, 457-458]. Two such catalytically-deficient mutations, V18M and
A513T, are positioned distal from the ChAT active site and reduce ChAT protein levels
and enzymatic activity through unknown mechanism [457]. As these earlier studies were
performed in non-neural cells, it is currently unknown if these CMS-related mutations also
reduce ChAT steady-state protein levels in cholinergic cells. Thus, I generated expression
plasmids encoding for three different catalytically-deficient CMS-related ChAT mutations
(V18M, A513T, and T490N) that were then transiently expressed in mouse cholinergic
SN56 neural cells; T490N-ChAT differs from V18M and A513T as this mutation does not
reduce steady-state ChAT protein levels when expressed in human kidney BOSC 23 cells
[457]. Following anti-ChAT immunoblotting (Figure 3.1a) I confirmed that the steady-state
protein levels of both V18M- (p≤0.001) and A513T-ChAT (p≤0.05) are reduced compared
to wild-type ChAT in cholinergic SN56 cells, whereas the protein levels of T490N-ChAT
were unaffected as anticipated (Figure 3.1b). As introduced earlier, residue Val18 is located
within a highly-conserved and surface-exposed N-terminal proline-rich motif at residues
14

PKLPVPP20 that shares homology with the core PxxP-binding motif for SH3-domain-

containg proteins (Figs 1.10 and 1.11) [420, 474]. Therefore, to test whether residues within
this proline-rich motif beyond residue Val18 may regulate ChAT steady-state protein levels,
I also generated an expression plasmid encoding for ChAT with proline-to-alanine mutation
of residues Pro17 together with Pro19 (P17A/P19A). When transiently expressed in SN56
and analyzed by anti-ChAT immunoblotting, I observed that the steady-state protein levels
of P17A/P19A-ChAT is also reduced compared to wild-type ChAT (p≤0.001; Figure 3.1).
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Figure 3.1: CMS-related ChAT mutants demonstrate reduced steady-state protein
levels. (A) Anti-ChAT immunoblots from SN56 cells transiently expressing wild-type
(WT), P17A/P19A-, or CMS-related mutant ChAT (V18M-, A513T-, and T490N-ChAT).
Control cells were transfected with empty pcDNA3.1+ vector. Anti-actin immunoblotting
was completed as a loading control. (B) Steady-state protein levels of P17A/P19A(***p≤0.001), V18M- (***p≤0.001), or A513T-ChAT (*p≤0.05) are reduced compared to
wild-type ChAT (one-way ANOVA with Dunnett’s post-hoc test, mean ± SEM, n=5). In
agreement with previously reported results from human kidney BOSC 23 cells transiently
expressing mutant T490N-ChAT [457], no significant changes in the steady-state protein
levels of T490N-ChAT were observed in SN56 cells as compared to wild-type ChAT.

Both the P17A/P19A and CMS-related V18M mutations suggest a critical role for
the ChAT N-terminus in regulating ChAT protein function. The crystal structure of human
69-kDa ChAT suggests that residues Met1 to Ser11 are unstructured, while Gly12 through
Gln30 are structured and surface-exposed [420]. Therefore, to first locate which regions
within the ChAT N-terminus are functionally critical I generated expression plasmids
encoding for ChAT with progressive truncation of the N-terminus up to and including
residue Gln30 (1-5, 1-10, 1-15, 1-20 and 1-30). These N-terminally truncated ChAT
mutants were then transiently expressed in SN56 cells and cell lysates were analyzed for
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both steady-state protein levels, by anti-ChAT immunoblotting, and for cellular ChAT
activity. When compared to wild-type ChAT, I found that truncation of the ChAT Nterminus up to and including residue Glu10 (1-5 and Δ1-10) had no effect on either ChAT
steady-state protein levels (Figures 3.2a and 3.2b) or cellular ChAT activity (Figure 3.2c).
However, deletion of residues including Lys15 and up-to Gln30 (1-15, 1-20 and 1-30)
dramatically reduced steady-state protein levels of these truncated ChAT mutants in SN56
cells and abolished their cellular catalytic activity (p≤0.001).
Residue Lys15, like Val18, is located within the highly-conserved N-terminal prolinerich motif of ChAT the encompasses residues

14

PKLPVPP20. Proline residues impart

structural rigidity to polypeptides, and proline-rich motifs are often involved in cellular
signalling processes [474, 492-493]. On this basis, I further investigated the conserved Nterminal proline-rich motif to find whether mutation of this motif beyond the P17A/P19A
and CMS-related V18M mutations might also affect ChAT activity and cellular ChAT
protein levels. Plasmids encoding for ChAT with various N-terminal proline-to-alanine
mutations (P14A, P17A, P19A, and P20A) were generated and subsequently assessed in
SN56 cells alongside of P17A/P19A-ChAT. As illustrated in Figures 3.3a and 3.3b,
mutation of any proline residue within this proline-rich motif reduced ChAT steady-state
protein levels when compared to wild-type ChAT, with P17A/P19A-ChAT yielding the
greatest reduction (80%; p≤0.01). Moreover, mutation of these proline residues reduces
cellular ChAT activity, with P17A/P19A-ChAT being catalytically inactive (p≤0.001;
Figure 3.3c). Interestingly, though statistical differences in the steady-state protein levels
between individual proline mutants were not observed, mutation of residue Pro17 alone did
result in a greater reduction in cellular ChAT activity when compared to mutation of either
residues Pro14 (p≤0.05) or Pro20 (p≤0.01) alone. Collectively, these results, by disruption,
removal, or mutation of the ChAT N-terminal proline-rich motif, suggest a critical role for
this motif on ChAT function.
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Figure 3.2: N-terminal truncation of ChAT reduces ChAT steady-state proteins levels
and cellular ChAT activity. (A) Anti-ChAT immunoblots from SN56 cells transiently
expressing either full-length wild-type (WT) or N-terminally truncated ChAT mutants.
Control cells were transfected with empty pcDNA3.1+ vector. Anti-actin immunoblotting
was completed as a loading control. Truncation up-to and including residue Glu10 (1-5
and Δ1-10) had no effect on either steady-state protein levels (B) or cellular ChAT activity
(C) when compared to wild-type ChAT. Conversely, truncation of residues including Lys15
and up-to Gln30 (1-15, 1-20 and 1-30) reduces steady-state protein levels and cellular
ChAT activity compared to wild-type ChAT (***p≤0.001, one-way ANOVA with
Dunnett’s post-hoc test, mean ± SEM, n=3).
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Figure 3.3: Mutation of conserved N-terminal proline-rich motif of ChAT reduces
ChAT steady-state proteins levels and cellular ChAT activity. (A) Anti-ChAT
immunoblots from SN56 cells transiently expressing wild-type (WT) or various proline-toalanine ChAT mutants. Control cells were transfected with empty pcDNA3.1+ vector.
Anti-actin immunoblotting was completed as a loading control. (B) Proline-to-alanine
mutation reduces the steady-state protein levels of proline-mutant ChAT compared to wildtype ChAT with P17A/P19A-ChAT yielding the greatest reduction (**p≤0.01, one-way
ANOVA with Tukey’s post-hoc test, mean ± SEM, n=5). (C) Proline-to-alanine mutation
reduces cellular ChAT activity of proline-mutant ChAT compared to wild-type ChAT with
P17A/P19A-ChAT yielding the greatest reduction (***p≤0.001). Cellular activity of
mutant P17A-ChAT is reduced compared to either P14A- (*p≤0.05) or P20A-ChAT
(**p≤0.01, one-way ANOVA with Tukey’s post-hoc test, mean ± SEM, n=5).
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3.2: In vitro characterization of recombinant proline-mutant ChAT
The introduction of proline-to-alanine mutations within the N-terminal proline-rich motif
of ChAT could potentially alter ChAT protein secondary structure, thereby resulting in
reduced enzyme activity, gross structural instability, protein misfolding, and increased
protein degradation. To determine the structural stability of mutant ChAT, I purified
bacterially-expressed recombinant wild-type and proline-mutant ChAT proteins (Figure
3.4). I made the important observation that, in contrast to my results in mouse cholinergic
SN56 cells, expression levels of proline-mutant ChAT proteins (P17A-, P17A/P19A-, and
P19A-ChAT) in E. coli BL21 cells did not differ from that of wild-type ChAT protein (data
not shown). Moreover, the proline mutants behaved similarly to wild-type ChAT during
purification, yielding stable and pure recombinant protein preparations each with an
approximate molecular mass of 65-kDa in agreement with previously published results
from our laboratory (Figure 3.4a) [480]. Using these recombinant ChAT proteins, I first
determined whether proline-mutant ChAT displayed reduced in vitro enzymatic activity
similar to that observed in cells. One consideration when measuring ChAT activity from
cell lysates is that both ChAT protein expression and innate enzymatic activity factor into
these measurements, and therefore loss of cellular ChAT protein, such as that observed for
proline-mutant ChAT (Figures 3.2 and 3.3), can synergize with catalytic defects. Thus,
using equal amounts of purified recombinant wild-type and proline-mutant ChAT, I
measured the in vitro specific activity of recombinant ChAT by radioenzymatic assay
(Figure 3.4b). As anticipated, proline-to-alanine mutation of residue Pro17 either alone or
in combination with Pro19 significantly reduced in vitro specific activity of these prolinemutant ChAT proteins when compared to wild-type ChAT, with P17A/P19A-ChAT
yielding the greatest reduction (76%; p≤0.05). Surprisingly, unlike in SN56 cells, the in
vitro specific activity of P19A-ChAT did not differ from that of wild-type ChAT.
Given the surface-exposed positions of residues Pro17 and Pro19 within the human
69-kDa ChAT structure [420] it is unlikely that observed differences in in vitro specific
activity of recombinant P17A- or P17A/P19A-ChAT are due to substantial changes in
protein secondary structure or stability. To confirm this, I completed circular dichroism
(CD) analysis on purified recombinant ChAT and, importantly, observed no significant
61

Figure 3.4: Purification of bacterially-expressed recombinant wild-type and prolinemutant ChAT. (A) Representative Imperial Protein-stained SDS-PAGE gel loaded with
1.0 or 2.0 µg of purified bacterially-expressed recombinant wild-type (WT) and prolinemutant ChAT. (B) Proline-to-alanine mutation of residue Pro17 either alone or in
combination with Pro19 (i.e. P17A/P19A) reduces the in vitro specific activity of purified
recombinant mutant ChAT when compared to wild-type ChAT (***p≤0.001), with
P17A/P19A-ChAT yielding the greatest reduction compared to either P17A- (*p≤0.05) or
P19A-ChAT (***p≤0.001). No significant change in in vitro specific activity was observed
for mutant P19A-ChAT when compared to wild-type ChAT (one-way ANOVA with
Tukey’s post-hoc test, mean ± SEM, n=8).

differences in the gross protein secondary structure between the different recombinant
ChAT proteins tested (i.e. wild-type, P17A, P17A/P19A and P19A) (Figure 3.5a). To
assess the in vitro stability of recombinant wild-type and proline-mutant ChAT I performed
a thermal denaturation assay by tracking loss of helicity at 222 nm during a thermal melt
from 4 to 95C (Figure 3.5b). In support of my CD results showing the absence of gross
structural changes in the recombinant proline-mutant ChAT proteins, the denaturation
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Figure 3.5: In vitro analysis of recombinant wild-type and proline-mutant ChAT. (A)
Circular dichroism analysis of purified bacterially-expressed recombinant ChAT reveals
that both wild-type (WT) and proline-mutant ChAT are well-structured, primarily alpha
helical, and that there are no overall changes in gross protein secondary structure of prolinemutant ChAT as compared to that for wild-type ChAT. Mean residue ellipticity (MRE) was
measured over a wavelength range of 195-260 nm at 0.5 nm intervals. (B) Proline-toalanine mutation does not significantly affect the in vitro denaturation midpoint (Tm) of
recombinant P17A- (50.65 ± 0.081C), P19A- (49.45 ± 0.07C), or P17A/P19A-ChAT
(50.35 ± 0.07C) as compared to wild-type ChAT (51.15 ± 0.03C). Tm was determined by
tracking loss of helicity at 222 nm from 4-95°C.
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midpoint (Tm) of ChAT was not significantly altered by mutations involving the N-terminal
proline-rich motif as follows; wild-type (51.15 ± 0.03C), P17A-ChAT (50.65 ± 0.081C),
P17A/P19A-ChAT (50.35 ± 0.07C) and P19A-ChAT (49.45 ± 0.07C).

3.3: Proteasome inhibition increases ChAT steady-state protein levels and
cellular ChAT enzyme activity
My studies using purified recombinant ChAT suggest that mutation of the N-terminal
proline-rich motif can result in loss of enzymatic activity though does not result in gross
changes in protein secondary structure or thermal stability. Interestingly, in mammalian
SN56 cells N-terminal mutation of ChAT, including P17A/P19A and CMS-related V18M,
results in reduced ChAT protein levels (Figures 3.1 – 3.3), though the cellular mechanisms
responsible for this reduction in mutant ChAT protein levels have not been defined. Loss
of cellular protein levels can be due to enhanced protein degradation that is mediated
through either proteasomal or lysosomal proteolysis; it is currently unknown whether
ChAT is degraded by either of these cellular proteolytic pathways. Thus, I tested whether
treatment with either the proteasome inhibitor MG132 [26] or the lysosome inhibitor
chloroquine [117] could alter the steady-state protein levels and/or cellular activity of
ChAT in SN56 cells transiently expressing either wild-type (Figure 3.6a) or P17A/P19AChAT (Figure 3.6c). Importantly, following analysis of cell lysates by anti-ChAT
immunoblotting, I observed an increase in the steady-state protein levels for both wild-type
(p≤0.01; Figure 3.6b) and P17A/P19A-ChAT (p≤0.001; Figure 3.6d) in cells treated with
5 µM MG132 for 18 h when compared to cells treated with 25 µM chloroquine or to
DMSO-treated control cells. Additionally, by radioenzymatic assay MG132 treatment was
found to significantly increased the cellular activity of wild-type ChAT as compared to
treatment with either chloroquine or DMSO-control (p≤0.00; Figure 3.6e). In contrast,
treatment with either MG132 or chloroquine failed to increase the cellular activity of
P17A/P19A-ChAT (Figure 3.6e), suggesting that this mutant enzyme maintains impaired
cellular catalytic activity despite increased protein levels following MG132 treatment.
Proteasomal inhibition with MG132 was verified by accumulation of ubiquitinated
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Figure 3.6: Proteasome inhibition increases ChAT steady-state protein levels and
cellular ChAT activity. (A) Anti-ChAT immunoblots from SN56 cells transiently
expressing wild-type (WT) ChAT that were treated for 18 h with 5 µM MG132 or 25 μM
chloroquine (CQ). Proteasome inhibition by MG132 treatment or lysosome inhibition by
CQ treatment was validated by immunoblotting for the accumulation of either ubiquitinated
cellular proteins or for the lysosome-associated protein LC3B-II, respectively. Anti-actin
immunoblotting was completed as a loading control. (B) Steady-state protein levels of wildtype ChAT are increased in MG132-treated cells compared to either CQ-treated cells or
DMSO-treated control cells (**p≤0.01, one-way ANOVA with Tukey’s post-hoc test,
mean ± SEM, n=3). (C) Anti-ChAT immunoblots from SN56 cells transiently expressing
mutant P17A/P19A-ChAT that were treated and assessed as in (A). (D) Steady-state protein
levels of P17A/P19A-ChAT are increased in MG132-treated cells compared to CQ-treated
cells or DMSO-treated control cells (***p≤0.001, one-way ANOVA with Tukey’s posthoc test, mean ± SEM, n=3). (E) Cellular ChAT activity is increased in wild-type ChAT
expressing cells treated with MG132 as compared to either CQ-treated cells or DMSOtreated control cells (***p≤0.001, two-way ANOVA with Bonferroni’s post-hoc test, mean ±
SEM, n=3). Neither MG132 nor CQ treatment increased the cellular activity of mutant
P17A/P19A-ChAT.

proteins (Figure 3.6a), whereas lysosomal inhibition with chloroquine was verified by
accumulation of a lysosome-associated isoform of microtubule-associated protein 1A/1Blight chain 3 (LC3B-II; Figure 3.6c) [494].
Together these results suggest that wild-type and mutant P17A/P19A-ChAT may be
targeted for proteasomal degradation. To next determine whether CMS-related mutant
ChAT may also be regulated by the proteasome I tested whether proteasomal inhibition
could increase the steady-state protein levels of CMS-mutant ChAT, and if this may
correlate with increased cellular ChAT activity. Thus, SN56 cells transiently expressing
wild-type or CMS-related V18M-, A513T-, or T490N-ChAT were treated for 18 h with 5
µM MG132 and steady-state protein levels and cellular ChAT activity were measured. As
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shown in Figures 3.7a and 3.7b, proteasome inhibition significantly increased the steadystate protein levels of both A513T- (p≤0.05) and T490N-ChAT (p≤0.01) as compared to
DMSO-treated control cells. Though not statistically significant, I did observe a trend
towards increased steady-state protein levels of V18M-ChAT with MG132 treatment when
compared to DMSO-control (p=0.114). Lastly, MG132 treatment also increased the
cellular activity of both A513T- (p≤0.01) and T490N-ChAT (p≤0.001) as compared to
DMSO-treated control cells, but, like P17A/P19A-ChAT, had no effect on the cellular
activity of V18M-ChAT (Figure 3.7c).

3.4: Mutation of the N-terminal proline-rich motif enhances ChAT
ubiquitination
My results with MG132 suggest that cellular stability of ChAT protein is regulated through
proteasome-dependent degradation. Canonically, post-translational ubiquitination of
cellular proteins by covalent attachment of poly-Ub chains targets proteins for proteasomal
degradation [44, 60, 93]. Ubiquitination of ChAT protein has not been reported previously,
and therefore as a preliminary experiment I treated SN56 cells transient expressing either
wild-type or P17A/P19A with either 5 µM MG132 or 25 µM chloroquine for 18 h. Cells
were subsequently collected, lysed, and assayed by anti-ChAT immunoblotting for the
presence of higher molecular mass ChAT proteins that may be representative of
ubiquitinated forms of ChAT (Figure 3.8). As anticipated, I observed accumulation of
higher molecular mass ChAT proteins following treatment with 5 µM MG132 that were
not present in cells treated with either DMSO-control (Figure 3.8a, top panel, anti-ChAT
long-exposure) or in cells treated with 25 µM chloroquine (Figure 3.8b). Importantly, by
comparing the levels of higher molecular mass ChAT protein following MG132 treatment,
relative to total ChAT protein levels, I observed a greater abundance of higher molecular
mass P17A/P19A-ChAT as compared to that for wild-type ChAT (p≤0.01; Figure 3.8c).
The presence of higher molecular mass ChAT immunoreactive proteins following
proteasome inhibition suggests that ChAT may be ubiquitinated in cells. Therefore, I
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Figure 3.7: Proteasome inhibition partially restores the steady-state protein levels and
cellular activity of CMS-related ChAT mutants. (A) Anti-ChAT immunoblots from
SN56 cells transiently expressing wild-type (WT), V18M-, A513T-, or T490N-ChAT that
were treated with 5 μM MG132 for 18 h. Proteasome inhibition by MG132 treatment was
validated by immunoblotting for the accumulation of ubiquitinated cellular proteins. Antiactin immunoblotting was completed as a loading control. (B) Steady-state protein levels
of A513T- (*p≤0.05) and T490N-ChAT (**p≤0.01) are increased in MG132-treated cells
as compared to DMSO-treated control cells. Though not statistically significant, a trend
towards increased steady-state protein levels of V18M-ChAT with MG132 treatment was
observed when compared to DMSO-control (p=0.114, two-way ANOVA with Bonferroni’s
post-hoc test, mean ± SEM, n=4). (C) Cellular ChAT activity of wild-type (***p≤0.001),

A513T- (**p≤0.01), and T490N-ChAT (***p≤0.001) are increased in MG132-treated cells
compared to DMSO-treated control cells (two-way ANOVA with Bonferroni’s post-hoc test,
mean ± SEM, n=4).
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Figure 3.8: Proteasome inhibition reveals the presence of multiple higher molecular
mass ChAT proteins. Anti-ChAT immunoblots from SN56 cells transiently expressing
either wild-type (WT) or P17A/P19A-ChAT that were treated with either (A) 5 µM MG132
or (B) 25 µM chloroquine (CQ) for 18 h. Control cells were transfected with empty
pcDNA3.1+ vector. Proteasome inhibition by MG132 treatment or lysosome inhibition by
CQ treatment was validated by immunoblotting for the accumulation of either ubiquitinated
cellular proteins or the lysosome-associated protein LC3B-II, respectively. Anti-actin
immunoblotting was completed as a loading control. Treatment with MG132, but not CQ
or DMSO-control, resulted in the accumulation of multiple higher molecular mass
immunoreactive ChAT proteins in cells expressing either wild-type or P17A/P19A-ChAT.
(C) The levels of higher molecular mass ChAT proteins following MG132 treatment (A),
relative to total ChAT, is greater in cells expressing P17A/P19A-ChAT compared to wildtype ChAT (**p≤0.01, Student’s t-test, mean ± SEM, n=4).
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co-expressed wild-type or P17A/P19A-ChAT with HA-tagged ubiquitin in SN56 cells and
completed anti-HA IPs to isolate for ubiquitinated cellular proteins and to test for the
presence of ChAT protein ubiquitination. Following anti-ChAT immunoblotting from antiHA IP samples, I observed that both wild-type and P17A/P19A-ChAT are ubiquitinated,
and furthermore that treatment of cells with 5 µM MG132 for 18 h increased the recovery
of ubiquitinated ChAT compared to DMSO-treated control cells (Figure 3.9a). Importantly,
the abundance of ubiquitinated ChAT, relative to total ChAT protein levels from whole cell
lysates, is greater for P17A/P19A-ChAT. Treatment of cells with 25 µM chloroquine had
negligible effect on the recovery of ubiquitinated wild-type or P17A/P19A-ChAT (Figure
3.9b). To determine whether ubiquitination of CMS-mutant ChAT is also altered, I
completed anti-HA IPs from SN56 cells transiently co-expressing wild-type or CMSmutant ChAT with HA-tagged ubiquitin that were treated with 5 µM MG132 for 18 h. As
anticipated, by anti-ChAT immunoblotting from anti-HA IP samples I observed increased
recovery of ubiquitinated wild-type and CMS-mutant ChAT proteins following proteasome
inhibition by MG132 treatment. Importantly, the abundance of ubiquitinated ChAT,
relative to total ChAT protein levels from whole cell lysates, was greater for both V18Mand A513T-ChAT as compared to wild-type ChAT (Figure 3.9c). In support of Figure 3.1,
the ubiquitination of T490N-ChAT appears to be unchanged from that of wild-type ChAT.
To validate my results regarding enhanced ubiquitination of P17A/P19A-ChAT, I
performed anti-ChAT IPs from SN56 cells transiently co-expressing wild-type or
P17A/P19A-ChAT with HA-tagged ubiquitin that were treated for 18 h with either 5µM
MG132, 25 µM chloroquine, or with 2.5 µM lactacystin, another proteasome inhibitor [23,
25] (Figure 3.10a). Following anti-HA immunoblotting from anti-ChAT IP samples, I
observed increased recovery of ubiquitinated ChAT following proteasome inhibition by
treatment with either MG132 or lactacystin compared to DMSO-treated control cells. The
abundance of ubiquitinated ChAT, relative to total ChAT protein levels from whole cell
lysates, was greater for P17A/P19A-ChAT when compared to wild-type ChAT. Treatment
with chloroquine had no effect on recovery of ubiquitinated ChAT by anti-ChAT IP.
These initial experiments investigating ChAT ubiquitination were performed in
cells transiently overexpressing HA-tagged ubiquitin, and therefore I next wanted to
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Figure 3.9: ChAT ubiquitination is increased upon mutation of the N-terminal
proline-rich motif and in cases of CMS-related mutations. (A) Representative antiChAT and anti-HA immunoblots demonstrating that treatment of SN56 cells with 5 μM
MG132 for 18 h increases recovery of ubiquitinated wild-type (WT) and P17A/P19AChAT by anti-HA IP from cells co-expressing HA-tagged ubiquitin (HA-Ub) as compared
to DMSO-treated control cells. The abundance of ubiquitinated ChAT, relative to total
ChAT protein levels from whole cell lysates, is greater with P17A/P19A-ChAT as analyzed
by anti-ChAT immunoblotting. Control cells were transfected to transiently express ChAT
without HA-Ub or were transfected with empty pcDNA3.1+ vector. Proteasome inhibition
by MG132 treatment was validated by anti-HA immunoblotting for the accumulation of
ubiquitinated cellular proteins from whole cell lysates. Anti-actin immunoblotting was
completed as a loading control (n=5). (B) Treatment of SN56 cells with 25 μM chloroquine
(CQ) for 18 h had negligible effect on recovery of ubiquitinated wild-type or P17A/P19AChAT by anti-HA IPs from cells co-expressing HA-Ub as compared to DMSO-treated
control cells. Lysosome inhibition by CQ treatment was validated by immunoblotting for
the accumulation of the lysosome-associated protein LC3B-II (n=3). (C) Treatment of
SN56 cells with 5 μM MG132 for 18 h enhances recovery of ubiquitinated wild-type and
CMS-mutant ChAT by anti-HA IPs from cells co-expressing HA-tagged ubiquitin as
compared to DMSO-treated control cells. The abundance of ubiquitinated ChAT, relative
to total ChAT protein levels, is greater with mutant P17A/P19A-, V18M-, and A513TChAT compared to wild-type ChAT as evaluated by anti-ChAT immunoblotting (n=5).

confirm that ChAT is ubiquitinated in cells under conditions of endogenously-expressed
ubiquitin. Thus, I completed anti-ChAT IPs from SN56 cells transiently expressing only
either wild-type or P17A/P19A-ChAT and that were treated for 18 h with either 5 µM
MG132 or 25 µM chloroquine (Figure 3.10b). Following anti-ubiquitin immunoblotting
from anti-ChAT IP samples, I observed that both wild-type and mutant P17A/P19A-ChAT
are ubiquitinated in SN56 cells with endogenous ubiquitin. In addition, recovery of
ubiquitinated ChAT was again increased following proteasome inhibition by MG132, and

72

73

Figure 3.10: Anti-ChAT IP reveals enhanced ubiquitination of mutant P17A/P19AChAT. (A) Representative anti-ChAT and anti-HA immunoblots demonstrating that
proteasome inhibition by treatment of SN56 cells with 5 μM MG132 or 2.5 μM lactacystin
(Lac) for 18 h increases recovery of ubiquitinated wild-type (WT) and P17A/P19A-ChAT
following anti-ChAT IPs from cells co-expressing HA-tagged ubiquitin (HA-Ub) as
compared to DMSO-treated control cells. Distinct bands in anti-HA immunoblots
corresponding to different molecular mass species of ubiquitinated ChAT are indicated by
red arrows. The abundance of ubiquitinated ChAT, relative to total ChAT protein levels
from whole cell lysates, is greater with P17A/P19A-ChAT compared to wild-type ChAT.
Treatment with 25 μM CQ for 18 h had no effect on recovery of ubiquitinated ChAT.
Proteasome inhibition by MG132 treatment or lysosome inhibition by CQ treatment was
validated by immunoblotting from whole cell lysates for the accumulation of either
ubiquitinated cellular proteins (i.e. HA-Ub) or for the lysosome-associated protein LC3BII, respectively. Anti-actin immunoblotting was completed as a loading control (n=5). (B)
Ubiquitination of P17A/P19A-ChAT with endogenous ubiquitin is enhanced compared to
wild-type ChAT in SN56 cells transfected to transiently express only either wild-type or
P17A/P19A-ChAT. Ubiquitinated ChAT was analyzed by anti-ubiquitin immunoblotting
from anti-ChAT IPs samples. Proteasome inhibition by 5 µM MG132 treatment for 18 h
increases recovery of ubiquitinated ChAT compared to DMSO-control, whereas treatment
with 25 μM CQ for 18 h had no effect on recovery of ubiquitinated ChAT. Distinct bands
in anti-ubiquitin immunoblots corresponding to different molecular mass species of
ubiquitinated ChAT are indicated by red arrows. Control cells were transfected with empty
pcDNA3.1+ vector (n=4).

furthermore that the abundance of ubiquitinated ChAT, relative to total ChAT protein levels
from whole cell lysates, is greater for P17A/P19A-ChAT when compared to wild-type
ChAT. Of importance, these results with endogenously-expressed ubiquitin reflect my
earlier results using transient co-expression of ChAT with HA-tagged ubiquitin.
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3.5: ChAT protein can be targeted for proteasomal degradation by both
K48-dependent and K48-independent polyubiquitination
My results with the proteasome inhibitors MG132 and lactacystin and either HA-tagged or
endogenously-expressed ubiquitin suggest that ChAT protein stability is regulated by the
ubiquitin-proteasome system. As illustrated in Figure 1.4, proteins targeted for proteasomedependent degradation are modified by E3 ubiquitin ligases through covalent attachment
of monomeric ubiquitin onto lysine residues that then serves as a primer for construction
of K48-linked poly-Ub chains by addition of free ubiquitin onto residue Lys48 of substratebound ubiquitin. Subsequently, K48-linked poly-Ub chains are directly recognized by the
26S-proteasome, resulting in proteolysis of these polyubiquitinated proteins [44, 60, 93].
In addition to Lys48, ubiquitin contains six other lysine residues (K6, 11, 27, 29, 33 and 63)
that can be used for formation of poly-Ub chains that differ from K48-linked chains [44,
50]. These alternative poly-Ub chains can have non-proteolytic roles, with K63-linked
chains best known to regulate endosomal substrate trafficking, receptor endocytosis, kinase
activation and DNA repair [44, 51].
My initial work investigating ChAT ubiquitination was performed under conditions
of proteasome inhibition by treatment of cells with either MG132 or lactacystin, and thus I
wanted to further characterize ChAT ubiquitination in SN56 cells having active and
functional proteasomes. To this end, SN56 cells transiently expressing either wild-type
(Figure 3.11a) or P17A/P19A-ChAT (Figure 3.11b) were co-transfected to express HAtagged wild-type ubiquitin or different HA-tagged ubiquitin mutants that either cannot form
poly-Ub chains (K0), that can only form K48-linked chains (K48), or that can only form
non-K48-linked poly-Ub chains (i.e. K11, K48R, or K63) and anti-HA IPs were completed
to isolate ubiquitinated cellular proteins. Following anti-ChAT immunoblotting from antiHA IP samples, I observed that recovery of polyubiquitinated wild-type and P17A/P19AChAT was reduced in SN56 cells that co-express K48-ubiqutin as compared to wild-typeubiquitin. Alternatively, prevention of K48-linked polyubiquitination of ChAT by coexpression of either K0-, K11- (only K11-linked chains), or K48R-ubiquitin increased
recovery of polyubiquitinated wild-type and P17A/P19A-ChAT in anti-HA IPs. Co-
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Figure 3.11: Wild-type and P17A/P19A-ChAT can be targeted for proteasomal
degradation by both K48-dependent and K48-independent polyubiquitination.
Recovery of ubiquitinated wild-type (WT) ChAT (A) (n=3) and P17A/P19A-ChAT (B)
(n=3) is reduced in SN56 cells co-expressing HA-tagged mutant ubiquitin (Ub)-K48 (only
K48-linked polyubiquitin chains) compared to wild-type HA-Ub as assessed by anti-ChAT
immunoblotting following anti-HA IPs. Conversely, recovery of wild-type and mutant
P17A/P19A-ChAT is increased in cells with co-expression of HA-tagged Ub-K0 (no
polyubiquitin linkages) or either Ub-K11 or Ub-K48R that are unable to form K48-linked
polyubiquitin chains. Control cells were transfected with empty pcDNA3.1+ vector. Antiactin immunoblotting from whole cell lysates was completed as a loading control. (C)
Treatment with 5 μM MG132 for 18 h increases recovery of both K48-linked and non-K48linked (K48R) polyubiquitinated wild-type ChAT and P17A/P19A-ChAT in SN56 cells
co-expressing either HA-Ub-K48 or HA-Ub-K48R compared to DMSO-treated control
cells. Cellular ChAT ubiquitination was assessed by anti-ChAT immunoblotting following
anti-HA IPs. Proteasome inhibition by MG132 treatment was validated by anti-HA
immunoblotting (i.e. HA-Ub) for the accumulation of ubiquitinated cellular proteins from
whole cell lysates (n=4).

-expression with K63-ubiquitin (only K63-linked chains) had no effect on the recovery of
polyubiquitinated wild-type or P17A/P19A-ChAT as compared to co-expression with wildtype-ubiquitin. Closer examination of ubiquitinated P17A/P19A-ChAT from anti-HA IP
samples (Figure 3.11b, top panel, anti-ChAT immunoblot) revealed an additional higher
molecular mass ubiquitinated ChAT species in samples co-expressing K0, K11 or K48Rubiquitin when compared to cells co-expressing wild-type ubiquitin. This additional
ubiquitinated ChAT species suggests that increased P17A/P19A-ChAT ubiquitination may
be due to multi-ubiquitination of additional and/or alternative lysine residues within mutant
ChAT that may differ from those utilized for the basal ubiquitination of wild-type ChAT.
These results suggest that ChAT protein degradation by the proteasome is regulated
through K48-linked polyubiquitination. To confirm this, we treated cells for 18 h with 5
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µM MG132 that were transiently co-expressing either wild-type or P17A/P19A-ChAT with
HA-tagged wild-type, K48-, or K48R-ubiquitin (Figure 3.11c). As anticipated, proteasome
inhibition increased the recovery of K48-linked polyubiquitinated ChAT. Interestingly,
MG132 treatment also enhanced the recovery of non-K48-linked polyubiquitinated ChAT
when ChAT was co-expressed with K48R-ubiquitin. The abundance of both K48-linked
and non-K48-linked polyubiquitinated ChAT, relative to total ChAT protein levels from
whole cell lysates, appears greater for P17A/P19A-ChAT compared to wild-type ChAT.

3.6: ChAT protein half-life is reduced upon mutation of the N-terminal
proline-rich motif and can be increased by proteasome inhibition
My assessment of ChAT ubiquitination suggests that enhanced ubiquitination, and resultant
enhanced proteasome-dependent degradation, may be responsible for the observed
reduction in the steady-state protein levels of P17A/P19A-ChAT. To confirm that the rate
of degradation of P17A/P19A-ChAT is increased, I investigated whether the protein halflife of P17A/P19A-ChAT is reduced in SN56 cells when proteasomes are functional. To
measure protein half-life, I developed a novel fluorescent strain-promoted alkyne-azide
cycloaddition (SPAAC) pulse-chase procedure that utilizes non-radioactive labeling and
detection reagents (Figure 3.12). This protocol is an adaptation on classical 35S-methionine
pulse-chase labeling and is based on metal-free “click” chemistry whereby azide-labeled
compounds react specifically and efficiently with strained cyclooctynes, by 1,3-dipolar
cycloaddition, to form stable 1,2,3-triazole conjugates without the need of a metal catalyst
[495-496]. While SPAAC reactions have been used previously both in vitro and in vivo to
measure global changes in protein synthesis [497-500], my study is the first to apply the
use of SPAAC reactions to measure half-life of a specific cellular protein. Briefly, in my
protocol proteins are live-labeled (pulsed) with L-azidohomoalanine (AHA), a
biorthogonal methionine analog that contains a reactive azide moiety, under methioninefree conditions and then chased with excess methionine. AHA-labeled proteins are then
detected by reaction with 4-dibenzocyclooctynol (DIBO), a strained cyclooctyne, that
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Figure 3.12: Schematic overview of biorthogonal strain-promoted alkyne-azide
cycloaddition (SPAAC) pulse-chase for fluorescent determination of protein half-life.
(1) Briefly, proteins are live-labeled (pulsed) with L-azidohomoalanine (AHA), a
biorthogonal methionine analog that contains a reactive azide moiety, under methioninefree conditions and then (2) chased with medium containing methionine for desired times
(e.g. up-to 24 hours). (3) Cell are then collected, lysed, and (4) immunoprecipitation for a
protein-of-interest (e.g. ChAT) is completed. (5) AHA-labeled proteins are reacted with the
strained cyclooctyne 4-dibenzocyclooctynol (DIBO) that is modified with a fluorescent
tetramethylrhodamine (TAMRA) probe to form stable fluorescent triazole conjugates. (6)
AHA/TAMRA-labeled proteins are resolved on SDS-PAGE gels, and (7a) TAMRA
fluorescence is detected in-gel at an excitation/emission of 555/580 nm. In addition, (7b)
AHA/TAMRA-labeled proteins can be transferred to PVDF membranes and standard
immunoblotting can be completed for downstream analysis.
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is modified with a fluorescent tetramethylrhodamine (TAMRA) probe. Importantly,
treatment of HEK293 cells with AHA has been shown to be non-toxic, resulting in highlyspecific labeling of newly-synthesized proteins that does not affect ubiquitination or protein
degradation of these AHA-labeled proteins [498].
Using this pulse-chase protocol in SN56 cells transiently expressing either wild-type
or P17A/P19A-ChAT, I detected the global progressive loss of fluorescent AHA/TAMRAlabeled proteins from whole cell lysates during the 0-24 h chase period in the absence of
changes in total protein levels as measured in parallel by anti-actin immunoblotting (Figure
3.13a). Additionally, following anti-ChAT IP from ChAT-expressing SN56 cells livelabeled with AHA, I also observed progressive loss of fluorescent AHA/TAMRA-labeled
ChAT during the 0-24 h chase period. Importantly, the decline in protein levels of
immunoprecipitated AHA/TAMRA-labeled P17A/P19A-ChAT is more rapid than that of
wild-type ChAT. By quantifying the fluorescence intensities of AHA/TAMRA-labeled
ChAT, I determined that the protein half-life of P17A/P19A-ChAT (2.2 h) is significantly
reduced by ~10-fold compared to wild-type ChAT (19.7 h; F(1,41)=110.043, p≤0.0001;
Figure 3.13b). A 24 h time point was not included for the quantification of P17A/P19AChAT half-life as the fluorescence intensity was indistinguishable from background.
To validate the results of my novel SPAAC pulse-chase assay, I performed a
cycloheximide (CHX)-chase assay on SN56 cells transiently expressing either wild-type or
P17A/P19A-ChAT. CHX is a potent, though toxic, inhibitor of protein biosynthesis
commonly used for the molecular determination of protein half-life [501]. Thus, by antiChAT immunoblotting from ChAT-expressing SN56 cells that were treated with 100 µg/ml
CHX for 2 – 8 h (Figure 3.14a) I determined that the cellular half-life of P17A/P19A-ChAT
(4 h) is again ~10-fold shorter than that of wild-type ChAT (45 h; F(1,46)=36.802,
p≤0.0001; Figure 3.14b). Although the absolute half-life values determined for wild-type
ChAT and P17A/P19A-ChAT by these two methods differ, importantly they both revealed
that the protein half-life of P17A/P19A-ChAT is ~10% that of wild-type ChAT.
My earlier results show that proteasome inhibition by MG132 treatment resulted in
increased steady-state protein levels of both wild-type and P17A/P19A-ChAT (Figure 3.6).
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Figure 3.13: SPAAC pulse-chase reveals that ChAT protein half-life is reduced upon
mutation of the N-terminal proline-rich motif. (A) Fluorescent detection of
immunoprecipitated (IP) AHA/TAMRA-labeled wild-type (WT) and P17A/P19A-ChAT
following SPAAC pulse-chase (Figure 3.12) from transiently transfected SN56 cells.
Control cells were incubated without AHA (i.e. unlabeled). Fluorescent AHA/TAMRAlabeled proteins from either whole cell lysates or anti-ChAT IPs were detected in resolved
SDS-PAGE gels at an Ex/Em of 555/580 nm. Anti-ChAT and anti-actin immunoblotting
was completed on AHA/TAMRA-labeled samples for downstream data analysis and as
loading controls. (B) Protein half-life of P17A/P17A-ChAT (2.2 h) is reduced compared to
wild-type ChAT (19.7 h). ChAT fluorescence intensities from (A) were plotted on a semilogarithmic scale and linear regression was completed. The slopes of decay for wild-type
and P17A/P19A-ChAT were significantly different: F(1,41)=110.043, p≤0.0001, n=5.
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Figure 3.14: Validation of SPAAC pulse-chase by cycloheximide (CHX)-chase assay.
(A) SN56 cells, transiently expressing either wild-type (WT) or P17A/P19A-ChAT, were
treated with 100 μg/ml CHX for indicated time points (hours) and anti-ChAT
immunoblotting was completed. Anti-actin immunoblotting was completed as a loading
control. (B) Protein half-life of P17A/P17A-ChAT (4 h) is reduced as compared to wildtype ChAT (45 h). Steady-state ChAT protein levels from (A) were plotted on a semilogarithmic scale and linear regression completed. The slopes of decay for wild-type and
P17A/P19A-ChAT were significantly different: F(1,46) = 36.802, p≤0.0001, n=5.

Therefore, I tested next whether proteasome inhibition would correlate with an increase in
ChAT protein half-life. To determine ChAT protein half-life during proteasome inhibition,
I performed SPAAC pulse-chase on SN56 cells transiently expressing either wild-type
(Figure 3.15a) or P17A/P19A-ChAT (Figure 3.15b) that were treated with 5 µM MG132
throughout both the 4 h pulse and 24 h chase periods. Following anti-ChAT IP from AHAlabeled SN56 cells and quantification of fluorescence intensities of immunoprecipitated
AHA/TAMRA-label ChAT, I observed that proteasome inhibition by MG132 treatment
prevented the decay of wild-type ChAT protein as compared to DMSO-treated control cells
(half-life = 22.5 h; Figure 3.15c). Additionally, the protein half-life of P17A/P19A-ChAT
was also increased during MG132 treatment (16.8 h) as compared to
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Figure 3.15: Proteasome inhibition increase ChAT protein half-life. Fluorescent
detection of immunoprecipitated (IP) AHA/TAMRA-labeled wild-type (WT; A) or
P17A/P19A-ChAT (B) following SPAAC pulse-chase from transiently transfected SN56
cells that were treated with either DMSO-control or 5 µM MG132 throughout both the 4 h
AHA-labeling and the 24 h chase periods. Control cells were incubated without AHA (i.e.
unlabeled). Fluorescent AHA/TAMRA-labeled proteins were detected in resolved SDSPAGE gels at an Ex/Em of 555/580 nm. Anti-ChAT and anti-actin immunoblotting was
completed on AHA/TAMRA-labeled samples for downstream data analysis and as loading
controls. (C) Proteasome inhibition by MG132 treatment increased the protein half-life of
wild-type ChAT (no protein decay) as compared to DMSO-treated control cells (22.5 h).
Wild-type ChAT fluorescence intensities from (A) were plotted on a semi-logarithmic scale
and linear regression was completed. The slopes of decay for DMSO- and MG132-treated
cells were significantly different from each other: F(1,46) = 4.79241, p≤0.05, n=5. (D)
Proteasome inhibition by MG132 treatment increased the protein half-life of mutant
P17A/P19A-ChAT (16.6 h) as compared to DMSO-control (2.2 h). ChAT fluorescence
intensities from (B) were plotted on a semi-logarithmic scale and linear regression was
completed. The slopes of decay for DMSO and MG132-treated cells were significantly
different from each other: F(1,41)=18.9864, p≤0.0001, n=5.

DMSO-control (2.2 h; Figure 3.15d). No 24 h time point was included for protein half-life
quantification from DMSO-treated control cells expressing P17A/P19A-ChAT as the
fluorescence intensity was indistinguishable from background.

3.7: Identification of the heat shock proteins HSP70 and HSP90 as
putative ChAT protein interactors
To summarize my findings thus far, I initially sought to identify a functional role of the Nterminal proline-rich motif of ChAT and have shown that both cellular ChAT protein levels
and enzyme activity are dramatically reduced following alteration of this motif, particularly
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for the P17A/P19A and CMS-related V18M mutations. Furthermore, I also demonstrated
for the first time that cellular degradation of ChAT protein is modulated through the
ubiquitin-proteasome system, and that ubiquitination of mutant ChAT is enhanced. The
mechanism/s responsible for basal ChAT ubiquitination or enhanced ubiquitination of
catalytically-deficient ChAT have not been elucidated (Figure 3.16) [502].
Regulation of protein stability through the ubiquitin-proteasome system involves a
complex network of protein chaperones, E3 ubiquitin ligases, and other cellular proteostatic
factors. Therefore, to identify putative protein-interactors that may regulate ChAT protein
stability I utilized the BioID proteomics approach [483] to screen for direct and proximal
ChAT-interacting proteins. Briefly, in the BioID protocol cells expressing fusions proteins
consisting of a protein-of-interest (e.g. ChAT) fused to the 35-kDa HA-tagged promiscuous
biotin ligase BirA-R118G-HA (BirA*) are treated with exogenous biotin to allow for
proximity-dependent biotinylation of proximal and directly-interacting proteins. Cells are
then lysed, streptavidin pull-downs (PDs) are completed, and biotinylated proteins can be
analyzed by SDS-PAGE and identified by mass spectrometry (Figure 3.17a). To optimize
this protocol for my studies I chose to compare wild-type ChAT to P17A/P19A-ChAT as
this mutation had the greatest impact on ChAT ubiquitination and degradation following
modification of the proline-rich motif [502]. Thus, HEK293 cells transiently expressing
either wild-type- or P17A/P19A-ChAT-BirA* fusion proteins were treated with either
vehicle-control (water) or 50 µM biotin for 24 h to allow proximity-dependent biotinylation
of ChAT-interacting proteins. Subsequent analysis of protein samples from whole cell
lysates by anti-ChAT and anti-HA immunoblotting revealed expression of ChAT-BirA*
fusion proteins with an apparent molecular mass of ~100 kDa as compared to untagged
ChAT proteins at ~70 kDa (Figure 3.17b, top panels). The steady-state protein levels of
P17A/P19A-ChAT-BirA* was less than that of wild-type-ChAT-BirA* in agreement with
my previous results demonstrating enhanced ubiquitination and degradation of mutant
P17A/P19A-ChAT (Figures 3.10 and 3.13) [502]. Furthermore, the BioID-dependent
biotinylation of cellular proteins was analyzed by blotting of protein samples obtained from
streptavidin PDs with HRP-conjugated streptavidin (Strep-HRP). As anticipated, I detected
biotinylation of multiple cellular proteins in samples from biotin-treated HEK293 cells
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Figure 3.16: Model for the regulation of ChAT protein stability by the ubiquitinproteasome system. ChAT synthesizes the neurotransmitter acetylcholine using acetylCoA (AcCoA) and choline as substrates in cholinergic neurons. Steady-state protein levels
of wild-type (WT) ChAT are regulated by ubiquitination (Ub) and subsequent degradation
by the 26S-proteasome. Ubiquitination and proteasomal degradation of ChAT is enhanced
upon mutation of the N-terminal proline-rich motif of ChAT (i.e. P17A/P19A) as well as
for the CMS-related V18M- and A513T-ChAT mutants. These mutations also reduce the
cellular catalytic activity of mutant ChAT, thereby resulting in a synergistic impairment in
cellular acetylcholine production (red hashed arrow).
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Figure 3.17: Proximity-dependent biotin identification (BioID) for the determination
of novel ChAT protein-protein interactions. (A) Overview of BioID protocol. Briefly, a
protein of interest (e.g. ChAT), fused to the promiscuous biotin ligase BirA-R118G-HA
(BirA*), is expressed in mammalian cells (e.g. HEK293 cells). Upon the addition of
exogenous biotin to live-cell growth media, proteins that are either proximal-to or directly
bound-to BirA* fusion protein will be live-labeled with biotin. Cells are then lysed, and
biotinylated proteins are subsequently purified by streptavidin pull-down, resolved on
SDS-PAGE gels, and identified by mass spectrometry. (B) Optimization of BioID in
HEK293 cells transiently expressing wild-type (WT) or P17A/P19A-ChAT fused to HAtagged BirA*. Control cells were transfected with empty pcDNA3.1+ vector or plasmids
encoding either untagged ChAT or unfused BirA*. Cells were treated for 24 h with 50 µM
biotin to induce proximity-dependent biotinylation of ChAT-interacting cellular proteins
or with vehicle-control (water). Protein samples were prepared from both whole cell lysates
and from streptavidin pull-downs (PD: Strep), resolved on SDS-PAGE gels, and transferred
to PVDF membranes. Biotinylated cellular proteins were detected by blotting with HRPconjugated streptavidin (Strep-HRP). ChAT-BirA* fusion proteins were detected by antiChAT and anti-HA immunoblotting. Anti-actin immunoblotting from whole cell lysates
was completed as a loading control (n=2).

that expressed ChAT-BirA* fusion proteins, but not in control cells grown in the absence
of biotin (vehicle) or in cells expressing untagged ChAT (Figure 3.17b). Importantly, the
abundance of several of these biotinylated proteins was different in cells expressing
P17A/P19A-ChAT-BirA* as compared to wild-type-ChAT-BirA*; an ~70 kDa protein was
notably enriched in cells expressing P17A/P19A-ChAT-BirA*.
My initial BioID experiments suggest that multiple proteins interact with and may
differentially regulate P17A/P19A-ChAT as compared to wild-type ChAT. My primary
goal for using BioID was to identify putative ChAT protein-interactors that may be
responsible for the enhanced degradation of mutant ChAT observed earlier, and thus
biotinylated proteins enriched in cells expressing P17A/P19A-ChAT-BirA* were of prime
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interest to identify. Therefore, I completed a large-scale BioID experiment in HEK293 cells
expressing either wild-type-ChAT-BirA* or P17A/P19A-ChAT-BirA* and, following
streptavidin PDs, biotinylated proteins were visualized on a silver stained SDS-PAGE gel
(Figure 3.18). Two proteins of interest that were enriched in cells expressing P17A/P19AChAT-BirA* with apparent molecular masses of ~70 kDa and ~90 kDa were excised from
the gel, along with an intense band at ~100 kDa correlating with the estimated molecular
mass of the putative P17A/P19A-ChAT-BirA* fusion protein. In-gel protein samples were
digested with trypsin and identified by either matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF-MS) and/or by liquid chromatographyelectrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). Initial identification
by MALDI-TOF-MS revealed the ~70 kDa protein as the heat shock protein HSP70 and,
as anticipated, the ~100 kDa protein as ChAT-BirA* (Figure 3.18). By comparing the
peptides masses generated by MALDI-TOF-MS to the NCBI protein database I obtained a
30% sequence coverage for human HSP70 (20 peptides; Figure 3.19). The ~100 kDa
protein analyzed from cells expressing P17A/P19A-ChAT-BirA* was confirmed as ChATBirA* with a sequence coverage for human 69-kDa ChAT and bacterial BirA of 31% (20
peptides) and 42% (16 peptides) respectively (Figure 3.20). My data did not contain
peptides with masses that matched tryptic peptides that would cover the mutated residues
in the P17A/P19A-ChAT sequence. Identification of the BioID-enriched ~90 kDa protein
could not be achieved by MALDI-TOF-MS due to low sample yield, though subsequently
by using the more sensitive LC-ESI-MS/MS approach I was able to identify this protein as
HSP90 with a 16% sequence coverage (10 peptides; Figure 3.21). Furthermore, by using
LC-ESI-MS/MS I obtained a greater sequence coverage for HSP70 of 34% (25 peptides;
Figure 3.22). Importantly, tryptic peptides with masses indicating the addition of biotin
were detected for both HSP70 and ChAT-BirA* by MALDI-TOF-MS; these peptides
contained lysine residue that could be sites for biotinylation by BirA*.
To verify these proteins identified by MALDI and LC-ESI-MS/MS following
BioID, I performed anti-HSP70 and anti-HSP90 immunoblotting on biotinylated protein
samples obtained by streptavidin PDs from biotin-treated HEK293 cells expressing either
wild-type-ChAT-BirA* or P17A/P19A-ChAT-BirA* (Figure 3.23). Importantly, as
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Figure 3.18: Identification of the heat shock proteins HSP70 and HSP90 as novel
ChAT protein-interactions by BioID. Streptavidin pull-down samples prepared from
biotin-treated HEK293 cells expressing either wild-type (WT)-ChAT-BirA* or
P17A/P19A-ChAT-BirA* fusion proteins that were resolved and visualized on a silverstained SDS-PAGE gels. Two biotinylated proteins (~70 kDa and ~90 kDa) that were
enriched in samples expressing P17A/P19A-ChAT-BirA* were identified by MALDITOF-MS or LC-ESI-MS/MS as HSP70 and HSP90, respectively. An ~100 kDa protein
correlating with the estimated molecular mass of the P17A/P19A-ChAT-BirA* fusion
protein was confirmed by MALDI-TOF-MS as ChAT-BirA*. Biotin-treated control cells
were transfected to express untagged wild-type ChAT (n=1).
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Figure 3.19: MALDI-TOF-MS data for HSP70 following BioID. (A) Peptide coverage
map of human heat shock 70 kDa protein 1B (HSP70; NCBIprot database, RefSeq:
NP_005337.2) obtained by MALDI-TOF-MS from P17A/P19A-ChAT-BirA* BioID
samples (Figure 3.18). A total sequence coverage of 30% was obtained. (B) Peptide list of
20 unique peptides with indicated amino acid modifications and relevant MALDI-TOFMA data for HSP70. One peptide (bordered) was identified with a mass-shift correlating
with biotinylation of residue Lys507 of human HSP70.
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Figure 3.20: MALDI-TOF-MS data for ChAT-BirA* fusion protein following BioID.
(A) Peptide coverage map of human 69-kDa choline acetyltransferase (ChAT; NCBIprot
database; GenBank: AAI30618.1) obtained by MALDI-TOF-MS from P17A/P19AChAT-BirA* BioID samples (Figure 3.18). A total sequence coverage of 33% was obtained
for human 69-kDa ChAT. (C) Peptide coverage map of bacterial BirA (NCBIprot database;
GenBank: AEP13897.1) obtained by MALDI-TOF-MS from P17A/P19A-ChAT-BirA*
BioID samples. A total sequence coverage of 42% was obtained for bacterial BirA. Peptide
lists of either 23 (B; ChAT) or 16 (D; BirA) unique peptides with indicated modifications
and relevant MALDI-TOF-MA data. One ChAT peptide (B; bordered) was identified with
a mass-shift correlating with biotinylation of residue Lys4 of human ChAT.

anticipated I observed PD of endogenous HSP70 and HSP90 from biotin-treated cells
expressing P17A/P19A-ChAT-BirA*; streptavidin PD of these HSPs was not consistently
observed from cells expressing wild-type-ChAT-BirA* (2 of 4 trials). As controls, neither
HSP70 nor HSP90 were visualized in immunoblots prepared from streptavidin PDs from
biotin-treated control cells that expressed untagged ChAT. In addition, anti-ChAT and antiHA immunoblots revealed recovery of ChAT-BirA*, but not untagged ChAT, following
streptavidin PD, suggesting that ChAT-BirA* can undergo self-biotinylation. This has been
reported in other BioID studies for BirA*-tagged proteins [483] and confirms my MALDITOF-MS analysis of biotinylated P17A/P19A-ChAT-BirA* (Figure 3.20).

3.8: Co-immunoprecipitation of ChAT with HSPs is altered by mutation
of N-terminal proline-rich motif of ChAT
HSPs, such as HSP70 and HSP90, are well-characterized molecular chaperones capable of
performing protein triage decisions by either promoting the folding and stabilization of
cellular proteins or by targeting terminally misfolded proteins for degradation [118, 135].
As such, these HSPs may represent molecular chaperones involved in the stabilization of
ChAT and/or that may promote degradation of mutant or misfolded ChAT. Therefore, to
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Figure 3.21: LC-ESI-MS/MS data for HSP90 following BioID. (A) Peptide coverage
map of human heat shock protein HSP 90-beta isoform c (HSP90; NCBInr_new database,
RefSeq: NP_001258901.1) obtained by LC-ESI-MS/MS from P17A/P19A-ChAT-BirA*
BioID samples (Figure 3.18). A total sequence coverage of 16% with 10 unique peptides
with indicated modifications was obtained. (B) LC-ESI-MS/MS peptide list for human
HSP90 with relevant MS data following ChAT-BirA* BioID.

to verify these putative BioID interactions between ChAT and endogenous HSP70 and
HSP90, I performed co-IP assays from HEK293 cells expressing either untagged wild-type
or P17A/P19A-ChAT (Figure 3.24a). Interestingly, I was able to observe both HSP70 and
HSP90 in anti-ChAT co-IP samples from cells expressing either wild-type or P17A/P19AChAT. Furthermore, in addition to HSP70 and HSP90, I also found that endogenous
HSC70, a constitutively-expressed HSP that has analogous chaperone function and shares
similar substrate proteins to that of HSP70 [194], can co-IP with ChAT (Figure 3.24a).
Importantly, by comparing the levels of ChAT protein to that of HSPs in anti-ChAT co-IP
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Figure 3.22: LC-ESI-MS/MS data for HSP70 following BioID. (A) Peptide coverage
map of human heat shock 70 kDa protein 1B (HSP70; NCBInr_new database, RefSeq:
NP_005337.2) obtained by LC-ESI-MS/MS from P17A/P19A-ChAT-BirA* BioID
samples (Figure 3.18). A total sequence coverage of 34% with 25 unique peptides with
indicated modifications was obtained. (B) LC-ESI-MS/MS peptide list for human HSP70
with relevant MS data following ChAT-BirA* BioID.
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Figure 3.23: Immunoblot verification of putative ChAT interacting proteins following
BioID. Confirmation of endogenous HSP70 and HSP90 as putative ChAT-interacting
proteins by immunoblotting of protein samples following streptavidin pull-down (PD:
Strep). HEK293 cells, transiently expressing HA-tagged wild-type (WT)-ChAT-BirA* or
P17A/P19A-ChAT-BirA*, were treated for 24 h with 50 µM of exogenous biotin. Biotintreated control cells were transfected with empty vector or with vectors encoding for
untagged ChAT proteins. Biotinylated cellular proteins from whole cell lysates were
detected with HRP-conjugated streptavidin (Strep-HRP). ChAT-BirA* fusion proteins
were detected by anti-ChAT and anti-HA immunoblotting. Anti-actin immunoblotting
from whole cell lysates was completed as a loading control (n=4).
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Figure 3.24: Co-immunoprecipitation of ChAT with HSC/HSP70 and HSP90 from
HEK293 cells. (A) Immunoblots showing co-immunoprecipitation (co-IP) of ChAT with
endogenous HSC70, HSP70, and HSP90 following anti-ChAT co-IP from HEK293 cells
transiently expressing either wild-type (WT) or P17A/P19A-ChAT. Control cells were
transfected with empty pcDNA3.1+ vector. Anti-actin immunoblotting from whole cell
lysates was completed as a loading control. Co-IP of P17A/P19A-ChAT with HSP70 (B),
HSP90 (C), and HSC70 (D) is greater than that of wild-type ChAT (***p≤0.001, Student’s
t-test, mean ± SEM, n=4).
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samples, I found enhanced association of mutant P17A/P19A-ChAT with endogenous
HSP70 (p≤0.001; Figure 3.24b), HSP90 (p≤0.001; Figure 3.24c) and HSC70 (p≤0.001;
Figure 3.24d) relative to wild-type ChAT.
My initial BioID and co-IP experiments were performed in HEK293 cells as these
cells are easily transfected to transiently express heterologous proteins. As my earlier
experiments assessing ChAT ubiquitination and degradation were carried out with mouse
cholinergic SN56 cells, I next confirmed my novel results by performing anti-ChAT co-IPs
from SN56 neural cells expressing either wild-type or P17A/P19A-ChAT. Furthermore, to
assess whether enhanced association of ChAT with HSC/HSP70 and HSP90 would also be
seen in selected CMS-related ChAT mutant proteins, I also evaluated anti-ChAT co-IPs
from SN56 cells expressing either V18M- or A513T-ChAT. These two catalyticallydeficient CMS-related mutations were selected as they were shown earlier in my study to
enhance the ubiquitination and degradation of these ChAT mutant proteins [Figures 3.1,
3.7, and 3.9]. Importantly, I detected both endogenous HSC70 and HSP90 in anti-ChAT
co-IP samples from SN56 cells expressing either wild-type or mutant ChAT proteins
(Figure 3.25a). Unlike HEK293 cells, I did not observe constitutive expression of HSP70
in whole cell lysates from SN56 cells. By comparing the relative levels of ChAT proteins
to that of endogenous HSC70 in anti-ChAT co-IP samples, I found enhanced association
of both P17A/P19A- (p≤0.001) and V18M-ChAT (p≤0.05), but not A513T-ChAT, with
HSC70 as compared to wild-type ChAT (Figure 3.25b). Interestingly, there were no
significant differences in association of mutant ChAT with HSP90, but there was a trend
towards enhanced association of HSP90 with P17A/P17A-ChAT (p=0.09; Figure 3.25c).
Lastly, to confirm whether endogenous HSC70 and HSP90 interact with ChAT in
situ, I performed a proximity ligation assay (PLA) in SN56 cells transiently expressing
wild-type ChAT. As predicted, I observed in situ interaction of wild-type ChAT with
endogenous HSC70 and HSP90 in cells (Figure 3.26). Confocal images show that the
ChAT-HSP PLA complexes are predominantly cytoplasmic in agreement with the
previously reported subcellular distribution of human 69-kDa ChAT [414]. As controls,
PLA complexes were not observed in SN56 cells that were transfected with empty vector
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Figure 3.25: Co-immunoprecipitation of ChAT with HSC70 and HSP90 from mouse
cholinergic SN56 cells. (A) Immunoblots showing co-immunoprecipitation (co-IP) of
ChAT with endogenous HSC70 and HSP90 following anti-ChAT co-IP from mouse
cholinergic SN56 cells expressing wild-type (WT), P17A/P19A-ChAT, or the CMS-related
mutants V18M- or A513T-ChAT. Control cells were transfected with empty pcDNA3.1+
vector. Anti-actin immunoblotting from whole cell lysates was completed as a loading
control. (B) Co-IP of P17A/P19A-ChAT (***p≤0.001) and V18M-ChAT (*p≤0.05), but
not A531T-ChAT, with HSC70 is greater than that of wild-type ChAT (mean ± SEM, n=5).
(C) While there was a trend toward increased HSP90 interaction with P17A/P19A-ChAT
(p=0.09), no significant differences were observed for HSP90 interaction with mutant
ChAT as compared to wild-type ChAT in SN56 cells (mean ± SEM, n=5). Statistical
analysis for (B) and (C) was performed by one-way ANOVA with Dunnett’s post-hoc test.
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Figure 3.26: In situ interaction of ChAT with endogenous HSC70 and HSP90.
Detection of in situ ChAT-HSP interactions with HSC70 and HSP90 by proximity ligation
assay (PLA) in SN56 cells transiently expressing heterologous wild-type (WT) ChAT.
Formalin-fixed cells were first co-labeling with goat anti-ChAT together with either mouse
anti-HSC70 or mouse anti-HSP90 primary antibodies, then incubated with oligonucleotidelinked secondary antibodies. Following DNA ligation and DNA amplification using the
Duolink In Situ Orange Kit (Sigma), in situ ChAT-HSP interactions were imaged by
confocal microscopy at an excitation/emission of 554/576 nm. Positive in situ ChAT-HSP
interactions where visualized and are presented as fluorescent red dots while nuclei were
stained with DAPI (blue). Control cells were either transfected with empty pcDNA3.1+
vector or had primary antibodies omitted from the assay (No 1o antibodies). Images are
representative of 3 independent experiments; scale bars are 10 µm.
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and incubated with primary antibodies, or when primary antibodies recognizing ChAT,
HSC70, or HSP90 were omitted from the assay.

3.9: Inhibition of HSC/HSP70-substrate protein interactions promotes
accumulation of high molecular mass Triton-insoluble ChAT aggregates
Functionally, HSPs aid in the stabilization of cellular proteins by interacting with exposed
peptide sequences rich in hydrophobic amino acids, thereby preventing unintended protein
aggregation and promoting protein folding and solubility [118, 135, 202, 503]. Therefore,
to test whether HSC/HSP70 may regulate the folding of ChAT protein, I treated SN56 cells,
transiently expressing wild-type or mutant ChAT, with the HSC/HSP70 inhibitor 2phenylethynesulfonamide (PES), a small-molecule that interferes with HSC/HSP70substrate interactions leading to substrate insolubilization and the subsequent accumulation
of misfolded and aggregation-prone proteins [216-217]. Cells were treated with 20 µM PES
for 24 h, then levels of Triton-soluble and insoluble ChAT protein were assessed by
immunoblotting to determine levels of misfolded and/or aggregated ChAT (Figure 3.27a).
Importantly, I found that PES treatment of cells did not alter the Triton-soluble levels of
either wild-type or mutant ChAT proteins (Figure 3.27b), but levels of Triton-insoluble
wild-type (p≤0.01), P17A/P19A- (p≤0.001), V18M- (p≤0.01) and A513T-ChAT proteins
(p≤0.001) were significantly increased compared to DMSO-treated control cells (Figure
3.27c). Moreover, immunoblots of Triton-insoluble samples from PES-treated cells
revealed accumulation of high molecular mass ChAT-immunoreactive proteins and the
presence of insoluble ChAT that was retained in the loading pockets of the stacking layer
of SDS-PAGE gels (Figure 3.27a, top panel, anti-ChAT long-exposure). The accumulation
of high molecular mass Triton-insoluble ChAT was greater for mutant ChAT than for wildtype ChAT, with levels of Triton-insoluble P17A/P19A-ChAT having been the greatest.
Interestingly, high molecular mass Triton-insoluble P17A/P19A-ChAT was also observed
in DMSO-treated cells, though at a lower abundance than following PES treatment.
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Figure 3.27: Inhibition of HSC/HSP70-substrate protein interaction promotes
accumulation of high molecular mass Triton-insoluble ChAT aggregates. (A) AntiChAT immunoblots from SN56 cells expressing wild-type (WT) or mutant ChAT that were
treated for 24 h with either 20 μM PES, a HSC/HSP70 inhibitor, or DMSO-vehicle. Cells
were lysed in buffer containing 0.1% Triton X-100 and fractionated into soluble and
insoluble proteins. Triton X-100 insoluble proteins were solubilized prior to SDS-PAGE
by denaturing in 2x Laemmli sample buffer with 5% 2-mercaptoethanol. PES treatment
resulted in production of high molecular mass Triton-insoluble ChAT-immunoreactive
proteins that accumulated in the loading pockets of the SDS-PAGE gels (top panel, antiChAT long-exposure). The abundance of insoluble ChAT in the loading pockets appears
to be greater for mutant ChAT as compared to wild-type ChAT, with levels of Tritoninsoluble P17A/P19A-ChAT appearing the greatest. Anti-actin immunoblotting from both
Triton-soluble and -insoluble samples was completed as a loading control. (B) Treatment
with 20 μM PES had no effect on the total levels of Triton-soluble ChAT protein. (C) PES
treatment significantly increased the levels of Triton-insoluble wild-type (**p≤0.01),
P17A/P19A- (***p≤0.001), V18M- (**p≤0.01) and A513T-ChAT (***p≤0.001) proteins
compared to vehicle-control (two-way ANOVA with Bonferroni’s post-hoc test, mean ±
SEM, n=6). (D) Triton-insoluble protein samples from (A) were analyzed by semidenaturing detergent agarose gel electrophoresis (SDD-AGE) revealing the presence of
insoluble SDS-resistant ChAT aggregates in PES-treated cells. The abundance of these
SDS-resistant ChAT aggregates is greater for mutant ChAT compared to wild-type ChAT,
with P17A/P19A-ChAT being the greatest (n=6).

To assess whether high molecular mass Triton-insoluble ChAT observed following
PES treatment may consist of detergent-resistant ChAT aggregates, I performed semidenaturing detergent agarose gel electrophoresis (SDD-AGE) [491, 504] on Tritoninsoluble protein samples assessed in Figure 3.27a. Using anti-ChAT immunoblotting, I
observed accumulation of high molecular mass SDS-resistant ChAT protein aggregates
from lysates of PES-treated cells, but not generally from DMSO-treated control cells
(Figure 3.27d). The abundance of these insoluble SDS-resistant ChAT aggregates was
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greater for mutant ChAT as compared to wild-type ChAT, with P17A/P19A-ChAT having
been the greatest. Moreover, insoluble SDS-resistant aggregates of P17A/P17A-ChAT
were found in DMSO-treated cells, suggesting that this mutation may promote ChAT
insolubility and aggregation under basal conditions.

3.10: Inhibition of HSC/HSP70 or HSP90 ATPase activity reduces ChAT
steady-state protein levels
In addition to interaction with substrate proteins the protein-chaperoning function of
HSC/HSP70 requires activity of its N-terminal ATPase domain, and inhibition of this
domain by the small-molecule VER-155008 has been shown to promote the degradation of
HSC/HSP70 clients [213-214]. Thus, to determine if HSC/HSP70 activity is required for
ChAT protein stability, SN56 cells expressing either wild-type (Figure 3.28a), P17A/P19A(Figure 3.28b), V18M- (Figure 3.28c) or A513T-ChAT (Figure 3.28d) were treated with
varying concentrations (5-50 µM) of VER-155008 for 24 h. When analyzed by anti-ChAT
immunoblotting, I observed dose-related reductions in the steady-state protein levels for
both wild-type and mutant ChAT in VER-155008 treated cells. Interestingly, mutant ChAT
appears more sensitive than wild-type ChAT to HSC/HSP70 inhibition. Specifically, a
significant decrease in wild-type ChAT steady-state protein level was observed when cells
were treated with at least 20 µM VER-155008 (p≤0.05; Figure 3.28e), while lower
concentrations of VER-155008 were sufficient to significantly reduce protein levels of
P17A/P19A- (5 µM; p≤0.001; Figure 3.28f), V18M- (5 µM; p≤0.001; Figure 3.28g), or
A513T-ChAT (10 µM; p≤0.001; Figure 3.28h), as compared to DMSO-treated control
cells. Furthermore, treatment of ChAT-expressing cells with 50 µM VER-155008 reduced
ChAT steady-state proteins levels, compared to DMSO-treated control cells, as follows:
wild-type ChAT (38.6 ± 4.97%), P17A/P19A-ChAT (61.0 ± 4.17%), V18M-ChAT (75.7
± 2.82%) and A513T-ChAT (53.6 ± 2.69%).
Like HSC/HSP70, HSP90 has an N-terminal ATP-binding domain with ATPase
activity that is required for HSP90 chaperoning function, and pharmacological inhibition
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Figure 3.28: Inhibition of HSC/HSP70 ATPase activity reduces ChAT steady-state
protein levels in a dose-related manner. Anti-ChAT immunoblots from SN56 cells
expressing wild-type (WT; A), P17A/P19A- (B), V18M- (C) or A513T-ChAT (D) that
were treated for 24 h with 5-50 µM VER-155008, an inhibitor of HSC/HSP70 activity.
Control cells were treated with DMSO-vehicle. Anti-actin immunoblotting was completed
as a loading control. Steady-state protein levels of wild-type (E), P17A/P19A- (F), V18M(G) and A513T-ChAT (H) are reduced following treatment with VER-155008 as compared
to DMSO-control (**p≤0.01, ***p≤0.001, one-way ANOVA with Dunnett’s post-hoc test,
mean ± SEM, n=4). Mutant ChAT appears more sensitive to HSC/HSP70 inhibition where
treatment with 50 µM VER-155008 reduced ChAT steady-state proteins levels, compared
to vehicle-control, as follows; wild-type ChAT (38.63% ± 4.97), P17A/P19A-ChAT
(61.04% ± 4.17), V18M-ChAT (75.71% ± 2.82), and A513T-ChAT (53.60% ± 2.69).

of this domain by the small molecule 17-allylamino-17-demethoxygeldanamycin (17AAG) has been shown to promote proteasomal degradation of HSP90 clients [286-287].
Therefore, to determine whether HSP90 activity may also promote ChAT protein
stabilization, I treated ChAT-expressing SN56 cells with 0.5-2 µM 17-AAG for 24 h
(Figure 3.29). Analysis by anti-ChAT immunoblotting showed that treatment of cells with
concentrations of 17-AAG up to 2 µM had no effect on the steady-state levels of wild-type
ChAT protein (Figures 3.29a and 3.29e). Importantly though, treatment with 0.5-2 µM 17AAG did significantly reduce the steady-state levels of mutant P17A/P19A- (p≤0.001;
Figures 3.29b and 3.29f), V18M- (p≤0.001; Figures 3.29c and 3.29g), and A513T-ChAT
proteins (p≤0.001; Figures 3.29d and 3.29h) as compared to DMSO-treated control cells.
Overall, these data using the HSP inhibitors VER-155008 and 17-AAG suggest that
while the ATPase activity of HSC/HSP70 is necessary for both wild-type and mutant ChAT
protein stability, the ATPase activity of HSP90 may be uniquely critical for stabilization of
mutant ChAT, but not of wild-type ChAT protein. Interestingly, previous studies have
shown that treatment of cells with 17-AAG can lead to the expression of stress-inducible
HSP70 [287, 505-506]. Therefore, to assess whether 17-AAG-induced HSP70 may have a
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Figure 3.29: Inhibition of HSP90 by 17-AAG specifically reduces steady-state protein
levels of mutant ChAT. Anti-ChAT immunoblots from SN56 cells expressing wild-type
(WT; A), P17A/P19A- (B), V18M- (C), or A513T-ChAT (D) that were treated for 24 h
with 0.5-2 µM with 17-AAG, an inhibitor of HSP90 activity. Control cells were treated
with DMSO-vehicle. Anti-GAPDH immunoblotting was completed as a loading control.
(E) Treatment of cells with 17-AAG at concentrations up to 2 µM has no effect on the
steady-state levels of wild-type ChAT protein. By comparison, steady-state protein levels
of P17A/P19A- (F), V18M- (G), and A513T-ChAT (H) are reduced following treatment
of cells with 17-AAG as compared to DMSO-control (***p≤0.001, one-way ANOVA with
Dunnett’s post-hoc test, mean ± SEM, n=4).

protective role towards ChAT protein stability during HSP90 inhibition I performed
siRNA-mediated knock-down of HSP70 in SN56 cells, transiently expressing wild-type or
mutant ChAT, that were treated with 1 µM 17-AAG for 24 h (Figure 3.30). In support of
Figure 3.29, treatment with 17-AAG once again reduced the proteins levels of mutant
P17A/P19A-, V18M-, and A513T-ChAT but had no effect on the steady-state protein levels
of wild-type ChAT as compared to DMSO-treated control cells. While I found that 17AAG treatment did induce HSP70 protein expression in SN56 cells, siRNA knock-down
of HSP70 had no additional effect on the loss of steady-state protein levels of mutant ChAT
following 17-AAG treatment and, furthermore, failed to sensitize wild-type ChAT to 17AAG-induced loss of ChAT protein.

3.11: Proteasome inhibition prevents loss of ChAT protein following
HSC/HSP70 and HSP90 inhibition
My earlier results suggest that ChAT protein degradation is regulated by the proteasome
(Figures 3.6, 3.7, 3.15). Therefore, to test whether the loss of ChAT protein following
inhibition of either HSC/HSP70 or HSP90 was due to proteasome-dependent degradation
of ChAT, I co-treated ChAT-expressing SN56 cells with either VER-155008 or 17-AAG
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Figure 3.30: siRNA-mediated knock-down of HSP70 fails to sensitize wild-type ChAT
to 17-AAG-induced loss of ChAT protein. Anti-ChAT immunoblots from SN56 cells
transiently expressing either wild-type (WT) or mutant ChAT that were co-transfected with
25 nM of either anti-HSP70 siRNA or scramble-control siRNA for 72 h. In addition, cells
were treated for the final 24 h of siRNA incubation with either 1 µM 17-AAG or with
DMSO-vehicle control. 17-AAG-induced expression of and subsequent siRNA knockdown of HSP70 was assessed by anti-HSP70 immunoblotting. Anti-actin immunoblotting
was completed as a loading control (n=3).

along with the proteasome inhibitor MG132. Importantly, I observed that treatment of cells
expressing either wild-type and mutant ChAT with 40 µM VER-155008 for 24 h reduced
ChAT steady-state protein levels, and that co-treatment of cells with 5 µM MG132 for 18
h attenuated this effect (Figure 3.31a). In addition, treatment of ChAT-expressing cells with
1 µM 17-AAG alone for 24 h reduced the steady-state protein levels of mutant ChAT only,
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Figure 3.31: Proteasome inhibition by MG132 treatment prevents loss of ChAT
protein following inhibition of HSC/HSP70 or HSP90 activity. Anti-ChAT
immunoblots from SN56 cells transiently expressing wild-type (WT) or mutant ChAT that
were co-treated with either 40 µM VER-155008 (A) or 1 µM 17-AAG (B) for 24 h and
with 5 µM MG132 for the final 18 h of HSP inhibition (n=4). Lysosomal inhibition by cotreatment of ChAT-expressing cells with 50 µM chloroquine (CQ) for 18 h did not prevent
the effects of 24 h treatment with either VER-155008 (C) or 17-AAG (D) on ChAT steadystate protein levels (n=3). Control cells were treated with DMSO-vehicle or alone with
either VER-155008 or 17-AAG. Proteasome inhibition by MG132 treatment or lysosome
inhibition by CQ treatment was validated by immunoblotting for the accumulation of either
ubiquitinated cellular proteins or for the lysosome-associated protein LC3B-II,
respectively. Anti-actin immunoblotting was completed as a loading control.
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while co-treatment with 5 µM MG132 for 18 h also prevented this effect (Figure 3.31b).
As anticipated, and in support of my earlier findings, co-treatment of ChAT-expressing
SN56 cells for 18 h with 50 µM chloroquine to inhibit lysosomal proteolysis did not prevent
the effects of either 40 µM VER-155008 (Figure 3.31c) or 1 µM 17-AAG (Figure 3.31d)
on the steady-state levels of either wild-type or mutant ChAT protein.

3.12: Inhibition of HSC/HSP70 and HSP90 activity enhances ChAT
ubiquitination and reduces ChAT enzymatic activity
In addition to protein folding, HSPs perform essential protein quality control functions by
triaging stress-damaged or terminally misfolded proteins for degradation through the
ubiquitin-proteasome system [118, 135]. Therefore, to determine if inhibition of either
HSC/HSP70 or HSP90 may promote degradation of ChAT through enhanced ChAT
ubiquitination, I treated ChAT-expressing SN56 cells with either 40 µM VER-155008 for
24 h or 1 µM 17-AAG for either 8 or 24 h, along with 20 µM MG132 during the final 6 h
of HSP inhibition to prevent the degradation of ubiquitinated ChAT. By anti-ubiquitin
immunoblotting from anti-ChAT IPs, I observed that treatment of cells with VER-155008
resulted in enhanced ubiquitination of both wild-type and mutant ChAT as compared to
DMSO-treated control cells (Figure 3.32a). Furthermore, ubiquitination of mutant ChAT,
in particular P17A/P19A-ChAT, was greater than that of wild-type ChAT following VER155008 treatment when compared to DMSO-treated control cells. Surprisingly, while
treatment of cells with 17-AAG for 24 h had no effect on the ubiquitination of either wildtype or mutant ChAT proteins, treatment for 8 h did enhance ChAT ubiquitination, with
this effect being greater for mutant than for wild-type ChAT, particularly for P17A/P19AChAT, when compared to DMSO-control (Figure 3.32b).
Canonically, ubiquitination targets proteins for proteasomal and/or lysosomal
degradation, but it can also regulate subcellular trafficking, receptor endocytosis, and
enzymatic activity of various proteins [44]. Therefore, to determine if HSP inhibition may
also affect ChAT enzymatic activity, I treated SN56 cells transiently expressing
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Figure 3.32: Inhibition of HSC/HSP70 and HSP90 activity enhances ChAT
ubiquitination. (A) Representative anti-ChAT and anti-ubiquitin immunoblots from SN56
cells expressing wild-type (WT) or mutant ChAT that were treated for 24 h with 40 μM
VER-155008. To inhibit degradation of ubiquitinated ChAT cells were co-treated for the
final 6 h of VER-155008 treatment with 20 μM MG132. ChAT ubiquitination was then
assessed by anti-ubiquitin immunoblotting following anti-ChAT immunoprecipitation (IP).
Inhibition of HSC/HSP70 by VER-155008 treatment enhanced ChAT ubiquitination,
where levels of ubiquitinated mutant ChAT, particularly P17A/P19A-ChAT, are greater
than that of wild-type ChAT. Control cells were transfected with empty pcDNA3.1+ vector
and/or were treated with DMSO-vehicle. Proteasome inhibition by MG132 treatment was
validated by immunoblotting from whole cell lysates for the accumulation of ubiquitinated
cellular proteins. Anti-actin immunoblotting from whole cell lysates was completed as a
loading control (n=3). (B) Immunoblots following anti-ChAT IP from ChAT-expressing
SN56 cells that were co-treated for either 8 or 24 h with 1 μM 17-AAG and for the final 6
h with 20 μM MG132. Inhibition of HSP90 by treatment with 1 μM 17-AAG for 8 h, but
not for 24 h, enhanced ubiquitination of wild-type and mutant ChAT; the ubiquitination of
ChAT appears to be greater for mutant ChAT than for wild-type ChAT following 17-AAG
treatment, with levels of ubiquitinated P17A/P19A-ChAT being the greatest (n=3).

heterologous wild-type ChAT with either 40 µM VER-155008 or 1 µM 17-AAG alone or
in combination for 24 h, then analyzed cellular ChAT activity by radioenzymatic assay.
Interestingly, I found that the cellular activity of wild-type ChAT is reduced following 24
h treatment of cells with either 40 μM VER-155008, 1 µM 17-AAG, or a combination of
the two as compared to DMSO-treated control cells (p≤0.01; Figure 3.33). While treatment
with VER-155008 alone trended towards a greater reduction in cellular ChAT activity
when compared to 17-AAG alone (p=0.058), co-treatment of cells with VER-155008 and
17-AAG did lead to a greater reduction in wild-type ChAT activity as compared to 17AAG alone (p≤0.01). Importantly, these data show that while inhibition of HSP90 by 17AAG treatment had no effect on the steady-state protein levels of wild-type ChAT (Figures
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Figure 3.33: Inhibition of HSC/HSP70 and HSP90 activity reduces cellular enzymatic
activity of wild-type ChAT. Cellular enzymatic activity of heterologously-expressed wildtype ChAT is reduced following treatment of SN56 cells for 24 h with either 40 μM VER155008 or 1 µM 17-AAG alone or a combination of the two as compared to DMSO-control
treated cells (**p≤0.01). While treatment with VER-155008 trended towards a greater
reduction in cellular ChAT activity compared to 17-AAG (p=0.058), co-treatment with
these inhibitors did result in a greater reduction in ChAT activity as compared to 17-AAG
alone (**p≤0.01, one-way ANOVA with Tukey’s post-hoc test, mean ± SEM, n=3).

3.29 and 3.31), this treatment did significantly reduce the cellular enzymatic activity of
wild-type ChAT like that observed with HSC/HSP70 inhibition by VER-155008 treatment,
suggesting that the folding activity of both HSC/HSP70 and HSP90 are necessary in order
to generate fully-functional and active ChAT enzyme.
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3.13: ChAT interacts with the HSP-associated E3 ubiquitin ligase CHIP
The E3 ubiquitin ligase CHIP/Stub1 ubiquitinates proteins in an HSP-dependent manner
through direct interaction with either HSC/HSP70 or HSP90 and their bound substrate
proteins [76-78]. My results demonstrating enhanced ubiquitination and proteasomal
degradation of ChAT protein following HSC/HSP70 and HSP90 inhibition suggest that
ubiquitination of ChAT may be regulated by CHIP. Therefore, to first determine if ChAT
may interact with CHIP, I performed anti-ChAT co-IPs from SN56 cells co-expressing
either wild-type or mutant ChAT with FLAG-tagged CHIP (Figure 3.34a). As anticipated,
FLAG-CHIP was detected in anti-ChAT co-IP samples from both wild-type and mutant
ChAT-expressing cells by anti-FLAG immunoblotting. By comparing the levels of
immunoprecipitated FLAG-CHIP to that of ChAT protein, I observed enhanced co-IP of
FLAG-CHIP with mutant P17A/P19A- (p≤0.001), V18M- (p≤0.001) and A513T-ChAT
(p≤0.05) as compared to wild-type ChAT (Figure 3.34b). Subsequently, association of
wild-type and mutant ChAT with endogenous CHIP was confirmed by anti-ChAT co-IP
from ChAT-expressing SN56 cells with follow-up anti-CHIP immunoblotting (Figure
3.34c). Lastly, to assess whether ChAT can interact with CHIP in situ I also performed
PLA assays to visualize and confirm, by confocal microscopy, the presence of in situ
interactions between wild-type ChAT and endogenous CHIP in SN56 cells (Figure 3.35).
As predicted, I observed predominantly cytoplasmic in situ interaction of wild-type ChAT
with endogenous CHIP in cells. As controls, I did not observe in situ interactions in control
cells that were either transfected with either empty vector or when primary antibodies
towards ChAT and CHIP were omitted from the assay.

3.14: CHIP co-expression promotes proteasomal degradation and
insolubilization of ChAT
Interaction of ChAT with CHIP may promote the ubiquitination and proteasome-dependent
degradation of ChAT. Therefore, to determine if ChAT is a substrate for CHIP, I first tested
if co-expression of FLAG-CHIP promotes loss of ChAT protein in SN56 cells transiently
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Figure 3.34: Co-immunoprecipitation of ChAT with HSP-associated E3 ubiquitin
ligase C-terminus of HSC70-interaction protein (CHIP). (A) Immunoblots showing coimmunoprecipitation (co-IP) of ChAT with FLAG-CHIP from SN56 cells co-expressing
either wild-type (WT) or mutant ChAT with FLAG-tagged CHIP. Control cells were
transfected with empty pcDNA3.1+ vector or to express FLAG-CHIP alone. Anti-FLAG
and anti-actin immunoblotting from whole cell lysates was completed as loading controls.
(B) Co-IP of ChAT with FLAG-CHIP is enhanced for P17A/P19A- (***p≤0.001), V18M(***p≤0.001), and A513T-ChAT (*p≤0.05) as compared to wild-type ChAT (one-way
ANOVA with Dunnett’s post-hoc test, mean ± SEM, n=5). (C) Co-IP of heterologouslyexpressed wild-type and mutant ChAT with endogenous CHIP following anti-ChAT co-IP
from SN56 cells. Control cells were transfected with empty vector (n=3).
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Figure 3.35: In situ interaction of ChAT with endogenous CHIP. Detection of in situ
ChAT-CHIP interactions by proximity ligation assay (PLA) in SN56 cells transiently
expressing heterologous wild-type ChAT. Formalin-fixed cells were first co-labeling with
goat anti-ChAT together with rabbit anti-CHIP primary antibodies, then incubated with
oligonucleotide-linked secondary antibodies. Following DNA ligation and DNA
amplification using the Duolink In Situ Orange Kit (Sigma), in situ ChAT-CHIP
interactions were imaged by confocal microscopy at an excitation/emission of 554/576 nm.
Positive in situ ChAT-CHIP interactions were visualized and presented as fluorescent red
dots while nuclei were stained with DAPI (blue). Control cells were either transfected with
empty pcDNA3.1+ vector or primary antibodies omitted from the assay (No 1°). Images
are representative of 4 independent experiments; scale bars are 10 µm.
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expressing wild-type or mutant ChAT. By anti-ChAT immunoblotting (Figure 3.36a) I
observed that co-expression of FLAG-CHIP significantly reduced the steady-state protein
levels of wild-type (p≤0.001), P17A/P19A- (p≤0.05), V18M- (p≤0.001), and A513T-ChAT
(p≤0.001) as compared to cells co-transfected with equal amounts (µg) of empty vector
(Figure 3.36b). To assess whether the effects of FLAG-CHIP co-expression on reduced
ChAT protein levels were proteasome dependent, SN56 cells, transiently co-expressing
wild-type ChAT with FLAG-CHIP, were treated for 18 h with either 5 µM MG132 or 50
µM chloroquine alone or with these two inhibitors together in combination. Following antiChAT immunoblotting I found that proteasome inhibition by treatment with either MG132
alone or together with chloroquine partially ameliorated the FLAG-CHIP-induced loss of
wild-type ChAT protein (Figure 3.36c). As anticipated, treatment with chloroquine alone
failed to prevent the loss of wild-type ChAT protein in cells co-expressing FLAG-CHIP.
CHIP has two distinct functional protein domains, a C-terminal U-box domain that
contains E3 ubiquitin ligase activity and three N-terminal TPR domains that allow for and
facilitate interaction of CHIP with HSPs and their substrates (Figure 3.37a) [73, 76, 276,
315]. To determine if the E3 ligase activity of CHIP is required to promote CHIP-associated
loss of ChAT protein, and furthermore whether the TPR domains of CHIP are required for
ChAT-CHIP interaction, SN56 cells were transiently transfected to co-express wild-type
ChAT with either full-length wild-type FLAG-CHIP or mutant FLAG-CHIP missing either
the N-terminal TPR domains (ΔTPR) or the C-terminal U-box domain (ΔU-box). Cells
were collected, lysed in buffer containing 0.5% Triton X-100, and lysates were used for
completion of both anti-ChAT co-IPs and for the immunoblot assessment of Triton-soluble
and -insoluble ChAT proteins (Figure 3.37b). By anti-FLAG immunoblotting from antiChAT co-IP samples I observed that wild-type ChAT can co-IP with both full-length
FLAG-CHIP or FLAG-CHIP-ΔU-box but was unable to co-IP with FLAG-CHIP-ΔTPR.
Surprisingly, co-expression of either full-length FLAG-CHIP or FLAG-CHIP-ΔU-box
reduced the Triton-soluble levels of ChAT protein and led to a reciprocal increase in the
Triton-insoluble levels of ChAT. These effects on ChAT solubility were not observed when
ChAT was co-expressed with FLAG-CHIP-ΔTPR, suggesting that the TRP
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Figure 3.36: CHIP co-expression promotes proteasomal degradation of ChAT. (A)
Anti-ChAT immunoblots from SN56 cells co-expressing wild-type (WT) or mutant ChAT
with FLAG-tagged CHIP. Anti-FLAG and anti-actin immunoblotting was completed as
loading controls. (B) The steady-state proteins levels of wild-type (***p≤0.001),
P17A/P19A- (*p≤0.05), V18M- (***p≤0.001), and A513T-ChAT (*p≤0.05) are reduced
following co-expression of FLAG-CHIP as compared to control cells co-transfected with
empty pcDNA 3.1+ vector (two-way ANOVA with Bonferroni’s post-hoc test, mean ±
SEM, n=4). (C) Proteasome inhibition partially attenuates loss of ChAT protein following
co-expression of FLAG-CHIP. Immunoblots from SN56 cells co-expressing wild-type
ChAT with FLAG-tagged CHIP that were treated with either 5 µM MG132 or 50 µM
chloroquine (CQ) alone or in combination for 18 h. Control cells were treated with DMSOvehicle and/or transfected with either empty pcDNA 3.1+ vector or to express wild-type
ChAT alone. Proteasome inhibition by MG132 treatment was validated by immunoblotting
for the accumulation of ubiquitinated cellular proteins (n=6).
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Figure 3.37: The TPR domains of CHIP are critical for ChAT-CHIP protein
interaction and promote CHIP-mediated ChAT insolubilization. (A) Schematic
overview of the functional protein domains of the E3 ubiquitin ligase CHIP/Stub1. CHIP
contains three N-terminal tetracopeptide repeat (TPR) domains that facilitate interaction of
CHIP with HSPs and their substrates. Additionally, a C-terminal U-box domain imparts E3
ligase activity to CHIP. (B) The TPR domains, but not the U-box domain, of CHIP are
necessary for ChAT-CHIP protein interaction. Additionally, co-expression of either fulllength FLAG-CHIP or FLAG-CHIP-ΔU-box increased Triton-insoluble levels of wild-type
(WT) ChAT protein while ChAT co-expression with FLAG-CHIP-ΔTPR had no effect on
ChAT solubility. Shown are representative anti-ChAT and anti-FLAG immunoblots
following anti-ChAT co-immunoprecipitation (co-IP) from SN56 cells transiently coexpressing wild-type ChAT with either full-length FLAG-tagged CHIP or with mutant
FLAG-CHIP missing either its TPR domains (ΔTPR) or U-box domain (ΔU-box). Control
cells were transfected with empty pcDNA3.1+ vector or to express either wild-type ChAT
or full-length FLAG-CHIP alone. Cells were lysed in 0.5% Triton X-100, fractionated into
Triton-soluble and -insoluble fractions, and anti-ChAT co-IPs were completed from the
soluble fractions. Triton X-100 insoluble proteins were solubilized prior to SDS-PAGE by
denaturing in 2x Laemmli sample buffer. Anti-actin immunoblotting from Triton-soluble
and -insoluble proteins samples was completed as loading controls (n=5).

domains of CHIP are critical for not only ChAT-CHIP association, but also for the effects
of CHIP co-expression on ChAT protein solubility and degradation.
These initial studies investigating the role of CHIP on the regulation of ChAT
protein degradation and stability were completed in cells co-expressing ChAT with
heterologous FLAG-tagged CHIP. Though I was able to show that ChAT can co-IP and
interact in situ with endogenous CHIP (Figures 3.34c and 3.35), it is unknown whether
ChAT may be a substrate for degradation by endogenous CHIP. Thus, to determine if
endogenous CHIP regulates ChAT protein stability I monitored ChAT steady-state protein
levels from SN56 cells, transiently expressing wild-type or mutant ChAT, that were co121

transfected with siRNA targeting endogenous mouse CHIP (Figure 3.38). Surprisingly, as
assessed by anti-ChAT and anti-CHIP immunoblotting, while I was able to achieve a
greater-than 95% CHIP knock-down in cells, siRNA-mediated knock-down of endogenous
CHIP had no effect on the steady-state levels of either wild-type or mutant ChAT protein.

3.15: Oxidative stress by exposure of cells to H2O2 enhances ChAT
ubiquitination
In summary of my results investigating the regulation of ChAT by HSPs, I have shown that
ChAT interacts with and is a substrate for HSC/HSP70 and HSP90, where inhibition of
HSC/HSP70 protein interactions results in accumulation of insoluble ChAT protein, and
inhibition of HSC/HSP70 and HSP90 activity led to reduced cellular ChAT activity, along
with enhanced ChAT ubiquitination and proteasome-dependent loss of ChAT protein.
Furthermore, the effects of HSP inhibition appear greater for mutant ChAT (P17A/P19A-,
V18M-, and A513T-ChAT) than for wild-type ChAT (Figure 3.39).
HSPs, such as HSC/HSP70 and HSP90, have been best characterized for their role
in promoting the folding and stabilization of nascent proteins, as well as in refolding of
misfolding-prone and aggregated proteins during proteotoxic stress such as hyperthermia
[118, 135, 154, 371]. Oxidation of cellular proteins and subsequent formation of aberrant
stress-induced disulfide bonds during oxidative stress can induce protein misfolding with
severe functional consequences [361, 364-365]. Interestingly, ChAT has a higher-thanaverage cysteine content of 3.2% compared to 1.6% for intracellular mammalian proteins
[367] which, like the cysteine-rich E3 ubiquitin ligase Parkin, may sensitize ChAT to
oxidative damage [370]. Importantly, work performed in our laboratory by Shawn Albers,
M.Sc., has demonstrated that treatment of ChAT-expressing SN56 cells with 50 µM – 2
mM of H2O2, a potent inducer of cellular oxidative stress, results in the dose- and redoxdependent accumulation of higher molecular mass wild-type ChAT proteins that can be
observed by anti-ChAT immunoblotting specifically in non-reducing conditions (Figure
3.40a). Additionally, Shawn Albers has shown that treatment of ChAT-expressing SN56
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Figure 3.38: siRNA knock-down of endogenous CHIP has no effect on the steady-state
protein levels of wild-type or mutant ChAT. Anti-ChAT immunoblots from ChATexpressing SN56 cells that were transfected with 25 nM of either anti-CHIP siRNA or
scramble-control siRNA for 72 h. Cells were co-transfected to express wild-type (WT) or
mutant ChAT for the final 48 h of siRNA incubation. Control cells were mock-transfected
with siLentFect transfection reagent. Knock-down of CHIP was assessed by anti-CHIP
immunoblotting. Anti-actin immunoblotting was completed as a loading control (n=4).

cells for up-to 4 h with 1 mM H2O2 reduced the cellular activity of wild-type ChAT when
compared to vehicle-treated control cells (p<0.001; Figure 3.40b) [507]. Lastly, NunesTavares and colleagues [439] have demonstrated that cellular ChAT activity is reduced
following exposure of neural cells to Aβ oligomers, a hallmark of AD and stimulator of
cellular oxidative stress [429, 508-509].
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Figure 3.39: Model for the regulation of ChAT protein stability by the heat-shock
family of molecular chaperones. Under physiological conditions ChAT protein folding is
promoted by the molecular chaperoning-function of the heat shock proteins HSC/HSP70
and HSP90, resulting in stable and active ChAT enzyme. Though, if ChAT protein folding
becomes compromised, potentially in case of ChAT mutations (e.g. P17A/P19A, V18M,
and A513T) or following HSP inhibition (e.g. PES, VER-155008, and 17-AAG), misfolded
and/or insoluble ChAT is targeted for proteasomal degradation via enhanced ubiquitination
by a yet-to-be identified chaperone-associated E3 ubiquitin ligase. It is currently unknown
whether cellular stresses, such as oxidative stress, can induce ChAT dysfunction through
enhanced misfolding and subsequent degradation of ChAT, and/or if HSPs may assist in
the stabilization of ChAT protein during cellular stress.

The aforementioned studies suggest that ChAT protein function, and potentially
protein stability, may be altered during cellular exposure to oxidative stress. Additional
studies have demonstrated that the ubiquitination, and subsequent proteasomal degradation,
of various cellular proteins is altered during oxidative stress [510-512]. Importantly, as
presented earlier in this thesis, I have demonstrated that ChAT protein stability is regulated
by the ubiquitin-proteasome system, though it is unknown whether ChAT ubiquitination is
altered during oxidative stress. Therefore, ChAT ubiquitination was monitored in SN56
cells, transiently co-expressing wild-type ChAT with HA-tagged ubiquitin, that were
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Figure 3.40: H2O2 treatment promotes the generation of redox-dependent higher
molecular mass ChAT proteins and decreases cellular ChAT activity. (A) Anti-Myc
immunoblots from SN56 cells, transiently expressing Myc-tagged 69-kDa wild-type
ChAT, that were treated for 1 hour with 1 mM H2O2. Control cells were transfected with
empty pcDNA3.1+ vector or were treated with vehicle-control (0 µM; water). Treatment
of ChAT-expressing cells with H2O2 generated higher molecular mass ChAT proteins that
were observed on anti-Myc immunoblots only under non-reducing conditions. Anti-actin
immunoblotting was completed as a loading control (n=3). (B) Cellular ChAT activity is
reduced in SN56 cells following treatment with 1 mM H2O2 for 240 min as compared to
vehicle-treated cells (***p≤0.001, one-way ANOVA with Dunnett’s post-hoc test, mean ±
SEM, n=4). Experiments were completed previously by Shawn Albers, M.Sc. [507].
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treated for 30 – 60 min with 1 mM H2O2 to induce cellular oxidative stress. To prevent
degradation of ubiquitinated ChAT cells were co-treated for 18 h with 5 µM MG132 priorto and during treatment with H2O2. Following anti-HA IP and anti-ChAT immunoblotting
I observed that ChAT ubiquitination is enhanced following treatment of cells with 1 mM
H2O2 for either 30 or 60 min as compared to DMSO-treated control cells (Figure 3.41). No
differences in the abundance of ubiquitinated ChAT were detected when comparing the 30
min H2O2-treated cells to the 60 min-treated cells.

3.16: Oxidative stress by H2O2 treatment promotes the insolubilization of
ChAT protein
These preliminary ubiquitination experiments following H2O2 treatment suggest that ChAT
protein stability may be negatively affected by oxidative damage. Furthermore, work by
Shawn Albers showing the appearance of higher molecular mass ChAT proteins under nonreducing conditions following H2O2 exposure suggests that ChAT may be susceptible to
oxidative misfolding that is dependent on cysteine oxidation and formation of aberrant
disulfide bonds. Therefore, to first assess whether ChAT solubility, and potentially ChAT
protein folding, is altered during oxidative stress I treated SN56 cells transiently expressing
wild-type ChAT with varying concentrations of H2O2 for either 24 h (100 nM – 200 µM)
or for 1 h (1 µM – 2 mM). Cells were lysed with buffer containing 0.1% Triton X-100 and
Triton-soluble and -insoluble ChAT proteins were fractionated. Following anti-ChAT
immunoblotting I observed that treatment of ChAT-expressing cells for 24 h with 100 nM
– 200 µM H2O2 had no significant effect on the overall solubility of ChAT protein (Figure
3.42a). Interestingly, though no changes in Triton-soluble levels of ChAT were detected,
enhanced levels of Triton-insoluble ChAT were observed following 1 h treatment of cells
specifically with 0.5-2 mM H2O2 compared to vehicle-treated control cells (Figure 3.42b).
HSPs, such as HSC/HSP70 and HSP90, have been shown to bind to and chaperone
oxidized proteins to maintain and/or restore protein function during oxidative conditions
[371]. My earlier studies using the HSC/HSP70 inhibitor PES suggest that the folding and
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Figure 3.41: Oxidative stress by H2O2 treatment enhances ChAT ubiquitination.
Representative anti-ChAT and anti-HA immunoblots from SN56 cells transiently coexpressing wild-type ChAT with HA-tagged ubiquitin (HA-Ub) that were treated with 1
mM H2O2 for either 30 or 60 min. Levels of ubiquitinated ChAT protein were assessed by
anti-ChAT immunoblotting from anti-HA IP samples. Cells were treated with 5 µM
MG132 for 18 h prior-to and during H2O2 treatment to prevent proteasomal degradation of
ubiquitinated proteins. Control cells were either transfected with empty pcDNA3.1+ vector
or to express wild-type ChAT or HA-Ub alone, or were treated with vehicle-control (water).
Proteasome inhibition by MG132 treatment was validated by anti-HA immunoblotting
from whole cell lysates for the accumulation of ubiquitinated cellular proteins. Anti-actin
immunoblotting from whole cell lysates was completed as a loading control (n=3).
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Figure 3.42: Oxidative stress by H2O2 treatment promotes ChAT insolubilization.
Anti-ChAT immunoblots from SN56 cells transiently expressing wild-type ChAT that were
treated with either 0.1 – 200 µM H2O2 for 24 h (A) or with 1 µM – 2 mM H2O2 for 1h (B).
Control cells were treated with water-vehicle. Cells were lysed in 0.1% Triton X-100 and
Triton-soluble and -insoluble proteins were fractionated. Triton X-100 insoluble proteins
were solubilized prior to SDS-PAGE by denaturing in 2x Laemmli sample buffer with 5%
2-mercaptoethanol. No differences in ChAT protein solubility was detected following 24 h
of 0.1 – 200 µM H2O2 treatment (A; n=3). While no changes in the Triton-soluble levels of
ChAT were detected following 1h H2O2 treatment, levels of Triton-insoluble ChAT protein
were increased in cells specifically treated for 1 h with 0.5 – 2 mM H2O2 (B; n=3). Antiactin immunoblotting was completed as loading controls.
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solubility of ChAT protein may be promoted by interaction of ChAT with HSC/HSP70
(Figure 3.27). Therefore, to determine whether HSC/HSP70 may play a protective role
during acute oxidative stress by preventing oxidative insolubilization of ChAT, I co-treated
wild-type ChAT-expressing SN56 cells with 1-8 h of 100 µM H2O2 that had been pretreated for 24 h with 20 µM PES. Following anti-ChAT immunoblotting, I again observed
that treatment of cells with 20 µM PES increased the levels of higher molecular mass
Triton-insoluble ChAT protein as compared to DMSO-treated control cells (Figure 3.43).
Furthermore, PES treatment again led to the accumulation of Triton-insoluble ChAT
aggregates retained in the loading pockets of the stacking layer of SDS-PAGE gels.
Importantly, I observed that pre-treatment of cells with 20 µM PES sensitized ChAT to
H2O2-induced insolubilization such that treatment of ChAT-expressing cells for 4 or 6 h
with 100 µM H2O2 resulted in an enhanced accumulation of higher molecular mass Tritoninsoluble ChAT proteins as compared to PES or H2O2 treatment alone. Lastly, greater levels
of Triton-insoluble ChAT aggregates were observed in the loading pockets of SDS-PAGE
gels when cells treated with H2O2 for 4 or 6 h were first pre-treated with 20 µM PES.

3.17: Co-immunoprecipitation of ChAT with HSC70 is altered following
exposure of cells to H2O2
Protein misfolding stresses, such as oxidative stress, can promote the formation of aberrant
disulfide-bonds and exposure of hydrophobic regions within various cellular proteins,
increasing the affinity of HSPs for these misfolded proteins [246, 365, 371]. My ChAT
solubility experiments with H2O2 and PES treatment suggest that ChAT protein folding
may be negatively impacted following exposure to acute elevated levels of oxidative stress
(i.e. 1 mM H2O2), though under more moderate oxidative conditions (i.e. 100 µM H2O2)
that interaction of ChAT with HSC/HSP70 may protect ChAT from oxidative misfolding.
Therefore, I next assessed by co-IP assay whether interaction of ChAT with either HSC70
or HSP90 is enhanced in ChAT-expressing SN56 cells treated for 1 - 8 h with 100 µM
H2O2 or for 1 h with 1 mM H2O2. Following anti-HSC70 and anti-HSP90 immunoblotting
from anti-ChAT co-IP samples, I observed that co-IP of wild-type ChAT with endogenous
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Figure 3.43: HSC/HSP70 inhibition by PES treatment sensitizes ChAT to H2O2induced insolubilization. Anti-ChAT immunoblots from SN56 cells transiently
expressing wild-type ChAT that were pre-treated for 24 h with 20 µM PES then co-treated
for an additional 1-8 h with 100 µM H2O2. Control cells were treated with DMSO- or watervehicle (Veh) for PES or H2O2 treatment respectively. Cells were lysed in 0.1% Triton X100 and Triton-soluble and -insoluble proteins were fractionated. Triton X-100 insoluble
proteins were solubilized prior to SDS-PAGE by denaturing in 2x Laemmli sample buffer
with 5% 2-mercaptoethanol. Co-treatment of cells with PES and H2O2 had no effect on the
total levels of Triton-soluble ChAT protein. However, co-treatment with PES and 4-6 h of
H2O2 resulted in greater accumulation of higher molecular mass Triton-insoluble ChAT
proteins as compared to cells treated with PES or H2O2 alone. Deposition of Tritoninsoluble ChAT aggregates could be observed in the loading pockets of the SDS-PAGE
gels following co-treatment of cells with PES and 4-6 h H2O2 (top panel, anti-ChAT longexposure). Anti-actin immunoblotting was completed as loading controls (n=3).
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HSC70 is enhanced following acute exposure of cells to 100 µM H2O2 for either 1 or 2 h
as compared to vehicle-treated control cells (Figure 3.44). Interestingly, exposure of ChATexpressing cells with 1 mM H2O2 for 1 h or to 100 µM H2O2 for extended periods of time
(4 – 8 h) had no effect on ChAT-HSC70 co-IP. Lastly, co-IP of ChAT with endogenous
HSP90 appears to be unaffected by treatment with either 100 µM or 1 mM H2O2.

3.18: Inhibition of the co-chaperone Cdc48/p97/VCP prevents the
degradation of ubiquitinated ChAT
Previously in our laboratory we have shown that the co-chaperone Cdc48/p97/Valosincontaining protein (VCP) can stably interact with ChAT in IMR32 neural cells exposed to
oxidative Aβ [440, 508]. Interestingly, VCP has also been documented to modulate HSP
substrates through interaction with HSC/HSP70 [513] and HSP90 [514], and additionally
can regulate the subcellular trafficking and degradation of ubiquitinated proteins [98, 441442]. It is currently unknown if VCP may regulate ChAT ubiquitination and degradation
under basal conditions, and therefore to examine if ChAT protein stability is regulated by
VCP I treated SN56 cells, transiently expressing either wild-type or mutant ChAT, for 18
h with 5-10 µM Eeyarestatin I (Eer1), a small-molecule inhibitor of VCP [515-516].
Following anti-ChAT immunoblotting, I observed accumulation of high molecular mass
wild-type and mutant ChAT-immunoreactive proteins following cell treatment with 10 µM
Eer1, but not in control cells treated with DMSO-vehicle (Figure 3.45a). The abundance of
high molecular mass ChAT was greater for mutant than for wild-type ChAT, with levels of
P17A/P19A-ChAT being the greatest. Additionally, Eer1 treatment led to accumulation of
insoluble high molecular mass ChAT proteins for both wild-type and mutant ChAT that
were retained in the loading pockets of the stacking layer of SDS-PAGE gels.
VCP can promote the proteasome-dependent degradation of ubiquitinated proteins
from both the ER and the cytoplasm [441-442], and furthermore inhibition of VCP by Eer1
treatment has been shown to prevent the degradation of ubiquitinated VCP substrates [515516]. Thus, to determine if the higher molecular mass ChAT proteins observed following
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Figure 3.44: Co-IP of ChAT with endogenous HSC70 is enhanced following exposure
of cells to H2O2. Immunoblots showing co-immunoprecipitation (co-IP) of ChAT with
endogenous HSC70 and HSP90 from SN56 cells transiently expressing wild-type ChAT
that were treated with 100 µM H2O2 for 1-8 h or with 1 mM H2O2 for 1 h. Controls cells
were either treated with water-vehicle (Veh) or were transfected with empty pcDNA3.1+
vector. As assessed by anti-HSC70 and anti-HSP90 immunoblotting, co-IP of wild-type
ChAT with endogenous HSC70 is enhanced in cells treated with 100 µM H2O2 for 1-2 h,
whereas co-IP of ChAT with endogenous HSP90 is unaffected by H2O2 treatment. Antiactin immunoblotting from whole cell lysates was completed as a loading control (n=4).
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Figure 3.45: Inhibition of the co-chaperone Cdc48/p97/Valosin-containing protein
(VCP) prevents degradation of ubiquitinated ChAT. (A) Anti-ChAT immunoblots from
SN56 cells transiently expressing either wild-type (WT) or mutant ChAT that were treated
for 18 h with 5-10 μM Eeyarestatin I (Eer1), a VCP inhibitor, or with DMSO-vehicle
control. Inhibition of VCP with 10 µM Eer1 resulted in the generation of high molecular
mass ChAT-immunoreactive proteins and the presence of insoluble ChAT retained in the
loading pockets of SDS-PAGE gels (top panel, anti-ChAT long-exposure). Accumulation
of high molecular mass ChAT appears greater for mutant ChAT compared to wild-type
ChAT, with levels of P17A/P19A-ChAT being the greatest. Anti-actin immunoblotting was
completed as a loading control (n=3). (B) Inhibition of VCP attenuates the degradation of
ubiquitinated ChAT. ChAT ubiquitination was analyzed by anti-ubiquitin immunoblotting
following anti-ChAT IP from ChAT-expressing SN56 cells that were treated for 18 h with
10 μM Eer1. Control cells were transfected with empty pcDNA31+ vector and/or treated
with DMSO-vehicle. Proteasome function was maintained to allow for the degradation of
ubiquitinated ChAT in DMSO-treated control conditions. The abundance of ubiquitinated
ChAT following VCP inhibition appears to be greater for mutant ChAT, with levels of
ubiquitinated P17A/P19A-ChAT being the greatest. Anti-actin and anti-ubiquitin
immunoblotting from whole cell lysates were completed as loading controls (n=3).

VCP inhibition are ubiquitinated forms of ChAT, and therefore whether ubiquitinated
ChAT may be degraded in a VCP-dependent manner, I completed anti-ChAT IPs from
ChAT-expressing SN56 cells that were treated with 10 µM Eer1 for 18 h. Importantly, to
maintain proteasome function and thus to allow for the degradation of ChAT in cells treated
with DMSO-control I omitted the addition of MG132. By anti-ubiquitin immunoblotting
of anti-ChAT IP samples, I confirmed that VCP inhibition prevented the degradation of
ubiquitinated wild-type and mutant ChAT when compared to DMSO-treated control cells
(Figure 3.45b). The abundance of ubiquitinated ChAT following VCP inhibition was
greater for mutant ChAT when compared to wild-type ChAT, with levels of ubiquitinated
P17A/P19A-ChAT being the greatest. Lastly, higher molecular mass ubiquitinated ChAT
was observed in the loading pockets of SDS-PAGE gels following Eer1 treatment.
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CHAPTER 4: DISCUSSION
4.1: Significant Findings
Maintenance of ChAT protein stability and activity are essential for cholinergic neural
function, and thus are critical for the regulation of both central and autonomic neural
processes as well as somatic neuromuscular functions. Unfortunately, little is known
regarding the cellular factors that either stabilize ChAT protein or, conversely, that promote
the degradation of ChAT. Alterations in ChAT protein stability and enzymatic activity have
been documented and correlated with the pathogenesis of the neuromuscular disease CMS.
Previous studies from other laboratories have identified and characterized multiple CMSrelated ChAT mutations that result in reduced in vitro ChAT activity as well as reduced
steady-state protein levels when expressed in mammalian cells [411, 457-458]. One of
these CMS-related mutations, V18M, is positioned distal to the ChAT active site and is
located within a highly-conserved and surface-exposed proline-rich motif at residues
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PKLPVPP20 that shares homology with PxxP SH3-binding motifs [420, 457-458, 474].

The cellular mechanisms underlying the dysfunction of mutant V18M-ChAT protein are
still unknown, though mutation of residue Val18 could potentially result in disruption of the
ChAT N-terminal proline-rich motif; it is currently unknown whether this proline-rich
motif regulates ChAT function. Thus, the goal of my thesis was to first investigate a
functional role of the ChAT N-terminus on human 69-kDa ChAT protein, with a focus on
the highly-conserved proline-rich motif that surrounds the CMS-related residue Val18.
Second, and in conjunction with my first aim, I sought to determine cellular mechanisms
that regulate the basal stabilization and/or degradation of wild-type ChAT protein and/or
that regulate mutant ChAT protein stability.
In summary, this thesis details the characterization and establishment of a role for
the conserved N-terminal proline-rich motif in regulating the protein stability and activity
of human 69-kDa ChAT. To begin, I found that disruption of the ChAT proline-rich motif
by either N-terminal truncation or proline-to-alanine mutation, or in relation to the CMSrelated V18M mutation, reduces both the steady-state protein levels and cellular activity of
mutant ChAT when transiently expressed in mouse cholinergic SN56 cells. Interestingly,
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proline-to-alanine mutation of residues Pro17 and Pro19 together (P17A/P19A) rendered the
mutant enzyme inactive in cellular lysates and yielded the greatest loss of ChAT protein in
cells similar to that observed for N-terminal truncations that involved partial or complete
removal of the ChAT proline-rich motif. The in vitro catalytic activity of purified
bacterially-expressed recombinant P17A/P19A-ChAT is impaired, though this does not
appear to be due to substantial changes in either gross protein secondary structure or in
vitro thermal stability of mutant ChAT. Importantly, I demonstrated for the first time that
ChAT is ubiquitinated in cells and that the ubiquitination of mutant P17A/P19A- and
V18M-ChAT is enhanced, resulting in increased proteasome-dependent degradation and
loss of mutant ChAT protein in SN56 cells. The cellular loss of P17A/P19A-ChAT protein
correlated with a reduction in ChAT protein half-life as measured using a novel fluorescentbiorthogonal pulse-chase protocol. Proteasome inhibition prevented the degradation of
ubiquitinated wild-type and mutant ChAT, increasing the steady-state protein levels and
protein half-life of ChAT. Lastly, I observed that ChAT can undergo K48-dependent and
K48-independent polyubiquitination and proteasomal degradation. These data have been
peer reviewed and published in the Journal of Neurochemistry [502].
Of significance, these initial studies demonstrated that ChAT protein stability is
regulated by the ubiquitin-proteasome system, and that ubiquitination of catalyticallydeficient mutant ChAT is enhanced, thus identifying a mechanism that may be responsible
for the cellular loss of CMS-related ChAT mutant protein. The molecular mechanisms that
regulate basal ChAT ubiquitination and/or that promote enhanced ubiquitination of mutant
ChAT remained unknown following the aforementioned experiments, and thus I sought to
identify novel cellular mechanisms that regulate ChAT protein stability. By BioID, coimmunoprecipitation, and in situ PLA, I identified the heat shock proteins HSC/HSP70 and
HSP90 as novel ChAT protein-interactors in mammalian cells. Both of these molecular
chaperones are well-known for their role in promoting the folding and stabilization of
cellular proteins. Thus, by pharmacological means I found that inhibition of HSC/HSP70substrate interactions by treatment of SN56 cells with the HSC/HSP70 inhibitor PES
resulted in the accumulation of Triton-insoluble and SDS-resistant wild-type and mutant
ChAT protein aggregates. Furthermore, inhibition of HSC/HSP70 and HSP90 activity by
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treatment of cells with VER-155008 or 17-AAG, respectively, led to reduced cellular
ChAT activity, enhanced ChAT ubiquitination, and increased proteasome-dependent loss
of ChAT protein. Importantly, the effects of HSP inhibition were greater for mutant ChAT
(P17A/P19A-, V18M-, and A513T-ChAT) as compared to wild-type ChAT. HSPs can
alternatively promote the ubiquitination and degradation of misfolded proteins through
cooperative interaction with the E3 ubiquitin ligase CHIP/Stub1, and while I show that
ChAT interacts with CHIP by both co-IP assays and in situ PLA, siRNA-mediated knockdown of CHIP had no effect on either wild-type or mutant ChAT protein levels. However,
inhibition of the ER- and HSP-associated co-chaperone Cdc48/p97/VCP prevented the
degradation of ubiquitinated ChAT. Together, these results identify novel mechanisms for
the functional regulation of both wild-type and CMS-related mutant ChAT by prostabilizing HSPs and the pro-degradative co-chaperone p97/VCP which may have broader
implications for ChAT function during cellular stress and disease. These data have been
peer reviewed and published in Frontiers in Molecular Neuroscience [517]
An important function of HSPs is to chaperone cellular proteins when cells are
exposed to acute proteotoxic stresses, such as hyperthermia and oxidative stress, thereby
maintaining protein stability, solubility, and function. Earlier studies in our laboratory by
Shawn Albers, M.Sc., showed that cellular ChAT activity is decreased in cells exposed to
oxidative stress by H2O2 treatment, and furthermore that ChAT forms redox-dependent
higher molecular mass oligomers following H2O2 treatment [507]. In my work, I found that
the solubility of ChAT protein is decreased, and that ChAT ubiquitination is enhanced in
cells treated with H2O2. Furthermore, inhibition of HSC/HSP70-substrate interactions by
PES treatment further sensitized ChAT to H2O2-induced insolubilization and formation of
higher molecular mass ChAT protein aggregates. Lastly, as assessed by co-IP assays, the
association of ChAT with HSC70, but not HSP90, is enhanced following H2O2-treatment,
suggesting that HSC70 may help to prevent oxidative dysfunction of ChAT by chaperoning
ChAT protein and preventing ChAT misfolding during exposure to oxidative stress. These
initial experiments investigating the effects of oxidative stress on ChAT protein stability,
solubility, and function will help to inform and provide rationale for future work within the
Rylett Laboratory as will be discussed later in this thesis.
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Taken altogether, my results detail within this thesis support a model (Figure 4.1)
where the heat shock proteins HSC/HSP70 and HSP90 promote the folding, stabilization,
and catalytic activity of human 69-kDa ChAT in a cooperative manner, thereby ultimately
regulating ACh synthesis and cholinergic neural function. Furthermore, the basal turnover
of ChAT protein is regulated by the ubiquitin-proteasome system where the co-chaperone
p97/VCP promotes the degradation of ubiquitinated ChAT. I propose that ChAT mutations
that impair ChAT enzymatic activity, such as P17A/P19A and CMS-related V18M, do so
by interfering with the correct/complete conformational folding of ChAT in cells, thus
leading to ChAT destabilization and the generation of misfolded mutant ChAT protein.
Additionally, under cellular conditions that can promote protein misfolding, such as during
exposure to oxidative stress or when HSP functions are inhibited, ChAT protein folding
becomes compromised, resulting in the formation of misfolded and insoluble ChAT protein
aggregates. Subsequently, misfolded and dysfunctional ChAT protein is targeted for
cellular clearance via enhanced ubiquitination and proteasome-dependent degradation,
potentially through chaperone-mediated mechanisms. The identity of the E3 ubiquitin
ligase responsible for ChAT ubiquitination under either basal conditions or that promotes
enhanced ubiquitination of mutant and/or misfolded ChAT remains to be elucidated.

4.2: General Discussion
Canonically, HSPs such as HSC/HSP70 and HSP90 have been characterized for their role
in the folding and stabilization of nascent proteins, as well as refolding of aggregation- and
misfolding-prone proteins during proteotoxic stress [118, 135, 154-155]. In the present
studies I show that inhibition of HSC/HSP70 led to the insolubilization, destabilization,
and degradation of both wild-type and mutant ChAT, and while I found that inhibition of
HSP90 reduced cellular ChAT activity, this had no effect on the steady-state protein levels
of wild-type ChAT. In the currently accepted model (Figure 1.6) multiple HSPs can act
together to chaperone cellular proteins in a cooperative and processive manner, with initial
recognition and folding of non-native nascent proteins completed by a HSP40-HSC/HSP70
complex, followed by transfer of semi-folded HSP substrates to HSP90 by HSP70-HSP90
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Figure 4.1: Model for the dynamic regulation of ChAT protein stability and function
by molecular chaperones and the ubiquitin-proteasome system. (1) The heat shock
proteins HSC/HSP70 and HSP90 act in a cooperative and processive manner to promote
the folding, stabilization, and catalytic activity of human 69-kDa ChAT protein. (2) Under
basal conditions the co-chaperone Cdc48/p97/Valosin-conaining protein (VCP) regulates
the turnover of ChAT protein where inhibition of VCP by Eeyarestatin I (Eer1) treatment
prevents the proteasomal degradation of ubiquitinated ChAT. (3) ChAT protein folding can
become compromised following exposure of cells to either oxidative stress (i.e. H2O2) or
to HSP inhibition (i.e. PES/VER-155008 and 17-AAG), as well as in cases where mutation
of ChAT impairs ChAT enzymatic activity, such as with P17A/P19A and CMS-related
V18M, leading to the generation of misfolded ChAT protein. (4) Misfolded ChAT is then
targeted for cellular clearance through enhanced ubiquitination and proteasome-dependent
degradation, potentially through chaperone-mediated mechanisms. The E3 ubiquitin ligase
responsible for ChAT ubiquitination under either basal conditions or that promotes the
enhanced ubiquitination of mutant and/or misfolded ChAT remains to be elucidated.
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organizing protein (Hop) and subsequent final folding by HSP90 [178-180]. Thus, HSP90
works downstream of HSC/HSP70 to interact with semi- or pre-folded proteins where
formation of stable HSP90-substrate interactions is promoted by availability of labile
solvent-accessible hydrophobic domains, such as those found in ligand-binding domains
and enzyme active sites [234-236, 238, 246, 503]. As such, HSP90 plays an essential role
in the structural maturation and conformational activation of various cellular kinases and
enzymes involved in a wide array of cell signaling pathways, such as endothelial nitric
oxide synthase (eNOS) [518], the cell cycle-associated tyrosine kinase Wee1 [519], steroid
hormone receptors [244, 520], and the receptor tyrosine kinase ErbB2 [245, 503]. This
contrasts with HSC/HSP70 that interacts with a diverse and extensive range of nascent nonnative proteins (20% of all nascent proteins) that minimally contain solvent-exposed
regions enriched with 4-7 hydrophobic residues [167-168, 187, 202]. Thus, I propose that
ChAT protein folding, stability, and cellular activity is regulated in a similar processive
manner by HSC/HSP70 and HSP90 respectively. It is important to note that inhibition of
the ATPase activity of either HSC/HSP70 or HSP90 resulted in the loss of cellular ChAT
activity, suggesting that cooperation of these HSPs is essential for the formation of
natively-folded and active ChAT enzyme, and thus that these HSPs may be critical to
cholinergic neural function. Interestingly though, inhibition of HSC/HSP70 and/or HSP90
did not fully abolish ChAT enzymatic activity, nor did it result in complete loss of ChAT
protein in cells suggesting that these HSPs may work in collaboration with other cellular
molecular chaperones to promote ChAT protein folding, stability, and function.
Multiple co-chaperones regulate the function of HSPs, including HSP40, Hop, and
CHIP. Previous studies from our laboratory have shown that the co-chaperone
Cdc48/p97/VCP can interact with ChAT in IMR-32 neural cells exposed to Aβ [440]. VCP
is a member of the AAA-ATPase family that has diverse cellular functions, including the
ability to interact with and modulate HSC/HSP70 and HSP90 substrates [513-514], as well
as to interact with ubiquitinated proteins to regulate their subcellular trafficking and
degradation [97, 441-442]. Importantly, in the present studies I not only demonstrate for
the first time that ChAT is ubiquitinated in cells and that the degradation of ubiquitinated
ChAT is proteasome dependent, but also show that pharmacological inhibition of VCP led
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to the accumulation of ubiquitinated ChAT and prevented its degradation in cells with
functional proteasomes. Related to its proteolytic functions, studies have demonstrated a
role for VCP in the handling and degradation of protein aggregates [521], as well as in the
degradation of ubiquitinated proteins by the autophagy-lysosomal system [443-444]. While
the autophagy-lysosomal system is one possible mechanism involved in the VCP-mediated
degradation of ubiquitinated ChAT, my studies show that ChAT protein degradation is
largely unaffected by pharmacological inhibition of the lysosome and, conversely, is
regulated chiefly by the proteasome as assessed using the proteasome inhibitors MG132
and lactacystin. Interestingly, VCP is best known for its role in promoting the proteasomedependent degradation of ERAD substrates [441-442], where VCP is critical for the ERto-cytoplasm transfer of proteins ubiquitinated in the ER, thereby directly mediating
degradation of ERAD substrates by the cytosolic 26S-proteasome [522]. Furthermore, VCP
can directly influence the ubiquitination of ERAD substrates by interacting with the ERassociated E3 ubiquitin ligases gp78/AMFR and Hrd1/SYVN1 [522-524] that act
downstream of 78-kDa glucose-regulated protein (GRP-78), an ER-associated HSP known
to promote protein folding and stability of nascent proteins in a fashion similar to that of
HSC/HSP70 [525]. Therefore, an alternative possibility by which VCP regulates the
degradation of ubiquitinated ChAT may involve ERAD-associated mechanisms in addition
to those related to cytosolic HSPs, and thus I hypothesize that ChAT may be regulated by
various cytosolic and/or ER-associated chaperones that act cooperatively to promote ChAT
protein function. Importantly, while my data suggest that the proteasomal degradation of
ubiquitinated ChAT is promoted by VCP, it is unclear whether this pro-degradative
function of VCP is primarily HSP- or ER-associated. Lastly, though the E3 ubiquitin
ligase/s responsible for the ubiquitination of ChAT protein have yet to be identified, my
results establish the possibility that ChAT ubiquitination may be regulated by the E3
ubiquitin ligases gp78 and/or Hrd1; this requires further investigation.
Many neurological disorders, including AD, Parkinson’s, and Huntington’s disease
exhibit dysfunction of HSPs, accumulation of misfolded and aggregate-prone proteins, and
build-up of oxidative stress [10, 526]. Protein oxidation and subsequent formation of
aberrant stress-induced disulfide bonds during cellular exposure to oxidative stress can
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result in gross misfolding of cellular proteins with severe functional consequences [361,
365]. As an example, the cysteine-rich (7.5%) E3 ubiquitin ligase Parkin has been shown
to misfold, inactivate, and aggregate following exposure to H2O2 [368-370]. Of
significance to my studies, human 69-kDa ChAT also has a higher-than-average cysteine
content of 3.2% compared to 1.6% for intracellular mammalian proteins [367] which may
sensitize ChAT to oxidative damage. In support, previous studies from both our laboratory
and by others [439, 507] have demonstrated that cellular ChAT activity is reduced
following exposure of neural cells to oligomeric Aβ1-42, a molecular hallmark of AD and
stimulator of cellular oxidative stress [429, 508]. Additionally, our laboratory has shown
that Aβ1-42 treatment results in stable interaction of ChAT with VCP [440] and, together
with my results establishing a novel role for VCP in the degradation of ubiquitinated ChAT,
suggest that ChAT ubiquitination and subsequent protein stability may be altered during
cellular stress. Importantly, work in this thesis shows that acute exposure of ChATexpressing cells to H2O2-induced oxidative stress results in enhanced insolubilization and
ubiquitination of ChAT protein. One well-known function for HSPs, such as HSC/HSP70
and HSP90, is to maintain proteostasis during acute exposure to cellular stress [118, 135,
154-155], and as such during oxidative conditions these HSPs have been shown to
chaperone oxidized proteins in order to maintain and/or restore protein function [371]. My
results using pharmacological inhibitors of HSC/HSP70 and HSP90 suggest that these
HSPs regulate basal ChAT protein stability in non-stressed cells, and therefore it is likely
that they may also chaperone ChAT during oxidative stress. In support, by co-IP assay I
found that interaction of ChAT with HSC/HSP70 appears enhanced in H2O2-treated cells,
and furthermore that HSC/HSP70 inhibition promoted the H2O2-induced insolubilization
of ChAT protein. It is currently unknown whether exposure to oxidative Aβ results in
alterations in ChAT ubiquitination or solubility, or whether ChAT protein stability is
altered following exposure to other cellular stresses, such as hyperthermia, or during human
protein misfolding diseases such as AD.
In addition to their role as cellular protein chaperones that promote protein folding
and stabilization, HSC/HSP70 and HSP90 are also well-known for their ability to triage
mutated, misfolded, and aggregated proteins for degradation through coordination with the
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cytosolic U-box-containing and HSP-associated E3 ubiquitin ligase CHIP/Stub1 [76-78,
184]. In fact, HSP-mediated protein degradation often requires the formation of prodegradative trimeric complexes between substrate-bound HSC/HSP70 or HSP90 and the
N-terminal TPR domains of CHIP [76, 78, 293]. As such, CHIP has been shown to regulate
a diverse range of cellular functions through CHIP-mediated ubiquitination of HSC/HSP70
and HSP90 substrate proteins, including but not limited to the glucocorticoid receptor [184,
294], hypoxia-inducible factor 1-alpha (HIF-1α) [295], and the receptor tyrosine kinase
ErbB2 [230, 285]. In my present studies, I demonstrate that inhibition of HSC/HSP70 and
HSP90 enhances the ubiquitination of ChAT protein, and subsequently show that ChAT
interacts in situ with endogenous CHIP in SN56 cells. Furthermore, though overexpression
of CHIP promoted the proteasomal degradation of ChAT, siRNA-mediated knock-down of
CHIP failed to stabilize and prevent the degradation of ChAT protein. While unexpected,
one plausible reason for this observation is that other HSP-associated E3 ubiquitin ligases
may regulate ChAT ubiquitination as previous studies have demonstrated functional
redundancy for CHIP-mediated degradation of HSP clients in CHIP-/- mouse fibroblasts
[527]. As such, the E3 ubiquitin ligase Parkin has been shown to associate with both HSPs
and CHIP to co-regulate the chaperone-mediated degradation of HSP clients such as
neuronal nitric oxide synthase (nNOS) and various polyglutamine-expanded proteins [527528]. In addition, other cytosolic E3 ubiquitin ligases can also regulate the ubiquitination
of nascent and misfolded HSP clients, including E6-associated protein (E6-AP) and the Nend rule E3 ligase Ubr1 [529-530]. Interestingly, in my studies I found that the HSPbinding TPR domains of CHIP, but not the catalytic U-box domain, are required for both
the interaction of CHIP with ChAT as well as for the loss of ChAT protein following CHIP
overexpression. Importantly, CHIP has been previously shown to compete with other profolding TPR-containing co-chaperones, such as HOP, for binding to the C-terminal EEVDmotif of HSC/HSP70 and HSP90 thus promoting the destabilization of HSP substrates
[276, 318]. Thus, I hypothesize that alternative HSP-related E3 ubiquitin ligases, such as
Parkin or E6-AP, may regulate the ubiquitination of ChAT protein, potentially in
cooperation with CHIP, whereas CHIP overexpression likely promotes ChAT protein
degradation by interfering with the pro-folding functions of HSPs that stabilize ChAT.
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To my knowledge, work in this thesis demonstrates for the first time the
ubiquitination of human 69-kDa ChAT protein in mammalian cells. Subsequent
characterization of ChAT ubiquitination revealed that ubiquitinated ChAT is degraded in a
proteasome-dependent manner, and furthermore that proteasome inhibition by MG132
treatment prevents degradation of both K48-linked and non-K48-linked polyubiquitinated
ChAT. Canonically, cellular proteins targeted for proteasomal degradation are done so
through covalent modification with poly-Ub chains containing at least four K48-linked
ubiquitin molecules [44, 54, 93]. However, studies investigating either the APC, a RINGdomain E3 ubiquitin ligase involved in cell cycle regulation, or the ERAD-associated cochaperone p97/VCP have identified K11-linked poly-Ub chains as an alternative signal for
proteasomal degradation [94-95, 97-98]. These studies, together with my results, suggest
that ChAT degradation may be regulated by K48- and/or K11-linked polyubiquitination.
Interestingly, in cells with functional proteasomes where ChAT ubiquitination was limited
to modification with proteolytic K11-linked poly-Ub chains I observed impaired
degradation of polyubiquitinated ChAT. Therefore, I hypothesize that K48-mediated
proteasomal degradation represents the dominant mechanism for degradation of ChAT
protein in cells, with K11-mediated degradation potentially representing either a low
abundance or compensatory mechanism for ChAT protein degradation when K48-mediated
degradation is prevented or impaired. Furthermore, given that VCP can interact with K11linked polyubiquitinated proteins [98], and that interaction of ChAT with VCP in enhanced
in neural cells exposed to Aβ1-42 [440], ubiquitination of ChAT with alternative K11-linked
poly-Ub chains may represent a unique modification of ChAT during cellular stress, though
this requires future confirmation.
The initial goal of my thesis was to determine a functional role for the highlyconserved N-terminal proline-rich motif of human 69-kDa ChAT at residues 14PKLPVPP20.
Subsequently, my studies have demonstrated that this motif is essential for the catalytic
activity of ChAT both in vitro and in cells, as well as for the cellular stability of ChAT
protein. Briefly, I show that the ubiquitination and proteasomal degradation of mutant
P17A/P19A-ChAT is enhanced compared to wild-type human 69-kDa ChAT, correlating
with a loss in cellular steady-state protein levels and a reduction in the protein half-life of
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P17A/P19A-ChAT. In studies performed by others, disease-related ChAT mutations have
been identified in CMS patients that reduce both in vitro enzymatic activity and cellular
steady-state protein levels of ChAT when expressed in mammalian cells [411, 457-458],
though the mechanisms underlying the loss of CMS-mutant ChAT protein in cells remains
unknown. One of these catalytically-deficient CMS-related mutations, V18M, is located
within the N-terminal proline-rich motif of ChAT and was found previously to reduce both
the in vitro catalytic efficiency and the steady-state protein levels of the mutant enzyme
[457-458]. Importantly, my results show that the ubiquitination and proteasomal
degradation of mutant V18M-ChAT is increased when compared to wild-type ChAT,
paralleling my observations made for catalytically-inactive P17A/P19A-ChAT. Moreover,
I observed increased ubiquitination of an additional non-active site and catalyticallydeficient CMS-related mutant, A513T-ChAT, that has been previously shown to also
display reduced steady-state ChAT protein levels in cells [457]. Given these data, ChAT
mutations positioned either within or outside of the N-terminal proline-rich motif that
reduce ChAT catalytic activity may also promote enhanced ubiquitination and proteasomal
degradation of mutant ChAT, thereby synergistically enhancing the catalytic defects of
these mutants in vivo. Thus, I propose that enhanced ubiquitination and subsequent
proteolytic degradation may be a common feature among various CMS-related mutant
ChAT proteins, suggesting that prevention of proteasomal degradation may enhance the
cellular activity of some CMS-related ChAT mutants. In support of this, I have shown that
proteasome inhibition increases the steady-state protein levels and cellular enzymatic
activity of both wild-type and the CMS-related ChAT mutants A513T- and T490N-ChAT.
Conversely, while proteasome inhibition did increase the steady-state protein levels of
mutant P17A/P19A- and CMS-related V18M-ChAT, these mutants remained catalytically
impaired in cells. Thus, these results suggest that inhibition of ChAT ubiquitination and/or
proteasomal degradation may represent a novel avenue for the in vivo stabilization and
synergistic enhancement of the enzymatic activity of certain CMS-related ChAT mutants.
While my results show that mutation of the N-terminal proline-rich motif enhances
ChAT ubiquitination and degradation in cells, the cellular mechanisms responsible for
these effects remain to be elucidated. Interestingly, the N-terminal proline-rich motif of
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ChAT shares structural and sequence homology with the core “PxxP” SH3 binding motif
[420, 474-477]. Interactions between SH3 motif- and SH3 domain-containing proteins have
been shown to regulate the subcellular trafficking, activity, and stability of multiple cellular
proteins, most often by modulating changes in protein phosphorylation through SH3
domain-containing adaptor proteins, such as Grb2 and Nck, and various cellular protein
tyrosine kinases [476-479]. Prior to work completed in this thesis, only a handful of proteinprotein interaction involving human ChAT had been identified, of which include the protein
kinases PKC and CaMKII and the co-chaperone p97/VCP [438]. Importantly, work in our
laboratory has shown that hierarchical phosphorylation of ChAT by either PKC or CaMKII
alters the cellular activity of ChAT, indicating that ChAT enzymatic function is influenced
by dynamic phosphorylation [410, 426-427, 440]. Furthermore, studies by others have
demonstrated that phosphorylation can influence the ubiquitination and degradation of
multiples members involved within the EGFR/MAPK signalling network through various
phospho-binding E3 ubiquitin ligases, such as members of the Cbl family [531-533]. It is
currently unknown whether ChAT engages in SH3-dependent protein-protein interactions
mediated through its N-terminal proline-rich motif. Furthermore, it is unknown if ChAT
mutations, specifically those found within the N-terminal proline rich motif (i.e. V18M),
alter the phosphorylation of ChAT, and whether this may correlate with loss of cellular
activity and protein stability of mutant ChAT.
As discussed above, in this thesis I found that the ubiquitination and degradation of
specific CMS-related ChAT mutants (i.e. V18M- and A513T-ChAT), as well as mutant
P17A/P19A-ChAT, is enhanced in cells. All three of these mutations are positioned distal
to the ChAT active site [420, 457], and while the mechanisms responsible for the loss of
mutant ChAT protein in mammalian cells are not yet fully clear, one possibility is that these
mutations may produce local labile changes to the ChAT protein secondary structure that
are then responsible for both the catalytic impairment of ChAT and that target these ChAT
mutants for chaperone-mediated degradation. Importantly, using purified bacteriallyexpressed recombinant ChAT proteins I found that mutation of the ChAT N-terminal
proline-rich motif does not produce substantial changes to the overall gross protein
secondary structure or the in vitro thermal stability of purified recombinant ChAT as
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measured by circular dichroism analysis. As such, it is not obvious how these mutations
destabilize ChAT protein in vivo, and thus by BioID I sought to identify ChAT proteininteractors responsible for the stabilization and/or enhanced degradation of mutant ChAT
in mammalian cells. Though I did not detect any SH3-mediated ChAT protein-protein
interactions by BioID, I did identify the heat shock proteins HSC/HSP70 and HSP90 as
novel ChAT protein-chaperones and observed by co-IP assay enhanced interaction of
mutant ChAT with these HSPs as compared to that seen for wild-type ChAT. Furthermore,
I show that various ChAT mutants (i.e. P17A/P19A, V18M, and A513T) have increased
sensitivity to pharmacological inhibition of both HSC/HSP70 and HSP90 where,
importantly, HSP90 inhibition resulted in the proteasomal loss of mutant but not of wildtype ChAT. In general, HSPs aid in the stabilization of their substrates through a process
of kinetic partitioning, whereby they interact with exposed hydrophobic domains within
cellular proteins that is thought to prevent client protein misfolding and aggregation [6,
167-168, 503]. In support of this, I found that inhibition of HSC/HSP70-substrate
interactions by PES treatment resulted in loss of ChAT protein solubility and the generation
of Triton-insoluble and SDS-resistant ChAT aggregates, with the abundance of these PESinduced insoluble ChAT proteins being greatest for mutant ChAT. Interestingly, Tritoninsoluble aggregates of mutant P17A/P19A-ChAT protein was observed in cells with
functional HSPs, suggesting that the folding of this mutant ChAT protein may be
compromised under basal conditions, resulting in the production of catalytically-impaired
ChAT that may be susceptible to misfolding and inactivation. While my results suggest that
HSC/HSP70 and HSP90 are critical for the stabilization of mutant ChAT, these HSPs are
also known to promote the degradation of misfolded proteins through the ubiquitinproteasome system [6, 76-78, 118]. Importantly, I observed enhanced ubiquitination of both
wild-type and mutant ChAT following HSP inhibition, suggesting that impairment of HSPmediated folding of ChAT protein may promote the ubiquitination and degradation of
misfolded ChAT. Therefore, taken together my data suggest that mutations, such as CMSrelated V18M and A513T, may compromise ChAT protein folding and the conformational
activation of ChAT in vivo, leading to enhanced chaperone-mediated ChAT degradation
and/or enhanced dependence of mutant ChAT proteins on HSPs to maintain mutant ChAT
stability and function. It is important to note that my HSP observations related to mutant
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ChAT are significant as protein misfolding and enhanced functional dependence on
molecular chaperones is frequently observed for mutated and disease-relevant proteins
[125, 534]. Thus, my observations may represent a general HSP-related mechanism for the
regulation of ChAT protein stability that may apply to not only various CMS-related ChAT
mutants beyond those studied presently, but also to the maintenance of ChAT function
during cellular stress and disease, such as that observed in this thesis for ChAT-expressing
cells exposed to oxidative stress by H2O2 treatment.
An important outcome of my studies was the development of a novel approach to the
study of cellular protein half-life. The biochemical determination of protein half-life can
provide insight into the stability, regulation, and function of cellular proteins. Two differing
methods are commonly used to determine protein half-life; ribosomal inhibition by CHX
treatment, a potent yet cytotoxic inhibitor of protein synthesis [501], or pulse-chase
experiments that utilize radioactive
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S-methionine live-labeling [535-537]. While

35

S-

methionine labeling is held as the gold standard for pulse-chase analysis, metabolic
radiolabeling has been found to induce cellular damage and reduce cell survival, suggesting
that care is needed when interpreting results gathered by this approach [538-539]. In
response to these concerns, I have developed an alternative and novel protocol for the
biorthogonal determination of protein half-life by fluorescent labeling of nascent proteins
using “click chemistry” [502]. My protocol is a direct adaptation on 35S-methionine pulsechase labeling whereby newly synthesized nascent proteins are first live-labeled in culture
with the biorthogonal amino acid L-azidohomoalanine (AHA), a non-radioactive and azidecontaining methionine analog, that are then reacted with fluorescently-tagged strained
cyclooctynes to form stable fluorescent triazole conjugates using metal-free SPAAC
reactions [495-496]. Importantly, using this novel protocol I not only determined the
protein half-life of human 69-kDa ChAT, but have also shown that ChAT protein half-life
is reduced following mutation of ChAT N-terminal proline-rich motif (i.e. P17A/P19A) or
that it is increased following cellular proteasome inhibition by MG132 treatment. While
SPAAC reactions have been used previously both in vitro and in vivo to measure global
changes in protein synthesis [497-500], to my knowledge my studies are the first to use
SPAAC reactions to measure the protein half-life of a specific cellular protein of interest.
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My protocol has several advantages over the more standardized CHX or

35

S-methionine

pulse-chase assays, foremost being that AHA live-labeling of HEK293 cells has been
previously shown to be highly specific for newly-synthesized proteins and, importantly, is
non-toxic to cells [498]. Second, AHA-labeled proteins can be used for both fluorescent
and immunoblotting analysis from the same sample preparation, thereby eliminating the
need to prepare both labelled and non-labelled protein samples when performing similar
35

S-methionine pulse-chase experiments. Lastly, an additional advantage of my protocol is

the ever-growing selection of commercially available biorthogonal amino acids and
complementary fluorescent or chemiluminescent probes that can be used in copper-free
SPAAC reactions. This advantage allows for increased flexibility when designing pulsechase experiments and increases the compatibility of my protocol with commonly-used
laboratory equipment and procedures without the reliance on radioactive 35S-methionine or
cytotoxic CHX. Overall, I propose that my SPAAC pulse-chase protocol represents a novel,
non-toxic, and non-radioactive alternative/replacement to classical CHX or 35S-methionine
pulse-chase methods, and furthermore is an important example of the utility for click
chemistry in the safe and effective alteration of existing and well-practiced methods.

4.3: Study Limitations and Alternative Approaches
The major limitation for any study is the choice of biological model/s and the associated
techniques used to assess study objectives. For my studies, to determine the effects of
ChAT mutations on the regulation of ChAT protein stability and function I used transiently
transfected cells lines due to their availability, ease of use, and speed by which I was able
assess my initial experimental aims centered around mutated forms of human ChAT
protein. Given that ChAT is a defining cholinergic protein, the use of cholinergic neural
cells in my studies was imperative to minimalize the acquisition of misleading results
associated with studying neural proteins in non-neural cells. In addition, as transient
transfection was to be my primary means to express wild-type and mutant ChAT protein in
cells, transfection efficiency and the ability to express heterologous proteins were major
considerations for an appropriate cell line for my study. Many well-documented neural cell
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lines exist, including human neuroblastoma SH-SY5Y cells [540-541], a cell line that has
been extensively used for the study of cholinergic molecular mechanisms related to
neurogenerative diseases [542-544]. Though useful for the study of either endogenous
neural proteins or for the generation of stable cell lines, SH-SY5Y cells are notoriously
difficult to transfect, transiently express heterologous proteins at low levels relative to other
mammalian cell lines, and often experience transfection-related cytotoxicity. Therefore, to
circumvent these limitations, for the majority of my studies I used mouse cholinergic SN56
cells [485, 545], a neural cell line that has been used by other groups to study both
cholinergic and ChAT function in cell culture [546-550]. Ultimately, my choice for using
mouse SN56 cells was four-fold, being that these cells are easy to transfect by multiple
methods (e.g. calcium phosphate and Lipofectamine), express relatively higher levels of
heterologous protein, are resistant to transfection-induced cytotoxicity, and in culture
require minimal serum (2 – 5%) and grow quickly with a doubling-time of ~24 hours.
Importantly, SN56 cells also have an undifferentiated cholinergic phenotype [485, 547],
whereas SH-SY5Y cells require differentiation to attain this phenotype [544, 551]. These
attributes together make SN56 cells an excellent and effective option for the molecular
study of cholinergic processes in cell culture that require transection-based methods.
Though SN56 cells proved useful throughout my thesis, there were limitations to
my study of human ChAT protein function in these cells. First, my studies were completed
in undifferentiated SN56 cells, and while these cells do have a basal cholinergic phenotype,
differentiation using retinoic acid and dibutyryl-cAMP has been shown to enhance the
cholinergic properties of SN56 cells, correlating with enhanced endogenous ChAT activity
and ACh content, reduced cell division, and neurite outgrowth [485, 547]. It is currently
unknown what impact differentiation would have had on my results, though I hypothesize
that any effects may have been negligible as the mechanisms found to regulate ChAT
protein stability in this thesis, i.e. the ubiquitin-proteasome system and HSPs, are known to
be well-conserved between many different tissue types. A second limitation to my use of
SN56 cells is that I studied a human protein in mouse cells. While this is common when
studying disease-related human proteins in mouse models [552-553], this limitation is often
avoidable in cell culture studies due to the variety of available human cell lines. As
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discussed above, mouse SN56 cells are an excellent option for cholinergic studies requiring
transfection, and while the mouse proteome does differ from that found in human cells, a
high degree of compositional and function proteomic similarity has been observed between
cells from these two species [554-555]. Interestingly, in my studies I observed results that
differed in some respects when analyzing anti-ChAT co-IPs completed from either human
kidney HEK293 or mouse SN56 cells. Specifically, unique to HEK293 cells I observed coIP of ChAT with stress-inducible HSP70 and saw enhanced interaction of P17A/P19AChAT with HSP90; co-IP of ChAT with HSC70 and HSP90 was observed in both HEK293
and SN56 cells. Of note, HEK293 cells have elevated constitutive expression of HSP70
due to the E1A-mediated immortalization of these cells [556-557], whereas in SN56 cells
the stress-induced expression of HSP70 was limited to cells exposed to either hyperthermia
(data not shown) or to the HSP90 inhibitor 17-AAG (Figure 3.30). Therefore, observational
differences made between these two cell lines are likely multifactorial (i.e. species/tissue
type and HSP expression) and may be unique to HEK293 cells. It is unknown if my results
would have also differed if assessed in human cholinergic cells, such as SH-SY5Y cells.
As is common for cell-based studies, transient transfections were used throughout my
experiments as I required straightforward, routine, effective, and consistent heterologous
expression of multiple proteins of interest including engineered and CMS-related ChAT
mutants. A limitation of this approach is the typical overexpression of heterologous protein
observed when using expression vectors, such as pcDNA3.1, that contain strong
constitutive promoters [558]. As it is often unknown whether overexpressed heterologous
proteins behave like or are regulated in a similar fashion to their endogenous counterparts,
studies that can wholly or partially investigate endogenous proteins have an advantage by
limiting the potential for unintended effects due to protein overexpression. Importantly,
though my studies relied on heterologous expression of wild-type or mutant ChAT, my
experiments focused on ChAT function as it was related to various endogenous proteins,
including ubiquitin, HSC/HSP70, HSP90, CHIP, and p97/VCP. It is currently unknown
whether endogenous ChAT protein is regulated likewise to that observed in my studies.
One alternative to transient heterologous protein expression is the generation of cells stably
expressing a heterologous protein of interest [559], though this carries risks associated with
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random genome integration of plasmid cDNA and unintended cellular consequences due
to long-term constitutive protein overexpression. To address these issues, modern
techniques have been developed that allow for guided genomic integration of inducible
cDNA (e.g. Flp-In T-Rex System; Thermo) or for genomic editing of endogenous proteins
using CRISPR-Cas9 technology [560-561], though transient transfection remains the most
standard and simplest approach for the expression of heterologous proteins in cell lines.
The most significant limitation of my study was the extensive use of immortalized cell
lines to study ChAT protein stability, and while the use of cell lines remains a standard
approach for the molecular study of protein function, care must be taken when interpreting
results generated from such studies. Specifically, most immortalized cell lines are derived
from genetically unstable tumorigenic cells, including SN56 cells [485, 545, 562-563], and
thus a major concern is that these cell likely harbour tumour-promoting proteomic changes
that could have an unforeseen or deleterious impact on experimental results. While this is
a well-known limitation, the availability and accessibility of immortalized cell lines has
made them an effective molecular tool, particularly for exploratory studies such as mine.
Alternatively, the use of non-tumorigenic primary cells or induced pluripotent stem cells
(IPSCs) has gained popularity due to the development of effective transfection techniques
for primary cells [564], as well as the creation of protocols for the growth, differentiation,
and use of IPSCs. While proposed to be a more physiologically-relevant tool for the study
of biological processes, the use of primary cells or IPSCs remains today both costly and
challenging, particularly due to difficulties in the isolation, culturing, and transfection of
these cells. Though these constraints may reduce the experimental flexibility of these cells
as compared to immortalized cell lines, I propose that it will be important to assess whether
select results from my thesis are reproducible in either primary neurons or IPSCs.
In addition to these study-wide limitations, experiment-specific limitations also need to
be addressed. First, to characterizing ChAT ubiquitination in SN56 cells I overexpressed
various ubiquitin mutants over-top of an endogenous ubiquitin background (Figure 3.11).
Unexpectedly, I observed enhanced recovery of ubiquitinated ChAT in MG132-treated
cells expressing heterologous K48R-ubiquitin that is unable to form proteolytic K48-linked
poly-Ub chains (Figure 3.11c). While this result may suggest that ChAT can be targeted
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for proteasomal degradation by non-classical polyubiquitin chains, such as K11-linked
poly-Ub chains, it is more likely that under these experimental conditions small quantities
of ChAT protein could be degraded through ubiquitination with endogenous K48-linked
poly-Ub chains. To address this limitation in future experiments, ChAT polyubiquitination
can be further characterized following anti-ChAT IPs using linkage-specific anti-ubiquitin
antibodies (e.g. K11, K48, and K63 linkages) in substitution of total-ubiquitin antibodies
that were used earlier in my studies (Figure 3.10).
A second experimental limitation is that my BioID experiments were completed in
human HEK293 cells, and not in cholinergic SN56 cells, primarily due to the superior
transfectability and transient expression of heterologous proteins typically seen in HEK293
cells. In support of my use of HEK293 cells, I found in initial optimization experiments
that the transient expression of multiple ChAT-BirA* fusion proteins was the greatest in
HEK293 cells as compared to either SN56 or SH-SY5Y cells, and that this correlated with
a greater abundance in the total amount of biotinylated cellular proteins that could be used
downstream for BioID (Appendix A). Additionally, another limitation of my BioID studies
is that my large-scale BioID experiment with follow-up mass spectrometry was completed
once without repetition (n=1), though this did result in the identification of HSP70 and
HSP90 as potential ChAT-interacting proteins (Figures 3.18 – 3.22). It is important to note
that while my large-scale BioID experiment was completed only once, biotinylated proteins
correlating with the molecular mass of HSP70 were observed in repeated optimization
experiments on streptavidin-HRP blots (Figure 3.17; n=2), and furthermore that HSP70 and
HSP90 were directly confirmed by immunoblotting from streptavidin PDs from follow-up
small-scale BioID experiments (Figure 3.23; n=4). While there are limitations to my use of
HEK293 cells for BioID, the goal of these experiments was ultimately to identify potential
ChAT-interacting proteins that could then later be confirmed by alternative methods, such
as by co-IP and in situ PLA assays, in cholinergic cells. As such, and importantly, my BioID
results were largely confirmed and expanded upon by follow-up studies in cholinergic
SN56 cells, though I propose that any future BioID experiments investigating ChAT
protein-interactions should be completed in cholinergic cells where feasible.
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Following BioID I used in situ PLA assays to test and confirm the presence of ChAT
protein-interactions with HSC70 and HSP90 in SN56 cells. One limitation to my approach
of these experiments was that cells were not co-stained with a second alternative anti-ChAT
antibody that could be used to verify that PLA-positive cells were expressing heterologous
human ChAT protein. The stringent nature of the in situ PLA technique is based on the
observation that, to generate a positive PLA reaction, two antibody-labeled proteins must
be no more than 40 nm apart from each other [565-567], and therefore it is unlikely to
generate PLA signals unless the tested proteins in questions are in direct contact.
Importantly, as no positive PLA signals was generated in control cells transfected with
empty vector that were incubated with anti-ChAT and either anti-HSP or anti-CHIP
antibodies (Figures 3.26 and 3.35), I propose that this limitation does not significantly
impact my results. However, in future PLA experiments involving heterologous expression
of human ChAT protein it will be important that this limitation be addressed.
Lastly, a fourth experimental limitation to my studies is the use of small molecule
inhibitors for the study of HSC/HSP70, HSP90, and p97/VCP function. While this is a
common approach to the study of molecular pathways, and provided that the inhibitors used
within my studies, including PES and VER-155008 (HSC/HSP70), 17-AAG (HSP90), and
Eer1 (VCP), have all been previously shown to be selective for and efficacious against their
intended targets [213, 217, 516, 568], off-target effects of these small molecules must
always be considered. The most common alternatives to small molecule inhibitors typically
involve reducing (knock-down) or eliminating (knockout) the endogenous expression of a
protein of interest. While knockout studies that do not require the generation of transgenic
animals are becoming more common and accessible due to the advent of CRISP-Cas9
technology [560-561], RNAi-mediated knock-down remains the standard approach for
cell-based studies that offers a high degree of experimental flexibility for the study of
endogenous proteins in cells. Unfortunately, in preliminary experiments I found that
siRNA-mediated knock-down of HSC/HSP70 reduced the cellular viability of SN56 cells
by 70-90% as compared to cells transfected with scramble-control siRNA when assessed
by alamar blue assay (Appendix B). Furthermore, while I was able to obtain an ~50%
knock-down of HSP90 in SN56 cells, this is most likely insufficient to prevent the cellular
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chaperoning functions of HSP90 due to the high endogenous levels of HSP90 (1-2% of all
cellular protein) [162, 227]. In relation to VCP inhibition, other studies have previously
shown comparable results between Eer1 treatment and siRNA-mediated knock-down of
VCP [515-516]. Though knock-down studies have been used to investigate the function of
many cellular proteins, one advantage of pharmacological inhibition is the possibility to
target different functional domains within a protein of interest. In my studies, this advantage
was most evident when using the HSC/HSP70 inhibitors PES (substrate binding) and VER155008 (ATPase activity) that produced differing though complementary results towards
ChAT protein solubility and stability in SN56 cells. Taken together, I propose that the use
of small molecule inhibitors within this thesis was a safe and effective approach to studying
the cellular mechanisms that regulate ChAT protein function.

4.4: Future Directions
Future work related to my studies can be separated into two categories involving either
short-term follow-up experiments or more long-term projects. To begin, in the short-term
it will be important to follow-up on select observations from my thesis given the
experimental limitations to my studies as discussed above. Subsequently, I propose that an
immediate follow-up study should be to test whether my core observations from SN56 cells
are reproducible in alternative cholinergic cells, such as differentiated human SH-SY5Y
cells and/or primary mouse neuron cultures. Importantly, these cell models can be used to
confirm that (a) P17A/P19A- and CMS-mutant ChAT are targeted for proteasomedependent degradation through enhanced ubiquitination, (b) that wild-type and mutant
ChAT interact with HSC/HSP70 and HSP90, (c) that HSP inhibition promotes the
insolubilization, ubiquitination, and degradation of ChAT protein, and (d) that the
solubility and ubiquitination of ChAT is altered following exposure to cellular oxidative
stress. Most if not all these follow-up experiments in alternative cholinergic cells will need
to be performed using heterologous-expressed wild-type and/or mutant ChAT protein, and
while this poses a potential setback due to transfection difficulties, recent studies have
detailed new and enhanced transfection techniques designed for difficult-to-transfect cell
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lines (i.e. SH-SY5Y cells) and primary neuron cultures [564, 569-570]. Furthermore,
alongside of these conformational studies using either human cholinergic cells lines or
primary neuron cultures it may be useful to also assess whether (a) endogenous ChAT is
targeted for proteasomal degradation, and (b) if HSP inhibition promotes degradation
and/or reduces the enzymatic activity of endogenous ChAT in cells. Unfortunately, as
tested previously in our laboratory, the relative protein expression of endogenous 69-kDa
ChAT in cholinergic cells is very low when compared to cells transiently transfected to
express heterologous ChAT (data not shown), making the molecular study of endogenous
ChAT protein very challenging. As such, these follow-up experiments investigating
endogenous ChAT are a possibility, though are not a priority.
In addition to these alternative cell model studies, the direct follow-up of specific
experiments from this thesis in SN56 cells would be to useful to further build on my studies
and expand our understanding of the mechanisms that regulate ChAT protein stability.
These include, for example, (a) the use of chain-specific anti-ubiquitin antibodies to
characterize ChAT polyubiquitination, (b) to assess whether inhibition of HSC/HSP70 by
PES treatment results in enhanced ChAT ubiquitination in addition to reducing the
solubility of ChAT protein as observed above (Figures 3.27 and 3.43), (c) to test if VCP
inhibition using Eer1 also promotes ChAT insolubilization, and (d) to investigate if ChAT
interacts with VCP under non-stressed conditions using co-IP and/or in situ PLA assays. In
addition, further experimentation related to my novel SPAAC pulse-chase protocol is
needed to build on and provide more evidence for the applicability, flexibility, and accuracy
of this novel technique as compared to more standard CHX or 35S-methionine pulse-chase
assays. To this end it will be important to perform SPAAC pulse-chase in alternative cell
lines, potentially including primary cells, using either heterologous or endogenous proteins
that have either an unknown (e.g. 82-kDa ChAT) or well-defined protein half-life (e.g. p53)
[571-572]. Additionally, given the wide-array of commercially available click chemistry
reagents, these follow-up SPAAC pulse-chase experiments could use alternative probes,
such as various DIBO-conjugated Alexa Fluors, or Biotin-DIBO (Thermo) that would
enable determination of protein half-life by streptavidin-HRP blotting without the need of
a fluorescence detector or the use of radioactivity. It is important to note that, aside from
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alternative reagents, all the above immediate follow-up studies to my experimental work
would utilize similar or exact techniques that were used throughout my thesis, allowing for
the quick and straightforward assessment of these experiments.
Results from my thesis support further long-term investigation into alternative
mechanisms beyond cytosolic HSPs that may regulate ChAT protein stability and function
under physiological conditions and/or during cell stress and disease (Figure 4.2). First, in
relation to my results detailing the effects of VCP inhibition, the stability and function of
ChAT protein could be assessed in relation to ERAD-associated mechanisms. As discussed
above, VCP is best known for its critical role in mediating ER-to-cytoplasm transfer of
proteins ubiquitinated in the ER [441-442, 522], and furthermore inhibition of VCP by Eer1
treatment has been previously shown to inhibit the degradation of ubiquitinated VCP and
ERAD substrates [515-516]. Thus, as in my studies I showed that VCP inhibition prevented
the degradation of ubiquitinated ChAT, it is possible that the basal ubiquitination of ChAT
may be regulated through ERAD-related mechanisms. Though I found that the E3 ubiquitin
ligase CHIP interacts with ChAT in situ, siRNA-mediated knock-down of CHIP had no
effect on ChAT protein levels, and thus the E3 ligase/s responsible for ChAT ubiquitination
remain to be elucidated. Ubiquitination of mammalian ERAD substrates is regulated by
two differing ER-bound E3 ubiquitin ligases, gp78/AMFR and Hrd1/SYVN1 [573-575].
Importantly, these E3 ubiquitin ligases and their ubiquitinated substrates can interact with
VCP through the ER-localized adaptor protein Ubx2 [576-577], acting together to mediate
the retrotranslocation of ERAD substrates into the cytoplasm for degradation by the 26S
proteasome [522-524]. Though pharmacological inhibitors of these E3 ubiquitin ligases are
not commercially available, siRNA-mediated knock-down has been used in the past as an
effective tool to study the functions of gp78 and Hrd1 and of their cellular substrates [578580]. Interestingly, gp78, Hrd1, and VCP act together downstream of GRP-78 and GRP94, two ER-localized molecular chaperones that are related-to and that share homologous
functions to HSC/HSP70 and HSP90 respectively [525, 555, 575, 581-582]. Thus, given
that my studies have demonstrated a role for the cytoplasmic chaperones HSC/HSP70 and
HSP90 on ChAT protein stability and function, it is possible that the homologous and ERassociated GRP-78 and/or GRP-94 may also chaperone nascent ChAT protein. Like gp78
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Figure 4.2: Hypothetical model for the regulation of ChAT protein stability by the
endoplasmic reticulum-associated degradation (ERAD) system. (1) Nascent ChAT
protein interacts with and is chaperoned by the heat shock proteins GRP-78 and GRP-94 in
the ER lumen. (2) Once localized to the cell cytoplasm, semi-folded ChAT protein interacts
with HSC/HSP70 and HSP90 in order to produce fully-folded and conformationally-active
ChAT enzyme. (3) If initial folding of nascent ChAT protein in the ER by GRP-78 and/or
GRP-94 is unsuccessful, ChAT may be ubiquitinated by the ER-localized E3 ubiquitin
ligases gp78/AMFR and/or Hrd1/SYVN1. (4) p97/VCP, linked to the ER by the adaptor
protein Ubx2, regulates retrotranslocation of ER-ubiquitinated ChAT into the cytoplasm
for degradation by the cytosolic 26S proteasome. VCP inhibition by Eeyarestatin I (Eer1)
treatment prevents the degradation of ubiquitinated ChAT. (5) Cellular stresses, such as ER
and/or oxidative stress (e.g. H2O2, Aβ), may promote the misfolding of ChAT protein and
subsequent degradation of ChAT through ERAD and/or cytosolic HSP mechanisms.
158

and Hrd1, knock-down studies have been used in the past to elucidate the cellular functions
and substrates of either GRP-78 [583-584] or GRP-94 [254, 585]. Therefore, alongside
siRNA knock-down studies, I propose that co-IP and in situ PLA assays could be used to
quickly and effectively assess whether ChAT may interact with various ERAD-associated
chaperones and E3 ubiquitin ligases, and if so to determine if interaction with these ER
proteins regulates ChAT protein stability in a manner consistent with their known ERADrelated functions. These initial studies can then be expanded upon by investigating ChAT
ubiquitination and degradation under conditions of ERAD impairment (i.e. knock-down)
or in cells exposed to various ER stress-inducing small molecules, including tunicamycin,
thapsigargin, and brefeldin A [586-587]. Lastly, one of the most well-studied roles for
ERAD is as a central hub for multiple protein quality control mechanisms that act together
to triage misfolded and mutated proteins for proteasomal degradation [588-589], and as
such ERAD may represent a cellular pathway responsible for the enhanced ubiquitination
and degradation of various CMS-related ChAT mutants.
Lastly, another important avenue for future investigation will be to identify the
cellular mechanisms that may promote ChAT stability and function during cellular stress
and disease. Results from my studies related to oxidative stress suggest that cytosolic HSPs,
particularly HSC/HSP70, may chaperone ChAT during cellular stress so to prevent stressinduced misfolding, loss of solubility, enhanced ubiquitination, and subsequent degradation
of ChAT protein. Though these preliminary studies were completed using H2O2, a potent
inducer of oxidative stress [590-591], alternative studies have demonstrated that ChAT
activity is altered in cells acutely exposed to AD-related and oxidative Aβ1-42 oligomers
[438-440]. Additionally, impairment of ChAT activity has been associated with the
pathogenesis of AD [432-435], an age-related neurodegenerative disease characterized
partly by the dysregulation of molecular chaperones, including HSPs, and various protein
quality control mechanisms [10, 329]. As such, an important question that will need
addressing is whether acute and/or prolonged cellular exposure to oxidative Aβ1-42 may
promote the insolubilization and ubiquitination of ChAT protein like that observed in my
studies following H2O2 treatment. Furthermore, a potential protective role for HSC/HSP70
and/or HSP90 towards ChAT function during Aβ-stress could be assessed by co-treatment
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of ChAT-expressing cells with Aβ1-42 in combination with inhibitors of either HSC/HSP70
(e.g. PES and VER-155008) or HSP90 (e.g. 17-AAG). Following these treatments, the
solubility, ubiquitination, and enzymatic activity of ChAT protein could be determined
using similar techniques to those used in the thesis, including but not limited to Triton X100 fractionation, IP/co-IP assays, and radioenzymatic assay to determine cellular ChAT
activity. Interestingly, multiple studies have reported on the potential therapeutic potential
for either activation of HSF1 (i.e. the heat shock response) or enhancement of HSC/HSP70
activity on the pathogenesis of protein misfolding neurodegenerative diseases, including
AD [592-594], and as such it would be interesting to test if these strategies may help to
ameliorate ChAT dysfunction during cellular stress and disease. It is important to note that,
in addition to oxidative stress, another key feature of many age-related neurodegenerative
diseases is heightened ER stress and ER dysfunction due to the accumulation of misfolded
proteins [595-596], and subsequently studies have shown that cellular exposure to cytotoxic
Aβ can directly induce ER stress [597-598]. Of significance, previous work from our
laboratory has shown that interaction of ChAT with the ER-associated co-chaperone
p97/VCP is enhanced in neural cells treated with Aβ1-42 [440], suggesting that the
regulation of ChAT ubiquitination and function may be altered following exposure to ER
and/or oxidative stress. Therefore, these proposed studies investigating the effects of Aβstress on ChAT protein stability may be intimately linked with my other proposed studies
assessing a potential role for ER-associated chaperones and ERAD-related mechanisms on
the regulation of ChAT protein function (Figure 4.2).

4.5: Significance and Concluding Remarks
In summary, for this thesis I initially set out to determine a functional role for the highlyconserved N-terminal proline-rich motif of human 69-kDa ChAT and found that both the
cellular protein stability and enzyme activity of ChAT protein is dramatically reduced
following alteration of this motif. In addition, I demonstrated for the first time that ChAT
protein levels are modulated through the ubiquitin-proteasome system, and furthermore
that the ubiquitination of catalytically-deficient ChAT, such as CMS-related V18M-ChAT,
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is increased. In search for cellular mechanisms that may regulate ChAT protein stability
and/or that are responsible for enhanced ubiquitination of mutant ChAT, I found evidence
that a network of cytoplasmic and ER-associated chaperones, which included the heat
shock proteins HSC/HSP70 and HSP90 along with the co-chaperone Cdc48/p97/VCP,
regulates ChAT protein stability and function. The regulation of specific catalyticallydeficient ChAT mutants (i.e. P17A/P19A, V18M, and A513T-ChAT) by these chaperones
is altered, suggesting a mechanism that may be relevant to other CMS-related ChAT
mutants or to ChAT protein during cellular stress and disease. Subsequently, in preliminary
experiments I observed evidence that HSC/HSP70 may play a role in the maintenance of
ChAT protein solubility, stability, and function during cellular exposure to oxidative stress.
For future studies, this thesis supports research into the mechanisms that regulate ChAT
ubiquitination and the role that ubiquitination may play in relation to ChAT dysfunction
during cellular stress. Lastly, my results merit additional assessment of the roles for various
cytosolic and ER-associated HSPs, along with the co-chaperone VCP, on ChAT stability
and function under both physiological conditions and during cellular stress and disease.
In conclusion, this thesis has established and characterized the roles of various
molecular chaperones and the ubiquitin-proteasome system on the regulation of human 69kDa ChAT protein stability and function. It is important to note that to date ChAT is the
sole enzyme known to synthesize the neurotransmitter ACh, and thus is both critical to and
necessary for the function of cholinergic neurons [390, 392, 599]. These neurons can be
found throughout the central, peripheral, and somatic nervous systems, where they are
involved in the regulation of numerous bodily functions. These processes include cognitive
functions such as behaviour, attention, and learning/memory, as well as various autonomic
(e.g. pupil dilation, heart rate, and gastric and renal function) and neuromuscular processes
(i.e. movement and motor control) [389-390, 392, 599-600]. Consequently, dysregulation
of ChAT function, ACh synthesis, and cholinergic neurotransmission has been observed in
multiple neurodegenerative and neuromuscular disorders including AD and CMS [387388, 411, 457-458]. Thus, by gaining a deeper understanding of the factors that regulate
ChAT protein stability and activity, the work presented within this thesis may have broader
implications to the study of ChAT protein function during cellular stress and in disease.
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APPENDICES
Appendix A: Optimization of BioID in multiple mammalian cell lines. Comparison of
ChAT-BirA* fusion protein expression and the levels of biotinylated cellular proteins in
human HEK293 as compared to either human SH-SY5Y (A; n=2) or mouse SN56 cells (B;
n=2) following BioID. Cells were transfected to transiently express either 69-kDa (A and
B) or 82-kDa (B) ChAT-BirA* fusion proteins using either Lipofectamine 2000 (A) or
3000 (A and B). Cells were treated for 24 h with 50 µM biotin to induce proximitydependent biotinylation of ChAT-interacting proteins prior to collection and lysis. Biotintreated control cells were transfected with empty pcDNA3.1+ vector or vectors encoding
for untagged 69- or 82-kDa ChAT proteins. Altogether, transfection of human HEK293
cells using Lipofectamine 3000 was found to be superior for both the transient expression
of ChAT-BirA* and for the accumulation and detection of cellular biotinylated proteins as
compared to either SH-SY5Y or SN56 cells. As such, this method was used to perform my
BioID experiments as detailed earlier (Figures 3.17 – 3.23). Biotinylated cellular proteins
from whole cell lysates were detected by blotting with HRP-conjugated streptavidin (StrepHRP). Relative expression of ChAT-BirA* fusion proteins and of untagged ChAT proteins
were assessed by anti-ChAT immunoblotting. Anti-actin immunoblotting from whole cell
lysates was completed as a loading control. Optimization experiments for BioID were
completed by Sabin Rajkarnikar, B.Sc.
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Appendix B: Optimization of siRNA-mediated knock-down of endogenous
HSC/HSP70 and HSP90. (A) Anti-HSC70 and anti-HSP90 immunoblots from SN56 cells
that were transfected for 72 h with 10-100 nM of either anti-HSC70 or anti-HSP90 siRNA.
Control cells were mock-transfected or transfected with 50 nM of scramble-control siRNA.
Following incubation with siRNAs an ~50% knock-down of either HSC70 and HSP90 was
observed. Anti-actin immunoblotting was completed as a loading control (n=2). (B) siRNA
knock-down of HSC70 promotes the stress-induced expression of both HSP70 and HSP90
in SN56 cells. Accumulation of stress-induced HSP70 was preventable by co-transfecting
cells with anti-HSP70 siRNA (n=2). (C) Knock-down of HSC70 either alone or together
with stress-induced HSP70 reduces the viability of SN56 cells as compared to scramblecontrol transfected cells (***p≤0.001; one-way ANOVA with Dunnett’s post-hoc test,
mean ± SEM). Cell viability was measured by alamar blue assay after 72 h of siRNA
incubation (n=2).
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Mutants
o Authors: Trevor M. Morey, Shawn Albers, and R. Jane Rylett
o Scope: Institutional
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•

Physiology and Pharmacology Annual Research Day; London, Ontario, Canada;
November 3, 2015.
o Poster: Decreased Activity and Increased Ubiquitin-Mediated Degradation of
Human Choline Acetyltransferase by Mutation of an N-terminal Proline-Rich
Motif.
o Authors: Trevor M. Morey, Shawn Albers, Brian H. Shilton, and R. Jane
Rylett
o Scope: Departmental
o Awarded first place prize - Neurosciences

•

Neuroscience 2015; Society for Neuroscience, Chicago, Illinois, USA; October 17-21,
2015.
o Poster: Decreased Activity and Increased Ubiquitin-Mediated Degradation of
Human Choline Acetyltransferase by Mutation of an N-terminal Proline-Rich
Motif.
o Authors: Trevor M. Morey, Shawn Albers, Brian H. Shilton, and R. Jane
Rylett
o Scope: International

•

Robarts Research Retreat; London, Ontario, Canada; June 8, 2015.
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a
N-terminal Proline-rich Motif.
o Authors: Trevor M. Morey, R. Jane Rylett
o Scope: Institutional

•

London Health Research Day; London, Ontario, Canada; April 1, 2015.
o Platform Presentation: Regulation of Human Choline Acetyltransferase
Protein Stability and Enzyme Activity by an N-terminal Proline-rich Motif.
o Authors: Trevor M. Morey, R. Jane Rylett
o Scope: Institutional

•

Physiology and Pharmacology Annual Research Day; London, Ontario, Canada;
November 4, 2014.
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a
N-terminal Proline-rich Motif.
o Authors: Trevor M. Morey, R. Jane Rylett
o Scope: Departmental
o Awarded first place prize - Neurosciences

•

Canadian Student Health Research Forum; Winnipeg, Manitoba, Canada; June 10-12,
2014.
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a
N-terminal Proline-rich Motif.
o Authors: Trevor M. Morey, R. Jane Rylett
o Scope: National; invite-only
o Awarded an honorable mention
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•

Robarts Research Retreat; London, Ontario, Canada; June 9, 2014.
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a
N-terminal Proline-rich Motif.
o Authors: Trevor M. Morey, R. Jane Rylett
o Scope: Institutional

•

Southern Ontario Neuroscience Association; London, Ontario, Canada; May 5, 2014.
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a
N-terminal Proline-rich Motif.
o Authors: Trevor M. Morey, R. Jane Rylett
o Scope: Regional

•

London Health Research Day; London, Ontario, Canada; March 18, 2014.
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a
N-terminal Proline-rich Motif.
o Authors: Trevor M. Morey, R. Jane Rylett
o Scope: Institutional
o Awarded first place prize – Neuroscience and Mental Health

•

Physiology and Pharmacology Annual Research Day; London, Ontario, Canada;
November 4, 2013.
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a
N-terminal Proline-rich Motif.
o Authors: Trevor M. Morey, R. Jane Rylett
o Scope: Departmental

•

Molecular and Cellular Biology Annual Research Day; Guelph, Ontario, Canada;
April 2009.
o Poster: The Effect of Noxa Serine-13 Phosphorylation on Hyperthermiainduced Apoptosis.
o Authors: Trevor M. Morey, Richard Mosser
o Scope: Departmental

Scientific and Technical Expertise:
•

Mammalian cell culture:
o Culture and maintenance of primary murine cells and mammalian cell lines.
o Plasmid transfection of adherent and non-adherent human cells lines.
o Generation of stably-expressing mammalian cells lines.
o Pharmacological experimentation.

•

Molecular techniques:
o Plasmid design and generation: PCR (for both insertion and mutagenesis
cloning), restriction digestion and purification, plasmid ligation.
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o Plasmid preparation: Bacterial transformation, plating, growth, and
purification.
o Immunoblotting: Mammalian cell lysis, protein sample preparation, 1D SDSPAGE, electroblotting, and protein detection by chemiluminescence using film
or ChemiDoc.
o Immunoprecipitation, co-immunoprecipitation, and affinity purification.
o Confocal microscopy
o Advanced techniques: BioID, PLA, SDD-AGE.
o Fluorescent and colorimetric plate-reader assays.
o Radioenzymatic assays, 32P-orthophosphate live-labeling and detection.
o Generation of novel assays (i.e. SPAAC pulse-chase).
•

Biochemical techniques:
o Recombinant protein purification: Expression in E. coli BL21, bacterial lysis,
Ni2+ affinity purification, TEV digestion, dialysis, cation exchange
purification.
o Biochemical plate-reader assays: enzymatic assays.
o Circular dichroism with tandem thermal denaturation for measurement of in
vitro protein structure and thermal stability.
o MALDI and ESI mass spectrometry to identify protein-protein interactors

Teaching Experience:
•

Phys1020 – Human Physiology, Western University, Sept. 2015 – April 2016.
o Supervisor: Christine Bell
o Position: Teaching Assistant

•

Phys1020 – Human Physiology, Western University, Sept. 2014 – April 2015.
o Supervisor: Christine Bell
o Position: Teaching Assistant

•

Phys1020 – Human Physiology, Western University, Sept. 2013 – April 2014.
o Supervisor: Tom Stavraky
o Position: Teaching Assistant

•

Phys3130y – Physiology Laboratory, Western University, Sept. 2013 – April 2013.
o Supervisor: Tom Stavraky
o Position: Teaching Assistant

•

Biol1090 – Introduction to Molecular and Cellular Biology, University of Guelph,
Jan. 2011 – April 2011.
o Supervisor: Kim Kirby
o Position: Teaching Assistant
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•

MCB4010 – Advanced Cell Biology, University of Guelph, Jan. 2011 – April 2011;
Jan. 2010 – April 2010.
o Supervisor: Dr. Richard Mosser
o Position: Teaching Assistant

•

MBG2000 – Introductory Genetics, University of Guelph, Sept. 2010 – Dec. 2010;
May 2010 – Aug. 2010; Sept. 2009 – Dec. 2009.
o Supervisor: Christine Schisler
o Position: Teaching Assistant
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